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Abstract 
 
Sialic acid binding Ig-like lectin-7 (Siglec-7), expressed primarily on NK cells, 
binds preferentially to alpha2,8 linked disialic acids such as present in the 
ganglioside GD3 that is upregulated in certain cancers. Siglec-7 is classified as 
an inhibitory receptor as it contains immunoreceptor tyrosine based inhibitory 
motifs. It has been shown to inhibit NK cytotoxicity in cellular assays thereby 
implying a role for it in NK cell mediated tumour surveillance.   
The aim of this project was to study factors affecting ligand recognition by 
Siglec-7 and its impact on NK cell functions. An investigation into the 
mechanism by which Siglec-7 mediates inhibitory signals to regulate NK cell 
biology was also carried out. Recognition of Siglec-7 for GD3 has been reported 
to be altered in the presence of complex gangliosides. This project was initiated 
with an aim to examine the role of such cis-interactions between GD3 and other 
gangliosides such as GM1 in biological systems and thereby its impact on NK 
cell biology. B16 (78) cell line was genetically modified to over-express both 
GD3 and GM1.  
This model system was then analysed using Siglec-7-Fc precomplexes for the 
recognition of GD3.  Siglec-7-Fc binding of B16 (78) cells with high expression 
of GD3 and GM1 was significantly lower compared to cells having high 
expression of GD3 and low expression of GM1.  However further investigation 
of these cis-interactions by confocal microscopy revealed that only less than 3% 
of the cells had patches of co-localization of the two gangliosides. Such lateral 
segregation of co-expressed GD3 and GM1 was also observed in another cell 
line model. Next, an investigation into the role of GD3 in modulating NK cell 
XV 
 
functions via Siglec-7 was carried out. Primary PBMCs and a Siglec-7 deficient 
NK cell line, NK92, were used for this purpose. The data obtained showed that 
Siglec-7 could negatively modulate NK cytotoxicity towards targets expressing 
disialylated ligands such as GD3. Furthermore Siglec-7 was also able to 
modulate integrin functions on NK cells. LFA-1 mediated adhesion of effectors 
to ICAM-1-Fc coated plates and the polarization of perforin granules to ICAM-1-
Fc coated beads were negatively affected by the expression of Siglec-7 in the 
NK92 cell line. Biochemical analysis of LFA-1 mediated signalling in NK92 cells 
showed negative regulation of Src kinase activation, in an Siglec-7 dependent 
manner. Overall these findings suggest a role for Siglec-7 in modulating NK cell 
recognition of tumours with aberrant glycosylation patterns. They also form the 
basis of further investigation into the mechanisms of inhibitory signalling 
mediated by Siglec-7 and could therefore be of potential clinical relevance in NK 
cell mediated tumour clearance. 
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Chapter 1    
Introduction 
The role of natural killer (NK) cells in the body’s defense against tumours is an 
area that generates considerable interest. Tumour cell elimination by NK cells is 
accomplished by a complex interplay of signals received from activating and 
inhibitory receptors expressed on these cells. Sialic acid binding Ig-like lectin-7 
(Siglec-7) is one of the inhibitory receptors present on NK cells. The role of 
Siglec-7 in modulating NK cell responses to tumours is not well understood. 
Disialylated gangliosides such as GD3 are one of the well known ligands for this 
receptor and are found to be over-expressed in certain tumours. The focus of 
this project is to examine the role of Siglec-7 - ganglioside interactions in 
modulation of NK cell responses to tumour cells.  
This chapter will provide an overview of the immune system with particular 
emphasis on human NK cells and Siglec-7 as well as the biosynthesis and 
functions of gangliosides and their role in tumours  
1.1 Vertebrate immune system  
The immune system is a complex network of cells and secreted molecules 
whose primary function is to protect the body from external and internal 
influences that are detrimental to homeostasis. It is made up of two arms – 
innate immunity and adaptive immunity. The innate system is present in 
invertebrates, vertebrates and plants and came into existence much earlier than 
adaptive immunity which is present only in vertebrates (Janeway., 2001, PNAS) 
(Albert B, Molecular biology of the cell., 2002). While attempting to clear the 
host of pathogens and toxins, the immune system must also be able to clearly 
discriminate self from non-self and maintain self-tolerance.  
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1.2 Innate immune system 
The innate immune system is the first line of defense against foreign antigens. It 
is made of cellular and non-cellular components which include the epithelial 
barrier, mucus layer covering the epithelial lining, the complement system, 
membrane bound receptors and intracellular proteins (Chaplin, 2003).  
The cellular components of the innate immune system include leukocytes that 
are derived from common myeloid progenitor cells and natural killer (NK) cells 
which arise from common lymphoid progenitors. Leukocytes are further divided 
into neutrophils, monocytes, eosinophils, and basophils. The cells of the innate 
immune system function by phagocytosis, release of cytokines, chemokines, 
enzymes and factors such as reactive oxygen species (ROS). They also have 
an important function in the activation of the adaptive immune system. They do 
this by processing antigens and presenting them to T-cells and B-cells and by 
the release of factors such as cytokines. Neutrophils are the first line of defense 
against bacterial and fungal infections and have a clear role in generating an 
inflammatory response and shaping adaptive immunity (Mocsai, 2013). 
Activated neutrophils facilitate recruitment of other cells to the site of 
inflammation and also engage in cross-talk with dendritic cells (DC), NK cells, T 
cells and B cells resulting in their maturation, activation, proliferation and 
functional responses (Mantovani et al., 2011)(	 Claudio Costantini and Marco A. 
Cassatella., 2011). Monocytes, macrophages and dendritic cells belong to the 
group of mononuclear phagocytic cells. They contribute to shaping of the 
immune system during infections and tumour development by – phagocytosis of 
dead and infected cells, production of cytokines and presenting antigens to T-
cells and B-cells. They express a number of pathogen recognition receptors 
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(PRRs) which help them with their primary function of phagocytosis of dead and 
infected cells (Geissmann et al., 2010).  
PRRs recognize certain structures conserved between species known 
collectively as pathogen associated molecular patterns (PAMPs). They can also 
be from endogenous damaged cells - these are known as damage associated 
molecular patterns (DAMPs).  The four classes of PRR identified to date include 
– Toll-like receptors (TLR), C-type lectin receptors, Retinoic acid-inducible 
gene-I-like receptors (RLRs) and Nod-like receptors (NLR) (Takeuchi and Akira, 
2010). These receptors are expressed either on the cell surface or are present 
in the cytoplasm and recognize proteins on bacteria, viruses, fungi and 
parasites. Sensing of PAMPs and DAMPs results in the release of cytokines, 
chemokines, type I interferon and other proteins classically associated with 
inflammatory responses (Takeuchi and Akira, 2010), (Akira, Uematsu and 
Takeuchi, 2006), (Kawai and Akira, 2010).  
 
1.3 Adaptive immune system 
The adaptive immune system is made up of cells belonging to two types – cells 
that mature in the thymus (T-cells), and cells that mature in the bone marrow, 
(B-cells). Following their development in the thymus and bone marrow, they 
move into the secondary lymphoid organs – lymph nodes and spleen. From 
these organs, they migrate towards site of infection, under the influence of 
adhesion and chemokine receptors (Bonilla and Oettgen, 2010). Both T-cells 
and B-cells express an array of activating and inhibitory receptors during 
different stages of their development and maturation. These receptors are 
crucial in maintaining homeostasis in the immune system and preventing 
unwanted responses. T-cells are characterized by the expression of the T cell 
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receptor (TCR) comprising of the α, β, γ, δ chains, by a process of somatic 
recombination, known as VDJ recombination. The TCR is associated with a 
receptor CD3 (ξ, δ, γ, ε), which is required for signaling of the TCR (Santana 
and Rosenstein, 2003). The TCR receptor recognizes antigenic peptides 
expressed on MHC class II on APCs and the ubiquitously expressed MHC I. 
This interaction also requires the recognition of MHC class I by CD8 and MHC 
class II by CD4 (Smith-Garvin, Koretzky and Jordan, 2009). Antigen recognition 
results in the clustering of TCR receptors at the immunological synapse and 
activation of immunoreceptor tyrosine-based activation motifs (ITAM) present 
on CD3 by the Src family of kinases, which triggers the signaling cascade in the 
T cells (Kane, Lin and Weiss, 2000). T-cells can be broadly classified as 
cytokine producing helper T cells (TH / CD4+) and cytotoxic T cells (CD8+). 
Cytotoxic action of CD8+ T cells is mediated either by pre-formed cytotoxic 
granules containing granzymes and perforin or by the expression of FasL. This 
is parallel to the mechanism adopted by NK cells and has been detailed below. 
Apart from mounting an immune response against pathogens, T-cells are also 
very important in activating B-cells, NK cells and DCs. B-cells are responsible 
for mediating humoral immunity via the production of antibodies (Bonilla and 
Oettgen, 2010). B-cells express ITAM containing receptors – Igα and Igβ which 
along with the B-cell co-receptor, CD19 helps in signal transduction following 
ligand binding or antibody cross-linking (Kurosaki, Shinohara and Baba, 2010).  
 
1.4 Natural killer (NK) cells  
NK cells are a unique population of immune cells that fall under the innate 
immune system as they require no prior sensitization to antigens. However they 
also share features common to the cells of the adaptive immune system and 
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hence are thought to be at the interface of these two systems. They represent 
2-18% of the total lymphocyte population in human blood (Purdy and Campbell, 
2009). They are characterized by numerous germline encoded receptors that 
unlike T-cell and B-cell receptors do not require somatic recombination. Human 
NK cells can be broadly divided into two subsets depending on the expression 
levels of CD56 as CD56dull and CD56bright. These two subsets differ in their 
expression of perforin and therefore cytotoxic potential with the CD56dull being 
more cytotoxic. 90% of the peripheral blood and splenic NK cells belong to the 
CD56dull CD16+ category and respond better to ligands expressed on target 
cells (Long et al., 2013a). The smaller subset of the CD56bright CD16+ cells, 
mainly present in tissues, respond stronger to soluble factors such as cytokines 
(Vivier et al., 2008).  
NK cells get recruited to the site of infection via chemokines and recognize 
tumour targets or virally affected cells by means of a diverse group of activating 
and inhibitory receptors. They mediate their cytotoxic functions by (i) release of 
preformed cytotoxic granules containing perforin or granzyme (ii) by the 
expression of death ligands such as FAS ligand (FASL) and TRAIL (TNF-
receptor apoptosis inducing-ligand) and (iii) expression of cytokines such as 
interferons (IFN-γ), tumour necrosis factor (TNF-α) and granulocyte-
macrophage colony-stimulating factor (GM-CSF). Upon ligand binding, the 
receptors for FASL and TRAIL, expressed on target cells, recruit “death 
domain” containing proteins which activate the caspase signalling cascade and 
initiate apoptosis of target cells (Chua, Serov and Brahmi, 2004;Montel et al., 
1995). Pore forming perforin and the serine protease granzyme also bring about 
target cell death by activation of the caspase signaling cascade (Trapani and 
Smyth, 2002).  
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In 1986, Karre and colleagues hypothesized that NK cells were able to spare 
certain tumours expressing major histocompatibility complex (MHC) class I 
ligands. This mechanism of recognizing potential targets was opposite to that of 
T cells which relies on ligand presentation by MHC class I and II molecules and 
came to be known as the “missing self” hypothesis (Karre, 2008;Karre et al., 
1986). However with the discovery of the numerous activating and inhibitory 
receptors expressed by these cells, it has now become clear that sensitivity of 
target cells to NK effectors does not solely depend on the absence of MHC 
expression but also on the expression of ligands for the activating receptors. 
The ligands expressed on target cells can either be non-self ligands expressed 
on cells infected with pathogens or stress ligands expressed by cells 
undergoing tumour transformation. NK cell effector responses result from the 
integration and balance of signals arising from these activatory and inhibitory 
receptors (Moretta and Moretta, 2004).   
Cytotoxicity bought about by NK cells can either be natural cytotoxicity or by 
antibody dependent cytotoxicity (ADCC). Natural cytotoxicity is bought about 
activating receptors (discussed below) whereas antibody dependent cellular 
cytotoxicity (ADCC) is solely under the control of the low affinity Fc receptor, 
CD16 (FcγRIIIa) (Lanier, 2003). 
The function of NK cells can be broadly categorized as follows  
1) Defence against tumours and infections - NK cells continuously scan the 
body for cells that have undergone transformation or have been virally 
transformed. Cells with increased expression of ligands for activating receptors 
or having a down-regulation of MHC class I molecules fall prey for these 
effectors. NK cells act on these cells by mechanisms described above and keep 
the infection under control till an effective T cell response has been mounted.  
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2) Maintaining homoeostasis in the organism – An important role for these cells 
in clearing away immature dendritic cells, antigen presenting cells and activated 
T cells has been demonstrated, thus proving to be essential in homeostatic 
mechanisms (Ferlazzo et al., 2004). NK cells are also involved in bidirectional 
cross-talk with dendritic cells. Cytokines produced by dendritic cells enhance 
NK effector functions. On the other hand, cell to cell contact between NK cells 
and dendritic cells is important in DC maturation and activation (Ferlazzo et al., 
2004;Gerosa et al., 2005;Morandi et al., 2012;Walzer et al., 2005). Recently, 
their role in preventing autoimmunity has begun to be recognized for example in 
multiple sclerosis, rheumatoid arthritis, type-1 diabetes and systemic lupus 
erythematosis (SLE) (Erkeller-Yuksel, Lydyard and Isenberg, 1997;Rodacki et 
al., 2007;Schleinitz et al., 2010) (Gur et al., 2013) 
3) Reproduction - NK cells are also found in the uterine tissues. Altered NK cell 
functions have been found in women with recurrent abortions, pre-ecclampsia 
and infertility (Kwak-Kim and Gilman-Sachs, 2008) (Vacca, Mingari and 
Moretta, 2013). 
 
NK cells express receptors belonging to two main categories – activating and 
inhibitory (listed in table 1). These receptors interact with MHC and non-MHC 
ligands expressed on normal and diseased cells (Lanier 2005). Some of the 
receptor families consist of members which are only activatory while others are 
made of both activatory and inhibitory receptors. NK cell response to a target 
depends on many factors such as surface density of receptors (Sivori et al., 
2000), their synergistic activation (as seen in experiments involving multiple 
activating receptors), activation state of NK cells (Vitale et al., 1998) and 
strength of the inhibitory signals. In some cases, factors in the tumour 
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microenvironment such as hypoxia and presence of tumour derived lactate 
dehydrogenase also negatively affects the expression of activating receptors, 
(Balsamo et al., 2013) (Husain et al., 2013). Structurally these receptors can 
also be classified as belonging to either the immunoglobulin (Ig) super family or 
the C-type lectin receptor family.  
 
1.4.1 Activating receptors  
Some of the activatory receptors implicated in tumour cell clearance include – 
those belonging to the family of natural cytotoxicity receptors (NCR), NKG2D, 
DNAM-1, 2B4. The NCR family consists of NKp44, NKp30 and NKp46. They 
are associated with ITAM containing adaptor proteins such as DAP12, via 
positively charged residues in their transmembrane domains. 
Although these receptors have been clearly associated with clearance of 
tumours of different origins, their ligands remain elusive, especially those of 
NKp46 and NKp44 (Hudspeth, Silva-Santos and Mavilio, 2013). Using reporter 
cell lines and recombinant fusion proteins, tumour cell lines and some primary 
tumours such as melanomas have been shown to express ligands for these 
receptors (Glasner et al., 2012;Lakshmikanth et al., 2009) (Byrd et al., 2007) . 
Tumour and non-tumour related ligands identified for NKp30 include - B7-H6, 
BAT3 and pp65 proteins (Brandt et al., 2009) (Pogge., 2007). The Influenza 
virus hemagluttinin has been reported to be one of the ligands for NKp46 
(Mandelboim et al., 2001). Certain α 2,3 sialic acid containing glycans, heparin 
and heparan sulfate has also been suggested as putative ligands for the NCRs. 
These studies used recombinant forms of the receptor and involved invitro 
techniques such as microarrays and surface plasmon resonance (SPR) (Hecht 
et al., 2009;Ito et al., 2011;Ito et al., 2012). These receptors have also been 
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shown to be important in the clearance of some viral infections such as, 
influenza, human cytomegalovirus (HCMV), and HIV and have also been 
implicated in certain autoimmune diseases such as diabetes (Gazit et al., 2006) 
(Magri et al., 2011) (Mendelson et al., 2010)  (Fauci, Mavilio and Kottilil, 2005) 
(Guret al., 2013). 
 
The receptor, NKG2D, recognizes self-proteins that are upregulated by cells 
under stress. NKG2D is not expressed as a heterodimer and recognizes non 
MHC class 1 ligands (Zafirova et al., 2011). NKG2D associates with and signals 
through the YINM motif containing adaptor protein, DAP10. It also associates 
with DAP12 in some species. The ligands recognized by this receptor in 
humans include – MHC class-I related proteins A and B (MICA and MICB) and 
UL-16 binding proteins (ULBP) while in mice it is – GPI anchored group of 
histocompatibility antigens 60 (H60), the family of retinoic acid early inducible 
proteins (RAE-1) and the transmembrane UL-16-binding protein-like transcript 1 
(MULT1) (Long et al., 2013b) (Raulet et al., 2013). The expression of ligands 
such as MICA and MICB is low on normal cells and is upregulated upon cellular 
stress (Gasser et al., 2005). Ligands for NKG2D have been found to be reliable 
markers for disease progression in cancers of breast (de Kruijf et al., 2012), 
ovary, (McGilvray et al., 2010), large intestine (McGilvray et al., 2009). They are 
therefore of potential value in tumour immunotherapy (Cho et al., 2010).  
Tumour cells and viruses have adopted different strategies to escape from 
recognition of these activating receptors.  Some notable examples include 
release of immunomodulatory cytokines such as TGFβ (Sun et al., 2012) 
(Eisele et al., 2006), shedding of ligands by metalloproteases (Liu et al., 
2010;Salih, Rammensee and Steinle, 2002) and downregulation of ligand 
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expression by microRNA’s (Tsukerman et al., 2012) (Bennett et al., 2010) 
(Jensen et al., 2011) and also by preventing surface expression of activating 
receptors (Sunet al., 2012)  
KIRs are a group of highly polymorphic receptors which can either be activatory 
or inhibitory (Purdy and Campbell, 2009). These receptors can be divided into 
different groups depending on (1) their extracellular domain – 2 domains (2D) 
and 3 domains (3D) or (2) the length of their cytoplasmic domains – Long (L) or 
Short (S) (Uhrberg et al., 1997). Like other activating NK receptors, activatory 
KIRs are also associated with adaptor proteins DAP12 and FcεRI-γ which carry 
ITAM residues in their cytoplasmic domains and facilitate signaling (Kikuchi-
Maki, Catina and Campbell, 2005). KIRs recognize distinct subsets of the 
classical MHC-I molecules - HLA-A, B and C and this recognition is dependent 
on specific sequences on the HLA molecules. The inhibitory KIRs recognize 
epitopes on HLA-C (and some subsets of HLA-A and B) and strongly inhibit 
cytotoxicity of targets expressing this allotype (Moretta et al., 2009). Ligands of 
many of the activatory KIRs remain unidentified such as KIR2D-S2/S3/S5 and 
KIR3DS1(Joyce and Sun, 2011). There is extensive homology between the 
extracellular domains of the activating and inhibitory KIRs but the ligand binding 
specificities and affinities vary considerably between the different KIRs. A 
striking example includes the KIR2DS2 whose ligand specificity is not known 
although it differs from the inhibitory KIR2DL3 and KIR2DL2, with known 
ligands, by two and four amino acids respectively (Saulquin, Gastinel and 
Vivier, 2003). However this level of homology also results in some activatory 
and inhibitory receptors sharing the same HLA ligands but with different binding 
affinities. The activatory KIR2DS1 and inhibitory KIR2DL1 both bind HLA-C2 
KIR expression is clonal and highly diverse between individuals. 14 KIR genes 
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are present in the leukocyte receptor complex of human chromosome 19 and 
their segregation is independent of HLA. KIRs have gained much attention in 
the field of leukemia treatment by haploidentical stem cell transplantation (Decot 
et al., 2010) (Martner et al., 2013). Donor NK cells possess a set of inhibitory 
KIRs that recognize missing self class I ligands in the recipient and mediate 
improved outcome without causing graft-versus-disease.  
Figure 1.1 is a schematic representation of some of the activating receptors and 
their ligands (adapted from Watzl and Urlab, 2012) 
Figure 1.1 : Some of the activating receptors expressed on NK cells (bottom) and their 
ligands expressed on target cells (top). Receptors belonging to the immunogloubulin 
super family (Ig) are shown in oval while those belonging to the C-type lectin family are 
shown as half circles. Tyrosine based signaling motifs ITAM, YINM or ITSM are shown 
associated with the receptors. Adapted from (Watzl and Urlaub, 2012).  
 
Many other receptors act in concert to support and co-stimulate the above 
mentioned main activating receptors for example – the lymphocyte function 
antigen (LFA-1), 2B4, DNAM-1, CD2, NTBA. The role of LFA-1 in NK cell 
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cytotoxicity and signaling mechanism will be discussed here as a representative 
of NK activating receptors.  
LFA-1, a heterodimer of CD11a and CD18, is one of the many integrin 
receptors expressed by NK cells (Helander and Timonen, 1998). LFA-1 has 
been studied extensively in T-cell systems and is known to mediate adhesion, 
migration and immunological synapse formation. Adhesion of NK cells to their 
targets is critical to cytotoxicity events. LFA-1 is one of the important co-
stimulatory integrin receptors expressed on NK cells. Many early studies have 
demonstrated that the absence of LFA-1 was associated with defective natural 
cytotoxicity and antibody dependent cellular cytotoxicity of NK cells (Kohl et al., 
1984;Liu et al., 1994) (Shibuya et al., 1999). The role of LFA-1 in mediating NK 
cell signaling was dissected with the help of a unique model system involving 
the insect cell line (drosophila Schneider, S2) for the expression of ICAM-1 and 
ligands for other activating receptors (Barber and Long, 2003). Using primary 
IL-2 activated NK cells, it was demonstrated that the expression of ICAM-1/2 on 
S2 cells was enough to bring about perforin polarization and NK cell cytotoxicity 
in an LFA-1 dependent manner (Barber, Faure and Long, 2004). Freshly 
isolated resting NK cells however had differential requirements for granule 
polarization and degranulation.  In resting NK cells, LFA-1 was responsible only 
for adhesion and granule polarization while CD16 for degranulation (Bryceson, 
Ljunggren and Long, 2009). Synergistic signaling of LFA-1 with CD16 and 
receptors such as NKG2D and 2B4 was shown to enhance adhesion and 
cytolytic capacity of resting NK cells (Barber and Long, 2003;Bryceson, 
Ljunggren and Long, 2009;Bryceson et al., 2005). LFA-1 mediated adhesion, 
granule polarization and cytotoxicity have been shown to be sensitive to the 
action of inhibitory receptors such as KIR and CD94/NKG2A (Barber, Faure and 
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Long, 2004;Bryceson et al., 2005;Burshtyn et al., 2000) suggesting an 
important role for LFA-1 in NK effector functions. LFA-1 dependent conjugate 
formation and perforin polarization was also shown to require an intact 
cytoskeleton (Gross et al., 2010). Following adhesion to target cell, LFA-1 also 
plays a crucial role in the formation and maturation of the immunological 
synapse as well as the distribution of receptors at the synapse (Orange, 2008).  
Although LFA-1 has been intensely studied both in human and mouse NK cells, 
little is known about the exact signaling mechanisms and downstream effectors 
involved. The non-receptor protein tyrosine kinase (Pyk2) and the guanine 
nucleotide exchange factor, Vav-1, were some of the earlier identified signaling 
molecules implicated in LFA-1 dependent signaling (Gismondi et al., 2000) 
(Riteau, Barber and Long, 2003). The role of Vav-1 in regulating cytoskeletal 
changes crucial to NK cytotoxicity is well established (Dong et al., 
2009;Galandrini et al., 1999). Using the well known cytotoxic human NK cell 
line, NK92, synergistic signaling of LFA-1 and CD2 were shown to regulate the 
activation of the mitogen-activated protein kinase, Erk1/2 (Zheng et al., 2009).  
Mouse NK cells have been useful in studying the association of LFA-1 with 
different cytoskeletal proteins such as Talin, to initiate downstream signaling 
process vital to actin cytoskeletal reorganization and perforin polarization (Mace 
et al., 2010). In an interesting study, March and Long were able to show that 
integrin signaling and functions in NK cells is different to that of other systems 
such as neutrophils and T-cells (March and Long, 2011).  Their results 
demonstrated for the first time the dependence of LFA-1 signaling on ITAM 
containing adaptor,TCR ζ-chain as well as on the tyrosine kinase Syk and PLC-
γ in NK cells. This study also compared the differences in the signaling 
mechanism between LFA-1 and CD16 (March and Long, 2011).  
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Table 1.1 gives a list of activating and inhibitory receptors found on human NK 
cells. 
Table 1.1 – List of some of the activating (red) and inhibitory (blue) receptors 
expressed on human NK cells, their ligands, signalling adaptors/motifs and 
functions.  
Receptor Ligand 
Signalling 
motif 
Type 
NKp46 
Unknown, viral 
haemagglutinins? 
CD3ξ / FcεRIγ Activating 
NKp30 BAT-3, pp65 CD3ξ / FcεRIγ Activating 
NKp44 
Unknown, viral 
haemagglutinins? 
DAP12 Activating 
NKG2D ULBP, MICA, MICB DAP10/DAP12 Activating 
NKG2C/E HLA-E DAP12 Activating 
CD16 IgG CD3ξ / FcεRIγ Activating 
KIR-S HLA-C DAP12 Activating 
DNAM-1 Nectin-2, CD155 Unknown Activating 
LFA-1 ICAM-1  Activating 
NKp80 AICL Hemi-ITAM Activating 
2B4 CD48 ITSM Activating/Inhibitory 
KIR-L HLA-A, B, C ITIM Inhibitory 
CD94-NKG2A HLA-E ITIM Inhibitory 
Siglec-7 Sialic acid ITIM Inhibitory 
NKR-P1A LLT- ITIM Inhibitory 
ITSM – immunoreceptor tyrosine-based switch motif; ITIM – immunoreceptor 
tyrosine-based inhibition motif.  
 
1.4.2 Inhibitory receptors 
The threshold required for the activating receptors is tightly regulated by the 
expression of inhibitory receptors. This group includes some members of the 
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KIR family, CD94:NKG2A, FcγRIIb, Siglec-7. KIRs recognize the classical MHC 
class I molecules (HLA-A, B and C). The non-classical MHC class I molecules 
HLA-E (human) and Qa1 (mouse) expressed widely in tissues is recognized by 
the major inhibitory receptor, NKG2A, which is a C-type lectin, (Braud et al., 
1998).  
 These interactions are key for maintaining tolerance towards normal healthy 
cells by inhibiting cytotoxicity and cytokine production by these effectors. A 
feature shared by this group of receptors is the presence of ITIM motifs within 
their cytoplasmic domains. Phosphorylation of this motif results in the 
recruitment of Src homology 2 (SH2) domain containing protein tyrosine 
phosphatases such as SHP-1 and SHP-2 (Kabat et al., 2002). The amino acid 
sequence characteristic for this motif is V/I/LxYxxL/V (where x is any non-
conserved amino acid, Y - tyrosine, V – valine, L – leucine and I - isoleucine). 
Most inhibitory receptors carry two ITIM motifs, separated by 25 amino acid 
sequence, which provides the binding site for the tandem SH2 domains of SHP-
1 and SHP-2 (Long, 2008). Inhibitory KIRs also carry two ITIM motifs in their 
cytoplasmic domains, with the exception of KIR2DL4 and KIR2DL5. Mutational 
studies of the ITIM motifs have helped identify the tyrosine residues required for 
inhibitory functions. For example using ITIM mutations, Kabat et et al., have 
shown that like the KIRs, the first ITIM (membrane distal due to the receptor 
being a type II protein) had a greater effect on the inhibitory functions of NKG2A 
(Kabatet al., 2002). Because of their ability to block NK cell activation, inibitory 
receptors negatively regulate NK cell function associated with tumours and viral 
infections (Al Omar et al., 2011).Thus they provide an avenue for antibody 
based immunotherapy (Li et al., 2013). For example by blocking NK cell 
inhibitory KIRs, improved rituximab based NK ADCC response was observed in 
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a cell line model of anti-lymphoma therapy (Binyamin et al., 2008). The biology 
of the inhibitory receptor Siglec-7 is detailed in section 1.4.5.  
 
1.4.3 Signaling in NK cells 
As discussed above, NK effector responses result from the complex integration 
of signals derived from activatory and inhibitory receptors. Signaling of 
activating receptors is possible by their association with ITAM containing 
adaptors such as FcεRIγ, CD3ζ and DAP12 via positively charged residues 
(eg., arginine) in the transmembrane domain of the receptor. The ITAM 
sequence consists of a pair of YxxL/I motifs (where x is any non-conserved 
amino acid, Y - tyrosine, L – Leucine and I - isoleucine), separated by a 6-8 
amino acids (Love and Hayes, 2010) . These receptors include - CD16, NKp30, 
NKp46, activatory KIRs (Lanier, 2003). The adaptors can exist either as homo 
or heterodimers. The C-type lectin activating receptor, NKp80, however uses a 
hemi-ITAM motif for signaling (Dennehy, Klimosch and Steinle, 2011). 
Ligand binding has been shown to result in phosphorylation of these ITAM 
motifs by Src kinase family members and this becomes the docking site for the 
SH2 domain containing kinases such as Syk and Zap70 (Jiang et al., 2002). 
This results in the phosphorylation and activation of several other downstream 
signaling molecules such as SLP-76 (Kim and Long, 2012), phospholipase 
(PLC) - γ1 / γ2, linker for activation of T cells (LAT), p85 subunit of P13K 
(Upshaw et al., 2006), guanidine nucleotide exchange factor Vav-1 and Vav-2, 
extracellular signal-related kinase (Erk1/2) and p38 mitogen activated protein 
kinase (MAPK) (Vivier, Nunes and Vely, 2004) (Bryceson and Long, 2008) 
(Riteau et al., 2003)(figure 1.2). Phosphorylation of Vav-1 is required for the 
actin cytoskeletal changes, clustering of activation receptors, recruitment to the 
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membrane and formation of the immunological synapse (Graham et al., 2006). 
These downstream signaling events impact on the NK cell mediated cytotoxicity 
and cytokine production.  
NKG2D is expressed on the membrane as a dimer in association with four units 
of DAP10, which carries an YXXM signaling motif (Park et al., 2011). 
Phosphorylation of DAP10 by the Src kinase, Lck, results in the binding of p85 
subunit of phosphoinositide 3-kinase (PI3K) or the binding of the small adaptor, 
Grb2 (Billadeau et al., 2003). However, another isoform of NKG2D (identified 
first in mice deficient in DAP10), the short “S” isoform is able to associate with 
DAP12 in cells activated with IL-2 and mediate signaling similar to other DAP12 
associated receptors (Gilfillan et al., 2002) (Diefenbach et al., 2002). Segovis 
and group showed that signaling via NKG2D involved PI3K, which is regulated 
by the adaptor protein CrkL. This pathways affected NKG2D mediated cellular 
adhesion, granule polarization and cytotoxicity (Segovis et al., 2009). 
Some other activating receptors are able to signal in the absence of ITAM 
motifs. 2B4 belongs to the SLAM family of receptors that have a switch motif in 
their cytoplasmic domain, TxYxxV/I. SLAM receptors are physically associated 
with SLAM-associated adaptor protein (SAP) which facilitates activatory signals 
(Veillette, 2010). However in the absence of SAP, these receptors propagate 
strong inhibitory signaling (Donget al., 2009). Integrins such as LFA-1 also 
belong to this third category of activatory receptors, which are not known to 
have physical association with ITAM containing adaptors (discussed above). 
Figure 1.2 is a schematic some of the downstream signaling pathway of 
different activation receptors (adapted from Waltz and Urlaub, 2012). 
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Figure 1.2 Signalling events following ligand recognition by some of the NK activation 
receptors. Src family of kinases is central to the recruitment of the downstream effectors 
such as PI3K and Vav-1 to YINM motif of DAP10 (associated with NKG2D), SAP family of 
adaptors to ITSM and Syk tyrosine kinases to ITAMs . Solid arrows represent activation 
events while dashed arrows represent recruitment events (Waltz and Urlaub, 2012). 
 
As mentioned above, inhibitory receptors carry between 2 and 4 ITIM motifs. 
Ligand recognition by these inhibitory receptors results in the recruitment of Src 
homology 2 domain (SH2) containing phosphatases – SHP-1, SHP-2 and SHIP 
(in the case of mouse inhibitory Ly49 receptor) (Burshtyn et al., 1997) (Vely et 
al., 1997). SHP-1 and SHP-2 belong to the class of non-transmembrane 
associated phosphatases with broad expression patterns. Structurally, they 
have two SH2 domains on the N-terminus, a central catalytic domain and C-
terminus with potential tyrosine phosphorylation sites (Lorenz, 2009). The SH2 
domains dock onto the phosphorylated ITIM motifs and are important in 
regulating the activity of the catalytic domain. The C terminus carries nuclear 
and lipid raft localization signals. In a resting state, the N-terminal SH2 domain 
inhibits the activity of the catalytic domain by associating with it. The catalytic 
domain is released from this inhibitory state when the SH2 domains dock on to 
phosphorylated ITIM motifs of inhibitory receptors (Lorenz, 2009). SHP-1 null 
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mice have provided vital information about the role of this phosphatase in 
negatively modulating signaling by numerous ITIM carrying receptors.  
Mutational studies of the ITIMs of KIR, NKG2A and Siglec-7/9 showed that the 
proximal ITIM motif was sufficient to recruit SHP-1 and result in inhibition of the 
effector functions (Bruhns et al., 1999) (Avril et al., 2004).  However, there is 
lack of clear evidence as to how these ITIM motifs get phosphorylated. Lck, a 
member of the Src family of kinases, has been shown to be associated with the 
dicystine motifs on the cytoplasmic domains of the mouse inhibitory C-type 
lectin receptor, NKR-P1B, and is responsible for the phosphorylation of its ITIM 
motifs (Ljutic et al., 2005). However, a similar association has not been shown 
for any another ITIM bearing receptor. Further, the rapid phosphorylation of 
these ITIM bearing receptors achieved following pervanadate treatment 
suggests a possible constitutively phosphorylated state of these motifs (Long, 
2008).  The substrates targeted by SHP-1 have remained elusive due to the 
inherently difficult nature of these experiments. However, one particular study 
made use of a functional “substrate trapping” mutant of KIR2DL1-SHP-1, which 
picked up only Vav-1(Stebbins et al., 2003). Till recently the dephosphorylation 
of Vav-1 was thought to result in the termination of the downstream activatory 
signals. However some other novel mechanisms by which inhibitory signaling 
could intercept activatory signals has been reported. These include the active 
phosphorylation of the adaptor Crk by the kinase, Abl (Peterson and Long, 
2008) and continuous dephosphorylation of Vav-1 by the E3 ubiquitin ligase c-
Cbl (Kim et al., 2010). Figure 1.3 is a schematic representation of some of the 
inhibitory signaling pathways. 
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Figure 1.3 Integration of activating and inhibitory signals : Phosphosphorylation of Vav-1 
results in clustering of activation receptors and subsequent cytotoxicity. However, 
activation of SHP-1 by engagement of inhibitory receptors results in the 
dephosphorylation of Vav-1. Also Abl-dependent phosphorylation of Crk results in the 
dissocation of the Cbl-Crk-C3G complex. Both these events block actin remodeling and 
thereby dampen activation signals. Solid arrows represent activation events while blunt 
arrows represent inhibition (adapted from Waltz and Urlaub, 2012). 
 
Inhibitory receptors such as KIRs affect lipid raft polarization and actin 
cytoskeletal changes which impact on the formation of the immunological 
synapse (Lou et al., 2000) (Borhis et al., 2013)(Masilamani et al., 2006)(Faure 
et al., 2003). KIRs cluster at the immunological synapse in an actin independent 
manner and is surrounded by a ring of LFA-1 and ICAM-1 (Standeven et al., 
2004;Vyas et al., 2001). Using S2 target cell line expressing ligands for CD2, 
2B4, ICAM-1 and the inhibitory receptor KIR2DL1, a novel mechanism about 
how inhibitory receptors function at the immunological synapses was proposed. 
This study showed that KIR promoted the accumulation of activating receptors 
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at the inhibitory synapse while excluding LFA-1(Schleinitz, March and Long, 
2008). Thus the phosphorylation of activation receptors could be prevented 
following phosphatase recruitment by KIRs  (Dustin, 2010) (Long, 2008). 
 
1.4.4 NK cell licensing 
NK cell maturation and development involves a process known as education or 
licensing. This process enables NK cells to acquire or remain in a fully 
functional state and respond to loss of MHC on target cells and requires the 
interaction of the inhibitory receptors with self-MHC I during NK cell maturation 
and probably thereafter (Cruz-Munoz and Veillette, 2010;Jonsson and 
Yokoyama, 2009;Raulet and Vance, 2006). Therefore the absence of self MHC 
molecules results in NK cells being hyporesponsive. Different models have 
been suggested to explain how this process occurs – (a) the arming model, 
according to which  inhibitory receptor recognition of self-MHC favours 
functional maturation of NK cells (Yokoyama and Kim, 2006), (b) the disarming 
model which suggests that NK cells are made hyporesponsive in the absence 
of a self-MHC receptor, (c) the cis-interaction model which suggests that cis 
interaction between Ly49 receptor and MHC molecules on the same cell 
membrane results in functional NK cell responses and (Chalifour et al., 2009) 
(d) the rheostat model which is based on the quantitative strength of inhibitory 
signaling (Brodin et al., 2009). NK cells can also be rendered unresponsive by 
chronic stimulation of their activating receptors. Chronic engagement of NKG2D 
with its ligands resulted in aberrant NK cell mediated natural and antibody 
dependent cytotoxicity (Coudert et al., 2008).  
The use of MHC deficient mice have led to understanding the importance of 
inhibitory receptors in the process of NK cell education (Bryceson et al., 2006) 
22	
	
(Johansson et al., 2005). Contrary to the above described, uneducated NK cells 
from mice deficient in either Ly49 receptor or MHC class molecules responded 
strongly to infection with mouse cytomegalovirus (Hoglund and Brodin, 2010). 
 
1.4.5 Siglec-7 
Siglec-7, an NK cell inhibitory receptor, belongs to the family of sialic acid 
binding Ig-like lectins. Members of this family are distributed widely in the cells 
of the hematopoietic system with Siglec-7 being expressed on NK cells and a 
subset of monocytes and CD8+ T cells (Nicoll et al., 1999). This group showed 
that red blood cell (RBC) adhesion to COS cells transfected with Siglec-7 was 
abolished following sialidase treatment of the RBCs implying the role of this 
receptor in mediating cell – cell interactions (Nicoll et al., 1999). The 
extracellular domain of this receptor comprises of an N-terminal V-set Ig like 
domain and two C2-set Ig like domains. It has a unique preference for terminal 
disialic acids in α 2,8 linkages and to a lesser extend internally branched sialic 
acids in α 2,6 linkages (Blixt et al., 2003) (Nicoll et al., 2003). Disialic acids in α 
2,8 linkages are present on gangliosides belonging to the b-series such as 
GD3, GT1a and GT1c (discussed below and represented in figure 1.8) and also 
in serum glycoprotein fetuin, α 2-microglobulin, neural cell adhesion molecule 
(NCAM)(Attrill et al., 2006).  By virtue of an ITIM and ITIM-like motif in its 
cytoplasmic domain, Siglec-7 has been classified as an inhibitory receptor. 
Using mutational studies, the ITIM motifs (the proximal one in particular) was 
shown to recruit SHP-1 and SHP-2 and contribute to the inhibitory properties of 
this receptor (Falco et al., 1999) (Avrilet al., 2004).  
Like other members of the Siglec family, this receptor was also found to be 
present in a ‘masked’ state on NK cells (discussed below). This was attributed 
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to the presence of sialylated glycans on NK cells. mRNA analysis of NK cells 
showed strong expression of ST8Sia VI which facilitates the transfer of sialic 
acids onto O-linked glycans (Avril et al., 2006a). Treatment of NK cells with an 
enzyme, sialidase, is needed to remove these cis-interactions and facilitate 
Siglec-7 recognition of probes or ligands in trans (Nicollet al., 2003). Therefore 
these cis-interactions could be thought of as a mechanism evolved to modulate 
thresholds required by activating receptor on NK cells. Using murine targets, 
Nicoll et al showed that unmasked Siglec-7 is able to modulate NK cell 
cytotoxicity via recognition of the ganglioside GD3 expressed on target cells 
(Nicoll et al., 2003). The biological significance of GD3 and its role in tumour 
progression is discussed in section 1.7 of this chapter. 
The functional role of Siglec-7 as an inhibitory receptor was established using 
adhesion assays, FcεR mediated serotonin release by RBL cells in an over-
expression model, myeloid cell proliferation assays and by examining natural or 
redirected cytotoxicity of human NK cells against murine targets (Nicollet al., 
2003) (Avrilet al., 2004). Other studies have also confirmed the inhibitory role of 
Siglec-7 in different models. By recruiting SHP-1, Siglec-7 was shown to inhibit 
T cell receptor signaling in the Jurkat cell line and Ca2+ influx in a transfected 
monocytic cell line (Ikehara, Ikehara and Paulson, 2004) (Yamaji et al., 2005). 
Recombinant or cell surface expressed Siglec-7 bound strongly to 
lipooligosaccharides (LOS) from HS:19 strains of Campylobacter jejuni that 
either expressed GM1+GD1a+ or GD3+  (either in the purified form or heat 
inactivated bacteria), in a sialic acid dependent manner(Avril et al., 2006b). 
Taken together these studies imply that Siglec-7 has a role in modulating 
tumour responses of NK cells as well as in the modulation of host immune 
responses to infections. The significance of Siglec-7 in regulating immune 
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responses was further underscored by the finding of a rare subset of peripheral 
blood NK cells in patients infected with human immunodeficiency virus (HIV). 
Examining the various NK cell markers of healthy, acute and chronically 
infected patients, the authors found that the acutely infected patients had a 
CD56+Siglec-7- NK cell phenotype, which changed to a CD56-Siglec-7- subset 
in chronic infection (Brunetta et al., 2009). These aberrant subsets were 
impaired in their ability to degranulate as measured by CD107a release when 
stimulated by a susceptible target cell line. They were also less efficient in the 
production of cytokine, IFN-γ, when compared to the CD56+Siglec-7+ subset.   
 
1.5 Siglec family of receptors 
The family of sialic acid-binding Ig-like lectin (Siglec) consists of type I 
membrane proteins with variable number of extracellular domains. This family of 
lectins came into existence following a study of the sequence similarities and 
binding properties of CD22, Sialoadhesin and myelin associated protein (Kelm 
et al., 1994).  Many more members of this family were identified in several 
species eg., human, mouse, primates, over the next few years. 
 Siglecs are broadly divided into two classes – (1) a highly evolving, closely 
related CD33-like group and (2) a group consisting of Sialoadhesin, CD22 and 
myelin-associated glycoprotein. The first group varies considerably between 
different mammalian species whereas the second group has conserved 
orthologues between the different species. Figure 1.4 represents some of the 
members belonging to this family in humans (adapted from Crocker, Paulson 
and Varki., 2007). To date there are 15 siglecs identified in humans (largest 
group known so far) and 9 in mouse (Paulson, Macauley and Kawasaki, 2012). 
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Figure 1.4: Schematic representation of human Siglecs. C2-like domains – light green, V-
set domain – dark green; Red square – ITIM motif; Blue square – ITIM-like motif ; “+” – 
positively charged residue in transmembrane domain (Adapted from Crocker, Paulson 
and Varki., 2007). 
 
Evolutionarily the family of CD33 related siglecs arose from a small cluster of 
genes which underwent inverse duplication to form a large gene cluster (Cao 
and Crocker, 2011). Figure 1.5 shows the phylogenetic relationship between 
the human and mice siglecs. There is a clear orthologous relationship between 
Sialoadhesin, CD22 and Siglec-4 (MAG) of human and mice. Although the 
CD33 related siglecs do not have such a clear orthologus relationship, some of 
the mouse siglecs fall into the same clade as that of the humans. For eg., 
human siglec 7, 8 and 9 belong to the same group as the mouse Siglec-E while 
human Silgec-10 and mouse Siglec-G are closely related (Angata et al., 2001) 
(Varki and Angata, 2006).  
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26	
	
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Phylogenetic comparison of human and mouse siglecs: Phylogenetic tree 
derived from N-terminal and C-terminal sequences of human and mouse siglec. Siglecs 
belonging to the same clade have been shaded in grey. Adapted from (Angataet al., 2001) 
 
The expression of these sialic acid receptors is mostly restricted to 
hematopoietic cells and cells of the immune system. Structurally, the 
extracellular domain consists of a V-set immunoglobulin superfamily (Ig) domain 
and varying number of C2-set domains (as shown in figure 1.4). For example, 
sialoadhesin has 17 extracellular domains while Siglec-7 has only 3. The V-set 
domain contains key residues that facilitate binding of sialic acids. In the 
cytoplasmic domain, most members of this family have ITIM and ITIM-like 
motifs. The presence of ITIMs fits in with their role as regulators of the immune 
system. However some members of the human siglec (Siglec-14) and of the 
mouse (Siglec-H) have no ITIM motifs but instead associate with ITAM bearing 
adaptors such as DAP12 via their positively charged transmembrane region 
(Angata et al., 2006;Blasius et al., 2006) 
N-terminal amino acids C-terminal amino acids 
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As their name suggest, Siglecs are classically involved in sialic acid recognition. 
Sialic acids (NeuAc) are a family of 9-carbon sugars found usually as terminal 
structures of N-linked glycans, O-linked glycans and glycosphingolipids.   The 
second carbon (R2) on the sialic acid forms linkages with other sugars (as 
described in the figure 1.6) while the R5 can have various modifications such as 
N-acetyl group (NeuAc), a hydroxyl group (Kdn) or an N-glycolylneuraminic 
(NeuGc). Sialic acids are highly expressed on cell surfaces and confer the cell 
with a strong negative charge.   
Figure 1.6 Structure of sialic acid – The 
structure of the 9-carbon sialic acid. The 
carbon atoms are labelled 1-9. Positions R1-
R9 represent the different modifications 
possible at these positions. For example at 
position R2 – the carbon can form α 
linkages Gal(3/4/6), GalNAc (6), GlcNAc(4/6) and another sialic acid (8/9). Adapted from 
Essentials of glycobiology (2009).  
 
Structural studies of Sialoadhesin and Siglec-7 with sialic acid analogues have 
revealed the key residues involved in the interactions between siglecs and sialic 
acids. Some of these interactions are conserved between the different 
members. The arginine residue (at position 124 in the case of Siglec-7) in the V-
set domain forms a salt bridge with the carboxylate group of sialic acids (Alphey 
et al., 2003;Attrill et al., 2006b) (Attrill et al., 2006a). However, the specificity of 
each member for different ligands also depends on the underlying glycan 
linkages. While Siglec-7 has greater preference for disialic acids in α 2,8 
linkages, CD22 prefers sialic acids linked to a galactose by α 2,6 linkage.  
One of the characteristic features of this family is that most of the members 
interact with sialylated ligands on the same cell (“cis” interactions) and is 
28	
	
therefore masked from binding ligands in trans (figure 1.7). This has been 
attributed to the high concentration of sialic acid containing ligands on the same 
cells. This phenomenon was first identified for CD33 (Freeman et al., 1995) and  
CD22 (Razi and Varki, 1998) but then found to be characteristic for most of the 
members of the Siglec family except for Sialoadhesin (Razi and Varki, 1998). 
These low affinity cis interactions can be abolished by removing cell surface 
sialic acids either enzymatically by sialidase, chemically by periodate or in some 
cases by cellular activation, thereby “unmasking” the sialic acid binding site 
(Collins et al., 2004) (Razi and Varki, 1999). The cis-interactions however do 
not necessarily stop these lectins from interacting with multivalents ligand based 
probes or high affinity ligands expressed in trans or on adjacent cells. The 
classical example for this is the B cell receptor, CD22, which has been studied 
extensively. CD22 has been shown to be able to bind to sialylated ligands 
expressed in trans without the need for prior unmasking (Paulson, Macauley 
and Kawasaki, 2012)  
 
 
 
 
 
 
 
 
Figure 1.7 – Masked and unmasked state of Siglec receptors on cellular surfaces – (A) 
Low affinity cis-ligands mask the receptor binding site of Siglec receptors. Upon either 
sialidase treatment or cellular activation, the sialic acid binding site of the receptor is 
unmasked. (B) Presentation of high affinity ligands in trans also unmasks the receptor 
and facilitates ligand interactions 
  Masked Siglec      Unmasked 
Trans presentation of 
high affinity ligands
 Sialidase  
treatment  
 
Endogenous 
low affinity 
ligands  
BA
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The functional role of these lectins has been broadly described as sensing 
“self”, by the recognition of sialic acids. This is similar to role of inhibitory KIR in 
recognizing MHC expression.  Recent investigation of these receptors has 
shown that they also play important roles in regulating the immune system. 
Table 1.2 details some of the known functions of these receptors. The presence 
of the conserved internalization motif, YXXφ, has endowed some of the 
members of this family with endocytic capabilities (discussed in chapter 5).  
CD22, expressed on B cells, is one of the most well studied member of the 
siglec family especially with regards to its role in B cell receptor (BCR) 
activation (Poe and Tedder, 2012). Mice B-cells deficient in both CD22 and 
Siglec-G (mouse ortholouge of Siglec-10, with restricted expression on B-cells) 
showed classic signs of hyperactivation upon BCR ligation, which underscored 
their role as negative regulators of BCR (Jellusova et al., 2010;Kawasaki, 
Rademacher and Paulson, 2011;O'Keefe et al., 1996). CD22 and BCR are 
present in two distinct membrane domains and different models have been 
proposed to explain how CD22 is able to regulate BCR signalling. The most 
probable model was proposed by Lanoue et al., whose group used the over-
expression of α 2,6-linked sialyl transferase (αST6GalI) to generate CD22 
ligands on membrane immobilized hen egg lysozyme (HEL) cells. They showed 
that the expression of CD22 ligand in trans on HEL cells resulted in the 
dampening of the activation of B-cells (HEL specific) compared to cells, which 
lacked in the expression of CD22 ligands. The presence of trans ligands 
resulted in the redistribution of CD22 to the site of cell-cell contacts and co-
localization with BCR (Lanoue et al., 2002) (Collins et al., 2004).  
Mouse models have been useful in providing information about the functions of 
siglecs invivo and in regulating the innate and adaptive immune systems in 
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infections. Sialoadhesin expressed on macrophages have been shown to 
facilitate clearance of sialylated pathogens such as Camplyobacter jejuni and 
stimulate proinflammatory responses (Klaas et al., 2012). Siglec-E, expressed 
on mouse neutrophils, was shown to negatively regulate TLR responses (Boyd 
et al., 2009) and suppress early neutrophil recruitment in an LPS model of 
acute lung inflammation (McMillan et al., 2013). The mouse B cell siglec, Siglec-
G, has been implicated in preventing sepsis in mice on the one hand and 
negatively regulating RIG-I signaling during viral infection (Chen et al., 
2011;Chen et al., 2013). Recruitment of eosinophils, bought about by parasitic 
inflammation, is negatively regulated by Siglec-F, expressed on these cells (Kim 
et al., 2013).  
 
Table 1.2: Expression and some functions of the known human members of the siglec 
family. Adapted from (Cao and Crocker, 2011)(Varki and Angata, 2006) 
Receptor Cellular expression Functions 
Siglec-1 
(Sialoadhesin) 
Macrophages Phagocytosis of sialylated pathogens, production 
of pro-inflammatory cytokines (Klaaset al., 2012);  
Regulation of autoimmunity via suppression of 
regulatory T cells (Wu et al., 2009) 
Siglec-2 
(CD22) 
B cells Regulation of BCR signaling (Muller et al., 2013) ; 
and B cell self tolerance to TI-2 antigens (Poe and 
Tender, 2012) 
Siglec-3 Myeloid progenitors, 
monocytes 
Inhibition of Ca2+, cell growth and apoptosis, 
clearance of amyloid protein by microglia (role in 
pathophysiology of Alzheimer’s disease) 
(Malpass, 2013) 
Siglec-5 Neutrophils, B cells Increased respiratory burst in neutrophils; down 
regulation of phagocytic functions in group B 
streptococcal infections (Carlin et al., 2009a) 
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Siglec-6 Trophoblasts, B cells Suppressing invasiveness of trophoblasts (Lam et 
al., 2011); immunomodulation of B cells in HIV 
(Kardava et al., 2011) 
Siglec-7 NK cells, monocytes 
and subsets of CD8+T 
cells 
Inhibition of cytotoxicity (Nicollet al., 2003) and T 
cell signaling (Ikehara, Ikehara and Paulson, 
2004); role in pathophysiology of guillain barre 
syndrome (GBS) (Heikema et al., 2013) 
Siglec-9 Neutrophils, monocytes 
and conventional DC 
Suppresion of monocyte and neutrophil activation 
(Carlin et al., 2009b;Ohta et al., 2010); 
Downregulation of TLR-mediated proinfammatory 
cytokines following LPS stimulation (Ando et al., 
2008) 
Siglec-8 Eosinophils , basophils Induction of apoptosis 
Siglec-10 NK-like cells, B cells, 
monocytes and 
eosinophils 
Decrease tissue inflammation in case of tissue 
damage; mediate lymphocyte adhesion (Kivi et 
al., 2009) 
Siglec-11 Macrophages (microglial 
cells) 
Inhibition of production of proinflammatory 
mediators and phagocytosis 
Siglec-16 Macrophages 
Siglec-14 Neutrophils and 
monocytes 
Upregulates inflammatory responses in chronic 
obstructive pulmonary disease (Angata et al., 
2006;Angata et al., 2013) (Yamanaka et al., 2009)
Siglec-15 Macrophages and 
dendritic cells 
Development of functional osteoclasts (Ishida-
Kitagawa et al., 2012) 
 
1.6 Gangliosides and tumour associated carbohydrate antigens 
Since the main aim of this thesis was to investigate the role of gangliosides in 
modulating Siglec-7 functions on NK cells, some general background 
information on these molecules as well as their pathophysiological role in 
tumorigenesis will be detailed in the sections below.  
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1.6.1 Gangliosides and biosynthetic pathways 
Gangliosides belong to a class of glycosphingolipids, abundantly expressed on 
the cell membrane, especially in the nervous system. They are a very diverse 
family of biomolecules, characterized by one or more sialic residues linked to 
hydrophobic ceramide moiety. While the ceramide moiety is embedded into the 
plasma membrane, the hydrophilic sugar head group extends out into the 
extracellular medium (Sonnino et al., 2007). Gangliosides nomenclature is 
based on the Svennerholm classification for eg., GM1, GD3, GT1a etc. Here the 
G stands for gangliosides, the second letter (M, D and T) stands for 1,2 or 3 
sialic acids respectively and the number (1,2,3) depends on the order of their 
migration on thin-layer chromatography (Essentials of glycobiology, chapter 
10)(Yu et al., 2011). They are divided into 4 classes according to the number of 
sialic acids attached to the lactosylceramide (shown in figure 1.8) as 0, a, b and 
c series (Kolter, 2012). Ganglioside expression changes during the process of 
development. Gangliosides of the “0” and “a” series are expressed on all 
vertebrate cells. Those of the “b” and “c” series are particularly abundant in the 
cells of the central nervous system and is critical for normal brain development 
(Hakomori, 2003). Complex gangliosides are also over-expressed in tumours of 
neuroectodermal origin such as melanoma, glioblastoma and neruoblastoma 
and their role in promoting tumorigenesis will be discussed in section 1.6.2 
(Birkle et al., 2003). The ganglioside biosynthetic pathway begins with the 
formation of lactosyl ceramide (LacCer), which is a glucose and galactose 
residue attached to the ceramide backbone, via β-linkages (Figure 1.8). Then 
the simplest of gangliosides, GM3, is formed by the enzymatic addition of a 
sialic acid on to LacCer. The remaining gangliosides are formed by sequential 
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addition of sialic acid, N-acetylgalactosamine (GalNAc), galactose residues to 
GM3 from nucleotide sugar donors, by a group of enzymes known collectively 
as glycosyltransferases (sialyltransferases will be discussed in chapter 3). The 
synthesis of ceramide and glucosylceramide takes place on the cytoplasmic 
face of the endoplasmic reticulum (ER) and then turns towards the Golgi lumen 
where it gets converted to more complex gangliosides. Following trafficking 
through the Golgi, the final ganglioside product gets incorporated into the cell 
membrane with the hydrophilic sugar head group extending into the 
extracellular milieu (Rinaldi, Brennan and Willison, 2010a). 
 
Figure 1.8: Biosynthetic pathway of ganglioside: Beginning with LacCer, the sequential 
addition of sialic acid, galactose and galnac residues results in the formation of higher 
and complex gangliosides. The different glycosyltransferases are written out in black 
and italics and the gangliosides in red.  
 
Along with cholesterol and sphingomyelin, gangliosides are present on the cell 
membranes in distinct domains known as “lipid rafts”. The presence of lipid 
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rafts, their organization and isolation has been much debated due to inherent 
difficulties in isolating and visualizing them (Brown and London, 2000), (Calder 
and Yaqoob, 2007). The current definition is that rafts are dynamic, ordered, 
nanoscale, lipid enriched assemblies of proteins which can coalesce by 
interactions between lipids and proteins (Simons and Sampaio, 2011). The 
presence of saturated fatty acids in the cholesterol and sphingomyelin 
components of the rafts favours tight packing of the lipid molecules within these 
microdomains. Proteins associated with lipid rafts such as receptor and non-
receptor tyrosine kinases, integrins and G-protein coupled receptors undergo 
modifications such as palmitoylation and myristoylation (Kraft, 2013). Lateral 
interactions between the various components of rafts allows formation of larger 
platforms capable of taking part in various biological process such a trafficking, 
endocytosis, signaling and biosynthesis (Sonnino and Prinetti, 2013).  
Being expressed on the plasma membrane and present on lipid microdomians  
gangliosides have important functional roles for example cell-cell interactions, 
adhesion, proliferation and receptor signaling (Lopez and Schnaar, 2009) 
(Milani et al., 2010;Wang, Sun and Paller, 2002).  The regulation of different 
growth factors receptors by gangliosides is well studied. GM3 was found to 
interact directly with epidermal growth factor receptor and inhibit its 
autophosphorylation (Miljan et al., 2002) while GM1 has been shown to 
associate with the neural growth factor tyrosine kinase receptor, Trk, and induce 
its phosphorylation in the PC12 cell line (Mutoh et al., 1995).  
The role of gangliosides also expands to pathophysiological conditions such as 
inflammations (Ohmi et al., 2011), altering immune responses (Monteiro de 
Castro et al., 2004), autoimmunity (Kaida et al., 2004) and tumorigenesis  
(explained in section below ). 
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1.6.2 Carbohydrates modulate tumor responses 
Glycosylation is important for obtaining functional protein and lipid molecules 
that are components of cell membranes. However, tumour transformation of 
cells results in changes of the glycosylation pattern of proteins and lipids. Such 
changes can be a result of altered/neo expression, incomplete synthesis, over-
expression, transcriptional changes and loss of expression. These changes 
confer the tumour cells with certain advantages such as increased growth and 
proliferation, metastasis and even immune evasion mechanisms.  
Complex gangliosides are overexpressed in many tumours and are usually 
oncogenic markers for tumour progression. For example - melanomas have 
over-expression of GD3, neuroblastomas of GD2 and GD3, renal cell carcinoma 
of GM1, GD1a, GD2 and breast cancers of GD3, 9-o-acetyl GD3/GT3 (Cazet et 
al., 2010) (Furukawa et al., 2012). Numerous reports have shown that the 
overexpression of these gangliosides helps tumour cells maintain and expand 
their tumorigenic properties such as adhesion, proliferation, migration, 
vascularization and invasion (Birkleet al., 2003). Depletion of GD2 from a 
neuroblastoma cell line reduced its adhesion to collagen, in a reversible 
manner, favoring metastasis (Kazarian et al., 2003). The sialyltransferase, GD3 
synthase, which is responsible for the formation of the “b” and “c” series 
complex gangliosides has increased expression in high grade and estrogen 
receptor (ER) negative breast cancers (Ruckhaberle et al., 2009). Delannoy and 
group went to dissect the role of GD3 in breast cancer progression by using an 
ER negative breast cancer cell line, MD-MBA-231. This cell line, transfected 
with GD3 synthase, showed increased proliferation when cultured in the 
absence of serum, suggesting non-dependence on growth factors (Cazet et al., 
2012;Cazet et al., 2009). GD3 has also been found to enhance the proliferation 
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and invasion of GD3 expressing melanoma cell line (Hamamura et al., 2008). 
Furukawa and group have investigated the mechanism underlying this 
phenotype and found increased phosphorylation of focal adhesion kinases 
(FAK), p130Cas and paxillin in cells expressing GD3. They further went on to 
show that there was enhanced activation of integrin signaling in GD3 
expressing cells, in the presence of serum. Exposure of GD3 expressing cells to 
collagen resulted in the clustering of integrins in lipid rafts along with GD3 and 
FAK with subsequent upregulation of both integrin linked kinase (ILK) and Akt 
phosphorylation (Ohkawa et al., 2010). Src kinase family (SFK) member, Yes, 
was also shown to be regulated by GD3 in this model system, impacting on the 
tumour phenotype (Hamamura et al., 2011). These examples are suggestive of 
the importance of GD3 in tumour progression. The anti-GD3 antibody, R24, is 
therefore a promising candidate for antibody based cancer therapy (Torres 
Demichelis et al., 2013). 
Tumour associated gangliosides can also impact on immune responses. 
Surface expressed gangliosides as well as gangliosides shed from tumours 
have been shown to affect T-cell antigen presentation, proliferation and 
cytotoxic responses(Biswas et al., 2009). Gangliosides from renal cell 
carcinoma cell line were shown to induce activation induced cell death (AICD) 
of activated T-cells and this was correlated with increased cytochrome-c release 
and decreased expression of anti-apoptotic factors, Bcl-2 and Bcl-xL (Kudo et 
al., 2003). 
Other tumour associated carbohydrate antigens (TACAs) are also known to be 
important in tumorigenesis. For example, the blood group related Lewis 
antigens (LewisX, LewisY, Sialyl-LewisX), the carbohydrate structures present in 
mucins such as Tn antigen, Sialyl Tn, carcino embryonic antigen (CAE) and N-
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linked glycans (Adamczyk, Tharmalingam and Rudd, 2012). The enzyme, GnT-
V (N-acetyglucosaminyltransferase), is responsible for the synthesis of GlcNAc 
β1,6 Man (mannose) structure as part of the processing of N-linked glycans. 
Over-expression of this enzyme in human fibrosarcoma cell line showed 
increased N-linked glycosylation of α5β1 integrin resulting in a phenotype 
characterized by decreased adhesion and spreading but increased migration 
and invasiveness (Guo et al., 2002). Another tumour marker commonly 
associated with certain tumours is Sialyl-LeX and Sialyl-LeA. These 
tetrasacharide carbohydrate epitopes are ligands for selectins and their over-
expression as well as incomplete synthesis has been co-related with the 
increased metastatic potential of colonic tumour cell lines as well as clinical 
progression of tumours (Izawa et al., 2000). The disialylated Sialyl-LeA is 
expressed on non-malignant colonic epithelial cells and has been shown to be a 
counter-receptor for Siglec-7 (Miyazaki et al., 2012). This group reported that 
the expression of the disialylated Sialyl-LeA is decreased in malignant cells. 
Using human colon cancer cell line, which expresses only the mono-sialylated 
Sialyl-LeA, they showed that genetic manipulation of this cell line resulted in the 
expression of the disialylated Sialyl-LeA, decreased binding to E-selectin and 
increased binding to Siglec-7. Decreased expression of the enzyme 
ST6GalNAc6, which is responsible for the addition of sialic acid in 2,6 linkage to 
Sialyl-LeA, was shown to be responsible for the incomplete transformation of 
Sialyl-LeA to Disialyl-LeA (Miyazaki et al., 2004).  
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1.6.3 Ganglioside complexes  
Gangliosides have been known to be present on cellular surfaces in cryptic 
states (Nakakuma et al., 1992). Recent research has shown that gangliosides 
involve in either homo or hetero interactions with each other on cellular surfaces 
and modulate antibody recognition. This was first brought to light when sera of 
patients affected with Guillian Barrè syndrome revealed antibodies that 
recognized complexes of GD1a/GD1b gangliosides and not the individual 
components (Kaidaet al., 2004).  This phenomenon has been investigated 
recently. Using a novel method of combinatorial glycan array, different 
combinations of gangliosides were plated in a grid fashion on PVDF 
membranes in order to study the modulation of binding by lectins (Siglec-7, E 
and F), antibodies (anti-GM3) and toxins (tetanus toxin (TeNT Hc))(Rinaldi et 
al., 2009;Rinaldi, Brennan and Willison, 2010b). These experiments revealed 
different patterns of lectin recognition of the ganglioside complexes which were 
termed as complex enhanced, attenuated or independent. In the case of Siglec-
7, the recognition of the disialylated GD3 was significantly reduced in the 
presence of complex gangliosides such as GM1, GM2, GD1a, GD1b and GT1a 
(Rinaldiet al., 2009;Rinaldi, Brennan and Willison, 2010b). A schematic 
representation of the array with modulation of Siglec-7 recognition of GD3 in 
complex with other gangliosides is shown in figure 1.9. This data implies that 
interactions between gangliosides on cellular surfaces could modulate lectin 
recognition and impact on functional responses. 
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  GM1 GM2 GM3 GD1a GD1b GD3 GT1a GT1b GQ1b
 x     
GM1  x    
GM2   x    
GM3    x   
GD1a    x   
GD1b    x   
GD3    x   
GT1a    x  
GT1b     x 
GQ1b      x
 
Figure 1.9: Schematic representation of the ganglioside PVDF array: Modulation of 
Siglec-7 recognition of GD3 when in complex with other gangliosides, as shown by 
Rinaldi et al., 2009. Strong recognition of GD3 is shown as black circle. Lighter shades of 
circles represent reduced recognition of GD3 (Adapted from Rinaldi et al., 2009).  
 
A biological interpretation of these findings would be that the presence of 
complex gangliosides such as GM1 on tumours with GD3 overexpression could 
negatively impact on Siglec-7 recognition of GD3 and favour tumour clearance 
by NK cells. However tumours such as melanomas and breast cancer tumours 
selectively overexpress GD3. This upregulation could be thought of as a 
possible immune evasion mechanism. “Switching off” of the expression of 
gangliosides such as GM1 and simultaneously enhancing the expression of 
GD3 in these tumours could strengthen recognition by the inhibitory NK 
receptor, Siglec-7 and greatly facilitate tumour cell escape from NK cell lysis.  
The above observations formed the basis of this project which was to analyse 
the role of glycans in modulating NK cell tumour cell recognition via the 
inhibitory receptor, Siglec-7.  
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1.7 Aims of thesis  
The broad aim of this project was to understand the role of Siglec-7 in NK cell 
biology. Earlier work has shown that this receptor negatively affects NK cell 
functions, in particular cytotoxicity. However the mechanisms involved and the 
factors affecting ligand recognition have not been examined.  
Therefore, the more specific aims of this project were as follows: 
1. Role of GD3 in modulating Siglec-7 recognition:  As discussed above, 
gangliosides such as GD3 are overexpressed on tumours.  Therefore, it is of 
significance to understand how ganglioside expression modulates inhibitory 
receptor functions and overall NK cell immune responses in tumour clearance.  
2. Role of ganglioside complexes in affecting NK cell recognition:  Preliminary 
data (discussed in chapter 3) suggested that complexes of GD3 with structurally 
more complex gangliosides, for eg., GM1, inhibited Siglec-7 recognition of GD3. 
An attempt was made to investigate this finding in a biological setting and 
possible relevance to tumour immunosurveillance by NK cells.  
3. Modulation of integrin function by Siglec-7: Based on the recent finding that 
Siglec-E negatively regulates integrin signalling (discussed in chapter 4) and 
the fact that integrin signalling is affected in tumour cells, it was thought to be of 
considerable interest to study integrin regulation by Siglec-7 in the context of 
NK cell biology.  
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Chapter 2   
Materials and methods 
          
2.1 Reagents 
Gangliosides – Monosialoganglioside GM1, Sigma(G7641); Disialoganglioside 
GD3, Sigma (43683); Dicetylphosphate , Sigma (D2631);  Sphingomyelin, 
Sigma (S7004); Cholesterol, Sigma (C8667); SYBR green, Applied Biosystems 
(4039155); 3,3’,5,5-Tetramethylbenzidine (TMB) substrate reagent, BD OptEia 
(555214), Albumin, from bovine serum (BSA), Sigma (A2153). Protein A 
Sepharose 4B, Fastflow, Sigma (P9424) ;TransIT-LTI reagent, Mirus (2300); 
Carbonate-Bicarbonate buffer, Sigma (C3041); BD OptEIA TMB substrate, BD 
biosciences (555214); 0.1% Poly-L-Lysine, Sigma (P8920); Paraformaldehyde, 
Sigma (158127); Triton-X-100, Fisher (BP151-100); Vectashield, Vector labs(H-
1200); HindIII, NEB (R0104S); Xbal, NEB (R0145S); Rapid Alkaline    
Phosphatase, Roche (04 898 133 001); T4 ligase, Roche (10 481 220 001); 
Agarose; Protein A , Merk (539202); Neuraminidase (sialidase) from Vibrio 
Cholerae, Sigma (N7885); β-mercaptoethanol, Sigma (63689); Protease 
inhibitor cocktail tablets, Roche (11836170001), 0.5M EDTA 
(Ethylenediaminetetraacetic acid), Gibco (15575-020); Poly-L-Lysine (PLL) – 
Sigma (8920); Ficoll-paque, GE (17-1440-02). 
 Dubelco’s Minimal Essential Media (DMEM), Invitrogen (41966). ; RPMI 1640, 
Invitrogen (11875-093); Ham’s F12 Nutrient Media, Invitrogen (21765-029); 
Glasgow’s Modified Eagles Medium (SAFC – 51492C); Ultra-CHO media, 
Lonza (12724Q) ; Fetal Calf Serum (FCS), PAA (A15-649); Trypsin-EDTA 
(0.05%), Invitrogen (25300-054) ; Penicillin-Streptomycin (Pen-strep), Invitrogen 
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(15070-063 ); L-MSX, Sigma (M5379); GSEM supplement, Sigma (G9785); 
Dimethyl Sulfoxide (DMSO), Sigma (D2560); Interleukin-2 (IL2) , Peprotech 
(200-02); G418S, Formedium, Hygromycin, Roche (10843555001), Streptavidin 
Microbeads (Miltenyi, 130-048-101); Ultrapure 0.5M EDTA, Invitrogen (15575-
020); PP2 kinase inhibitor, Sigma (P0042); Phorbol 12,13-dibutyrate (PDBU), 
Sigma(P1269) 
 
2.2 Primary and secondary antibodies 
Primary and secondary antibodies used to detect antigens in flow cytometric, 
western blots, dot blot and (enzyme linked immunosorbent assay) ELISA 
analysis are listed in the table 2.1 and 2.2 respectively 
Table 2.1: List of primary antibodies used  
Antibody 
(Clone) 
Antigen 
Host 
species/nature/class 
Working 
concentration 
Source/product 
code 
R24 (2.5 
mg/ml) 
Anti-GD3 
Mouse/Monoclonal/IgG3 
 
5 µg/ml 
 
PRC LAB 
 
Anti-ICAM-1 
(HA58) 
ICAM-1 Mouse/Monoclonal/IgG1κ 0.5 µg/ml 
 
Ebiosciences 
  (13-0549-80) 
 
7.7a Siglec-7 Mouse/Monoclonal 1/5 dilution PRC LAB 
HI111 CD11a Mouse/Monoclonal/IgG1κ 10µl/ml 
Ebiosciences 
(11-0119) 
GAPDH 
(14C10) 
Carboxy 
terminus of 
human GAPDH 
Rabbit/Monoclonal/ IgG 1:1000 dilution   
Cell signalling 
(#2118) 
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Akt 
Carboxy 
terminal 
sequence of 
mouse Akt 
Rabbit/Polyclonal/IgG 1:1000 dilution   
Cell Signalling 
(#9272) 
 
Phospho-Akt 
Serine Rabbit/Polyclonal/ IgG 1:1000 dilution  
Cell Signalling 
(#9271) 
 
Phospho-Akt 
Threonine Rabbit/Polyclonal/ IgG 1:1000 dilution   
Cell Signalling 
(#9275) 
Syk 
N-terminus of 
human Syk (N-
19) 
Rabbit/Polyclonal/IgG 200 ng/ml 
Santa Cruz 
(#sc-1077) 
 
Phospho-Syk 
Tyr525/526 of 
human Syk 
Rabbit/Polyclonal/ IgG 1:1000 dilution  
Cell Signalling 
(#2711) 
Phospho-Syk 
Tyr323 of 
human Syk 
Rabbit/Polyclonal/IgG 1:1000 dilution 
Cell Signalling 
(#2715) 
Src (clone 
32G6) 
GST-Src fusion 
protein (residues 
1-110 of human 
Src) 
Rabbit/Monoclonal/IgG 1:1000 dilution  
Cell Signalling 
(#2123) 
Phospho-Src 
(D49G4) 
 
Try 416 of 
human Src 
Rabbit/Monoclonal/ IgG 1:1000 dilution 
Cell Signalling 
(#6943) 
Phospho-p38 
MAPK 
Thr180/Tyr182 
of human p38 
MAPK 
Rabbit/Polyclonal/ IgG 1:1000 dilution 
Cell Signalling 
(#9211) 
p44/42 MAPK 
(3A7) 
Total p44/p42 
MAP Kinase 
(Erk1/2) 
Mouse/Monoclonal/IgG1 1:1000 dilution 
Cell Signalling 
(#9107) 
Phospho-
p44/42 MAPK 
(ERK1/2) 
(clone E10) 
Thr202/Tyr204 
of human 
p44/42 MAPK 
Mouse/Monoclonal/ IgG1 1:1000 dilution 
Cell Signalling 
(#9106) 
p38 MAPK 
Total human 
p38 MAPK 
Rabbit/Polyclonal/ 1:1000 dilution 
Cell Signalling 
(#9212) 
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Phospho-p38 
MAPK 
 
 
 
Thr180/Tyr182 
of human p38 
MAPK 
 
Rabbit/Monoclonal/IgG 
 
1:1000 dilution  
 
Cell Signalling 
(#9215) 
 
P13K p85 
Human P13 
kinase p85 
Rabbit/Polyclonal 1:1000 dilution  
Cell Signalling 
(#4292) 
∆G9 
Anti-human 
Perforin 
Mouse/Monoclonal//IgG2bκ 
(FITC) 
5µg/ml 
Ebiosciences 
(119994) 
TBST – 1XTBS (0.1% Tween-20) 
 
Table 2.2: List of secondary and isotype control antibodies  
Antibody 
Host species Working 
Concentration 
Supplier 
Anti-human HRP Goat 1 µg/ml Sigma (A0170) 
Anti-rabbit-HRP Goat 1.3 µg/ml Sigma (A0545) 
Anti-mouse-HRP Rabbit 2 µg/ml      Sigma (A9044) 
Streptavidin-PE 
 
1 µg/ml 
       Ebiosciences 
(12-4317) 
 
F(ab')2 Anti-Mouse IgG 
PE 
 
Goat 1 µg/ml 
Ebiosciences 
(12-4010) 
Streptavidin-APC 
 
0.67 µg/ml 
Ebiosciences 
(17-4317) 
Anti-mouse IgG 
FITC 
 
Rat 
2.5 ug/ml 
E-biosciences  
(11-4011) 
Streptavidin  
HiLyte Fluor 555 
 
2 µg/ml 
Anaspec 
(#60666) 
HRP – Horse radish peroxidase; PE – R-Phycoerythrin; APC - Allophycocyanin 
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2.3 Molecular biology techniques 
Molecular biology techniques were used to clone different constructs into 
plasmid vectors for expression analysis.  
 
2.3.1 Vectors  
pcDNA 3.1(+) is a commonly used mammalian expression vector, carrying a 
CMV promoter and ampicillin resistance gene. This vector can carry either a 
neomycin or a hygromycin resistance. In this project, genes for expression of 
GD3 synthase, ST6Gal1 and ICAM-1 were cloned into this vector carrying 
hygromycin resistance.  
pCB6 – GD2 synthase was cloned into the pCB6 vector with neomycin 
resistance. This construct was kindly provided by Prof. Hugh Willison 
(University of Glasgow). 
pCDM8 vector – This expression vector, carrying the CMV promoter, is used for 
high-level transient expression of cloned cDNA in mammalian cells expressing 
the large T antigen. Human ICAM-Fc, previously cloned into this vector (PRC 
lab), was re-transformed into MC10616/P3 E.coli strain (Invitrogen), sequenced 
and then used for either transient or stable transfection of CHO cells.  
 
2.3.2 Extraction of messenger RNA  
Qaigen RNeasy Mini Kit was used to extract total RNA from cell lines. All steps 
were carried out at room temperature. 5 -10 X 10E6 cells were harvested and 
centrifuged for 5 minutes at 300 x g and supernatant carefully removed. In case 
of tissues, a small sample of tissue (frozen in liquid nitrogen) was used. 600 µl 
of lysis buffer (Buffer RLT supplemented with 1% beta mercaptoethanol) was 
added to the cell pellet and pipetted well. This lysate was then transferred into 
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QIAshredder spin columns and homogenized for 20 seconds. 600µl of RNAase 
free 70% ethanol was then added to the homogenized lysate and mixed well by 
pipetting up and down. 700 µl of this lysate was then moved into an RNeasy 
spin column (placed in a 2 ml collection tube) and centrifuged for 15 seconds at 
10,000 rpm. After discarding flow through, 700 µl of Buffer RW1 was added to 
the column and centrifuged at 10,000 rpm for 15 seconds. Then, 500 µl of 
Buffer RPE was added to the column and centrifuged again at 10,000 rpm for 
15 seconds. This step was repeated once more to complete washing the spin 
column membrane. Finally the column was placed in a new 1.5 ml collection 
tube and 30-50 µl of RNase-free water was added directly to the centre of the 
column membrane and centrifuged for 1 minute at 10, 000 rpm to elute the 
RNA. 2µl of the eluted RNA was used to measure concentration using the 
Nanodrop 1000, aliquoted and stored at -800C. 
 
2.3.3 Reverse Transcription of RNA to cDNA 
Qiagen QuantiTect Reverse Transcription kit (QAIGEN) was used to reverse 
transcribe messenger RNA extracted from cells into cDNA for use in 
downstream cloning and quantitative real-time polymerase chain reaction (PCR) 
analysis. genomic DNA Wipeout Buffer, Quantiscript Reverse Transcriptase 
(QRT), RT primer mix, and RNase-free water were thawed at room temperature 
whilst the template RNA was thawed on ice. The protocol was divided into two 
steps – 1) eliminating genomic DNA and 2) converting mRNA to cDNA. The 
following reactions were set up.  
4 µl of gDNA Wipeout Buffer (7x), template RNA (upto 1µg) and RNAase free 
water to a total volume of 28µl were mixed together. This mix was then 
incubated for 2 minutes at 420C and then immediately placed on ice and 
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transferred to a tube containing 12µl of Reverse-transcription reaction 
components (2 µl of QRT, 8µl of QRTB (5x) and 2µl of primer mix). After mixing 
all components in the tube well, the mix was incubated at 420C for 15 minutes 
and finally 3 minutes at 950C to inactivate the enzyme. cDNA was then 
aliquoted and stored at -200C. 
 
2.3.4 PCR amplification of cDNA  
KOD Hot start DNA polymerase (Novagen) was used to amplify prepared cDNA 
using primers carrying restriction enzyme sequences which would enable 
cloning of the amplified DNA into respective plasmid vectors. 50µl of the 
following mix was prepared for each PCR amplification - 10x Buffer KOD Hot 
Start DNA polymerase – 5µl; 25mM MgSO4 – 5 µl; dNTPs (2 mM) – 5 µl; PCR 
grade water; 1 µl of sense primer (10 µM); 1 µl of anti-sense primer (10 µM); 1 
µl of template DNA; 1 µl of KOD Hot Start DNA polymerase and 5 µl of DMSO.  
The following cycling conditions were used to carry out the PCR reaction – 
Polymerase activation – 950C for 2 min; Denature – 950C for 20 seconds; 
Anneal – Lowest primer Tm0C for 10 seconds; Extension – 700C (1 minute per 
Kb) and total number of cycles – 20-30.  
 
2.3.5 Agarose electrophoresis 
100 ml of 0.8-1% agarose gels were prepared using agarose added to 100ml of 
1xTAE buffer and then bought to boiling temperature in the microwave. The 
solution was then cooled, 5µl of Ethidium Bromide (stock @100 mg/ml) was 
added to the solution prior to pouring it out onto prepared electrophoresis trays.  
Once set, gels were transferred to electrophoresis tanks carrying 1xTAE buffer, 
combs removed and DNA samples (mixed with 6x loading dye) loaded onto 
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wells. Gels were then run at 100V for 40 – 60 minutes and DNA analysed using 
a UV transilluminator. Pictures were taken using an LCD camera.  
 
2.3.6 Gel extraction of DNA and purification  
Following agarose electrophoresis to resolve DNA samples, the DNA band at 
the right molecular weight was extracted from the gel using the QIAquick gel 
extraction kit. 100% ethanol was added to the Buffer PE prior to the purification 
protocol and all centrifugation steps were carried out at room temperature at 
13000 rpm. The DNA band was sliced from the gel under UV light. 3 volumes of 
Buffer QG was added to the gel (100µl for 100mg of gel) and incubated at 500C 
until the gel slice had completely dissolved, with occasional vortexing. The 
sample was then applied to a QIAquick spin column and centrifuged for 1 
minute. The column was then washed using 750 µl of Buffer PE and centrifuged 
for 1 minute. The flow through was discarded and the column spun again for 1 
minute to remove residual Buffer PE. The spin column was then placed in a 
clean 1.5 ml microfuge tube and DNA eluted using 50µl of water (RNAase-free). 
 
2.3.7 Measuring concentration of DNA/ RNA/purified protein  
The concentration of DNA/ RNA/purified protein was measured using the 
Nanodrop 1000. 2 µl of buffer TE (pH 8.0)/water/sample buffer was used to 
calibrate the instrument. 1.5 - 2µl of sample was then measured at absorbance 
260 and 280 nm. DNA samples with an absorbance ratio (A260/A280) of 1.8 – 
2.0 were used for downstream cloning and transfection of cell lines.  
 
2.3.8 Restriction enzyme digestion  
In this project, several DNA constructs were cloned into plasmid vectors for the 
purpose of cell transfections. The cloning process involved the use of different 
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restriction digest enzymes for DNA and vector backbone digestions, 
dephophatase treatments and ligations. Enzyme digestions were done either 
simultaneously or sequentially. Table 2.3 lists the item used in the digest mix.  
Table 2.3 : Restriction digestion enzyme mix 
DNA X ( 2 µg for insert and 1 µg for 
vector backbone)  
BSA (X10) 5 µl 
NE Buffer (x10) 5 µl 
Enzyme 1 2 µl 
Enzyme 2  2 µl  
H20 upto 50 µl  
 
The digest mixture was left to incubate for 2 hours in a 370C water bath. At the 
end of the digest, 3µl of Rapid Alkaline Phosphatase buffer (10x) and 3 µl of 
phosphatase enzyme were added to the vector backbone digest mix and 
incubated for 15 minutes at 370C. The enzyme was inactivated by incubating 
the digest mix for 2 minutes at 750C. Following enzyme digestion, 6x loading 
dye was added to the mix and loaded on to wells of a 0.8-1% agarose gel and 
ran as described above.  
 
2.3.9 DNA ligations 
Ligation of enzyme digested vector backbone and insert DNA is set up 
according to the concentration and size of the insert. 100ng of the vector 
backbone is mixed with 3 or 5 times more of plasmid insert DNA, 1.5 µl of T4 
ligation buffer (Roche) and 1µl of T4 ligation enzyme and made upto 15 µl with 
water. The ligation reaction was left to incubate for 1 hour at room temperature.  
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2.3.10 Bacterial transformation of ligation reactions or plasmid DNA  
DH5α competent cells are used for the purpose of transforming plasmid DNA 
and ligation products into bacteria. 5µl of ligation mix (or 1 µl of purified plasmid 
DNA) was taken and added to 50 µl of thawed DH5α bacterial cells (DSTT, 
University of Dundee) and incubated on ice for 30 minutes. This mixture was 
then heat-shocked at 420C (in a water bath) for 45 seconds and incubated 
again on ice for 10 minutes. 200 µl of warm Super Optimal Broth (SOB or SOC) 
media was added to the cells and allowed to recover for one hour in an 370C, 
shaking incubator. 50 – 100 µl of the transfection mix was then plated on to LB 
agar plate (with suitable antibiotic selection) and left to incubate at 370C, 
overnight.  
 
2.3.11 Bacterial culture 
Single bacterial colony were then selected and put into 3ml of LB media and 
cultured overnight at 370C. Bacterial culture was then spun down at 3000 rpm 
for 5 minutes, supernatant removed and plasmid DNA extracted using Wizard® 
Plus SV Minipreps DNA Purification kit (Promega). 
For large scale DNA extraction, Qiagen Plasmid Prep Maxi kits were used. A 
single colony of transformed bacteria was grown in 10 ml of selection media, 
overnight at 370C. This culture was then used to inoculate 200ml of selection 
media and incubated at 370C for 16 hours. Culture was then spun down for 10 
minutes at 10,000 rpm and extraction of plasmid DNA carried out according to 
manufacturer’s instructions 
 
2.4 Cell culture techniques 
2.4.1 Culture conditions for cell lines used in this project 
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B16 (78) – This mouse melanoma cell line was kindly provided by Dr. Hugh 
Willison (University of Glasgow). This cell line is a subline derived from a 
melanoma clone (Cloudman S91) obtained from a male mouse of the DBA 
strain (Yasamura et al., 1966). Cells were cultured in completed DMEM +7.5% 
FCS + 1% Pen-Strep, at 370C in 5% CO2 in a tissue culture incubator. Cells 
grew as adherent culture and were split 1 in 5 dilution when 80-90% confluent. 
Cells were harvested with 2-3 ml of Trypsin/EDTA for purposes of splitting.  Cell 
stocks were frozen down in 10% DMSO in FCS. 
 
NK92 - This NK leukemic cell line of human origin was a kind gift by Dr. Eric 
Vivier (CIML, Marsille, France). The origin of this cell line was from malignant 
non-Hodgkin’s lymphoma of a 50 year old male Caucasian. Cells were cultured 
in completed RPMI 1640 media (10% FCS and 1% Pen-Strep) + 100 IU/ml IL2. 
Lyophilized IL2 was diluted in 100 mM acetic acid to 5 µg/ml and aliquots frozen 
and stored at -800C. Cells were maintained at 1-2 x 10E5 cells per ml and split 
every 3-4 days.  Cells grew in suspension as clusters of 8-10 cells at 370C in 
6% CO2 in tissue culture incubator. They were frozen the on the second day 
following a split in 10% DMSO in FCS. 
 
CHO cells – Chinese hamster ovary cells, were cultured in complete Ham’s F12 
nutrient media with 10% FCS and 0.1% Pen-Strep and grew at 370C in 5% CO2 
in a tissue culture incubator. Cells are adherent and were maintained by 
splitting them 1 in 5 dilution when 80-90% confluent. Cells were harvested with 
2-3ml of trypsin/EDTA for splitting.  
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MBA-MD-231 cells (A human breast cancer cell line) – This cell line originated 
from epithelial cells of an adenocarcinoma from a 51 year old caucassian 
female. Cells were cultured in completed DMEM +10% FCS + 1% Pen-Strep, at 
370C in 5% CO2  in a tissue culture incubator. Cells grew as adherent cultures 
and were split 1 in 5 dilution when 80-90% confluent. Cells were harvested with 
2-3 ml of Trypsin/EDTA for purposes of splitting.  Cell stocks were frozen down 
in 10%DMSO in FCS. 
 
K562 – This cell line originated from the bone marrow tissue of a chronic 
myelogenous leukemia patient. The K562 was cultured in complete RPMI 1640 
(10%FCS+1% PS). They grew in suspension and were split for culture by 
diluting out 1:10 in complete media. 
 
2.4.2 Cellular transfection methods 
Transfection of nucleic acid (DNA) into cell lines can be achieved by different 
methods. In this project different approaches were tested with different cell lines 
and conditions optimized for individual cell lines.   
 
1) Calcium transfection of B16 cells  
Cells were plated onto to 15cm dishes 18-24 hours prior to transfection. On the 
day of the transfection, the culture media was replaced with fresh media. 30 µg 
of DNA, 62 µl of 2M CaCl2 were made up to a final volume of 1.5 ml with water 
in a 15ml falcon tube and mixed well. Another tube containing 1.5 ml of 2xHBS 
was gently vortexed and prepared DNA solution was added dropwise while 
vortexing. This mixture was then incubated at room temperature for 30 minutes 
and then added on to the cells. Media was replaced 24 hours after transfection. 
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For stable transfections, the culture media of the cells was replaced with media 
containing selection after 48 hours of transfection.  
 
2) Nucleofection of NK92 cells 
Amaxa Cell Line Nucleofector Kit R (Lonza) was used to transfect NK92 cells 
with cDNA of interest. 5 x 10E6 NK92 cells, cultured at 0.2 X10E6 cells per ml, 
were spun down and resuspended in 100µl of transfection reagent mixture (82µl 
of Nucleofector solution and 18µl of supplement). 5 µg of DNA was added to 
cell suspension and transferred to cuvettes provided in the kit. Cells were then 
nucleofected using A-024 program on the nucleofector device and transferred 
to warm media with IL-2 in 6-well dish.  24 hours post-transfection, growth 
media was replaced with media containing selection (0.5 mg/ml G418). 
 
3) Transfection of cells using TransIT 
18-24 hours prior to transfection, 3 x 10E6 cells were plated out onto 10 cm 
dishes in about 15 ml of complete growth media. To 1.5 ml of Opti-MEMI 
Reduced Serum media, 15 µg of DNA and 45 µl of TransIT-LTI reagent were 
added and mixed gently. This mixture was incubated at room temperature for 
15-30 minutes and then evenly distributed on to cells. Cells were left to incubate 
for 24-78 hours and then analysed by flow cytometry for antigen expression.  
 
2.4.3 Enrichment of transfected cells 
The different methods that have been used in this project to enhance the 
percentage of transfected population of cells include FACS or MACS sorting to 
obtain a polyclonal population of high antigen expressers and limiting dilution to 
obtain a stably transfected single cell clone.  
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1) Fluorescence activated cell sorting (FACS) – This method involves the 
separation of transfected cells from the wild type population by antibody 
staining and isolation by flow cytometry. FACS was carried out by Flow 
Cytometry Services, College of Life Sciences, University of Dundee.  
Transfected cells were cultured in complete media with selection for 7 days. 
Around 20x10E6 cells, B16 (78) or NK92, were harvested, stained with 
biotinylated cholera toxin subunit B (1µg/ml)(Sigma – C9972), R24 antibody (5 
µg/ml) or anti-Siglec-7 antibody (clone 7.7a) respectively. Streptavidin – PE or 
Fab anti-mouse PE were used as secondary antibodies respectively. High 
expressers were analysed and collected using a flow cytometric sorter. This 
positive fraction of cells were then washed and put back into culture. Once 
semi-confluent, cells were analysed for antigen expression by FACS staining 
and aliquots frozen at 2x10E6 per ml in FCS + 10% DMSO.  
 
2) Magnetic Activated cell sorting (MACS) - This method involves the use of the 
magnetic streptavidin beads to select for transfected cells stained with 
biotinylated antibody, followed by using MACS sorter to enrich them.  
Around 10XE6 B16 cells transfected with ICAM-1, were harvested and 
resuspended in labeling buffer (1x PBS + 2mM EDTA + 0.5% FCS) stained with 
0.5 µg of biotinyated anti-ICAM antibody. Following the manufacturer’s protocol, 
cells were resuspended in 90µl of labelling buffer and then incubated with 10 µl 
of Streptavidin Microbeads for 15 minutes at 40C. Cells were washed in labeling 
buffer and resuspended in 500 µl of labelling buffer. Labelled cells were then 
passed throµlh prepared and primed automacs separator, using appropriate 
program. Enriched cells were collected, washed and put back into culture.  
55	
	
 
3) Single cell cloning - Single cell cloning was carried out by the limiting dilution 
method. Transfected cells were plated at 10 cells, 2 cells and 1 cell per well in 
96-well tissue culture U plates, in 200 µl of complete media. Half of the media 
was replaced every 3-4 days. Once confluent, 5-10 clones from the plate 
containing < 10% of expanding clones were transferred to a 6 well plate and 
cultured further in selection media. Clones were screened by flow cytometry 
and positive clones (>70% expression) were frozen down.   
 
2.4.4 Culturing of CHO cells for production of Siglec-7-Fc  
1 litre of GMEM culture media was prepared with 100 ml of dialysed and filter 
sterilized FCS, 10 ml of PenStrep, 20ml of sterile glutamine synthase 
supplement (GSEM)(x50 stock) and 1ml of L-methionine sulfoxinime (L-MSX) 
(200mM stock). Frozen stock of CHO cell clone, stably transfected with Siglec-
7-Fc, was thawed and put into culture with the above prepared media.  
Once cells were established in culture, media was changed for either complete 
GMEM media (with 0.5% FCS) or serum free UltraCHO media (with 1% 
PenStrep). When cells became 100% confluent, the supernatants were 
collected and centrifuged at 2000 rpm for 10 minutes to remove debris. Finally 
10mM sodium azide was added to the supernatant and stored either at 40C or 
1ml aliquots were snap frozen in liquid nitrogen.  
 
2.4.5 Culturing of CHO cells for production of ICAM-1-Fc and ST6GalI 
24 hours following transfection of CHO cells with vectors carrying ICAM-1-Fc or 
ST6GalI, cell culture media was replaced with media containing selection,  
either hygromycin (0.2 mg/ml) or G418S (0.5 mg/ml). In case of a double 
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transfection, cells were cultured in media containing both hygromycin and 
G418S. Cells were allowed to be in selection for one week. As control, wild type 
CHO cells were grown in selection for the same duration of time. Cells were 
counted and plated in 96 well flat TC plates at 10 cells per well, 2 cells per well 
and 1 cell per well with 200ul of complete media. 24 hours later, 100 ul of media 
was changed for 100ul of selection media. Clones were allowed to grow in 
selection media. Stable transfected CHO cells expressing ICAM-1-Fc and 
ICAM-1-Fc + ST6Gal1 were expanded in T175cm2 flask till 100% confluent. 
Cells were harvested and transferred to roller bottles in 250 ml of complete F12 
media (10% FCS) and kept rolling at 10 rpm at 370C. Cells were allowed to 
adhere and adapt to the new culture conditions for 2 days before the media was 
exchanged for F12 media + 0.5% FCS. Cells were maintained in these 
conditions for 1 week, media collected (harvest 1) and fresh F12 + 0.5% FCS 
were added to the roller bottles. This was repeated another 3-4 times till <50% 
of the cells started sloughing off the surface of the bottle before terminating the 
cultures. Each harvest was spun down at 10, 000 rpm for 10 minutes, 
supernatant passed through a 0.2 µm filter and stored at 40C with 2 mM sodium 
azide. 
 
 
2.5 Extraction of PBMC and culture of cells 
PBMCs were extracted using Ficoll-paque extraction method from healthy 
volunteers. 15-20 ml blood was taken from donors and mixed with 10% of 
sodium citrate. This mixture was centrifuged for 30 minutes at 1300 rpm, no 
brake. Buffy coat was gently removed, added to tubes containing PBS and 
washed at 1000 rpm for 10 minutes (x3). Cells were then resuspended in RPMI 
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media, counted and 1-2 x10E6 cells added to 6 well TC plate. IL-2 was added 
to the wells at 200 IU/ml. After 4 days in culture, activated cells were used in 
assays. 
 
2.6  ICAM-1-Fc protein purification  
2.6.1 Preparation of protein A / G column for purification 
The following buffers were prepared a day or two prior to purification process. 
pH of all buffers were adjusted with concentrated HCl. All buffers were then 
sterilized using 0.22 µM filters, degassed and chilled.  
Elution buffer - 0.1M Glycine pH 3  
Column stripping buffer - 0.1M Glycine pH 2.5  
Neutralization buffer - 1M Tris pH 8 (Tris base) 
Binding buffer - PBS with 0.02% Sodium Azide 
 2.6.2 Purification of ICAM-1-Fc 
Cell culture supernatant from roller bottle culture was collected and centifuged 
at 10,000 rpm for 20 minutes. Supernatant was then filtered using a 0.22 µM 
vacuum filter, 5mM sodium azide added and stored at 40C. A new protein G 
column was prepared by first rinsing a chromatography column (731-1550, 
Biorad) with MilliQ deionized water. The column was then half filled with binding 
buffer and any air bubbles from below the support disc were dislodged by gently 
tapping the column. The column was then emptied of any liquid and preventing 
any air bubble from entering. 20% ethanol from protein A sepharose 4B slurry 
was replaced with binding buffer. Resin slurry was swirled to obtain a 
homogenous suspension and added to column without introducing any air 
bubbles. Resin was then allowed to settle in the column for 30 minutes and 
topped up with 1-2 cm of binding buffer. Purification was carried out at 40C, 
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using chilled, degassed buffers. The column was then connected to the inlet 
cap and column was allowed to equilibrate with 10 column volume (CV) of 
binding buffer. Filtered and degassed cell culture supernatant was passed over 
the column at 0.2-0.8 ml min-1 and eluate collected in a new bottle.  
 
Column was then washed with 10 CV of binding buffer. 1-3 CV of elution buffer 
was passed throµlh the column and 1ml elutions were collected into microfuge 
tubes containing 100 µl of neutralization buffer and mixed well. Protein is 
expected to come off in 1-3 CV. Column was again washed with 10 CV of 
binding buffer.  
To store columns, it was first cleaned off residual protein by passing 10 CV of 
stripping buffer followed by 10 CV of binding buffer. Column was then washed 
in 10 CV of 20% ethanol and sealed and stored at 40C  
Protein concentration of the eluate was checked using Nanodrop 1000 
readings. Positive fractions were then serially concentrated and buffer 
exchanged (>95%) with binding buffer using Vivaspin concentrators (10,000 
rpm molecular weight cut off) (spun at 4000 rpm, 10 minutes). 
                 
 
 
2.7 ELISA for testing Fc chimera 
96 well Immulon 4BX plates were coated with 1/200 dilution of Anti-human IgG 
(Fc specific) (Sigma, 12136) in 0.05M, pH 9.6 carbonate-bicarbonate buffer 
(Sigma, C3041), overnight. Plates were washed in PBS+0.25%BSA (wash 
buffer), 3 times and blocked with 200 µl of 5% milk in PBA. After washes, 100µl 
of dilutions of standards and Fc chimera supernatant were added to the wells, 
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incubated at room temperature for 2 hours and washed in wash buffer. Wells 
were incubated with 100µl of 5 µg ml-1 of biotinylated anti-ICAM antibody (13-
0549, Ebiosciences) or 10µg ml-1 of Biotinylated Sambucus niagra (SNA) lectin 
(B1305, Vector labs), incubated for 1 hour at room temperature and washed 
again. 100 µl of either 1:2500 dilution of alkaline phosphatase conjµlated anti-
human IgG (A9544, Sigma) or 1:1000 dilution of streptavidin-alkaline 
Phosphatase, made in 1 x TBS (0.25% BSA) were added to the plates and 
incubated for an hour. After washing plates in TBA, 100 µl of PNPP substrate 
(N1891, Sigma) was added to the wells. Plates were read every 5-10 minutes at 
405nm. In some assays, for detection of Fc, an Anti-Human IgG (Fc specific) 
Peroxidase (Sigma, A0170) was used followed by TMB substrate.  
        
 2.8 Preparation of red blood cells (RBCs) 
1-2 ml of blood was collected from healthy volunteers and diluted in 40 ml of 
1xPBS. No anti-coagulant was used in the process. Cells were washed three 
times in PBS by centrifµling at 1300 rpm for 5 minutes at room temperature and 
removing the supernatant. After the final wash, 20 ml of Alsevers reagent was 
added to the cells and the RBCs were allowed to settle at 40C. 
 
 
2.9 Sialidase treatment of cells 
Cells were harvested and washed twice in DMEM without FCS. Cells were 
resuspended in DMEM at 1 x 10E6 cells per ml and sialidase added at 0.17 
IU/ml. Treated cells were then incubated for 1 hour at 370C, 8 % CO2, with 
occasional agitation. Following incubation, cells were washed twice in DMEM 
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containing 10% FCS. For sialidase treatment of RBCs, 25 µl of packed RBCs 
were resuspended in 5 ml of DMEM media and treated with sialidase.  
 
         2.10 Red blood cell solid phase adhesion assay  
96 well 4HBX Immunolon plate was coated with 100 µl of goat anti-human IgG 
AT 1:200 dilution in carbonate-bicarbonate buffer (pH 9.6). Plate was incubated 
overnight at 40C. The plate was then washed three times with 200 µl of wash 
buffer (1xPBS + 0.25% BSA; PBA) and then blocked with 200 µl of 5% milk in 
PBA. After washing off the block, 100 µl of Siglec-7-Fc chimera at varying 
dilutions were added to the plate and incubated at 370C for an hour. Plate was 
washed 3 times in wash buffer and 100 µl of RBC suspension was added per 
well and incubated at room temperature for 1 hour. The wells were washed as 
follows to remove unbound RBCs. 150 µl of wash buffer was added to each well 
of the plate and placed on the orbital shaker for 3 seconds (moderate speed). 
Wash buffer was then removed from wells using one strong flick of the plate. 
This wash process was repeated 2 additional times. The plate was then dried 
and cells fixed with 50 µl of methanol. The plate was then allowed to dry in a 
tissue culture hood for 15 minutes. TMB substrate was prepared according to 
manufactures instruction and 100 µl added to the wells of the plate and 
incubated for 30 minutes at room temperature. The reaction was stopped by 
adding 50 µl of sulphuric acid and the plate was read at 450nm. 
 
2.11 Antibody staining of cells for flow cytometry analysis 
Cells were harvested using 5-10 ml of 1X PBS + 1mM EDTA and resuspended 
in FACS wash buffer (1xPBS + 2mM EDTA + 0.25% BSA + 2mM sodium azide) 
at 10 x10E6 cells per ml. 100 µl of cells were then plated per well in a 96-well 
61	
	
U-bottom non-tissue culture (TC) plate and spun down at 1300 rpm for 3 
minutes at 40C. Cells were then resuspended in 100 µl of the respective 
antibody at the titrated concentration of 5-10 µg/ml in FACS buffer and left to 
incubate for 30 minutes on ice. Antibody stained cells were then washed three 
times in 200 µl of FACS wash buffer and incubated with 100 µl of the secondary 
antibody (at a pre-determined concentration), for half hour on ice. Following 3 
washes with FACS buffer, cells were either stained with 1/300 dilution of 7AAD 
or fixed with 100µl of 1% PFA in FACS wash buffer. Cells were analysed by 
flow cytotmetry.  
 
2.12 Preparation of Fc-chimera complexes 
Siglec-7-Fc was precomplexed to anti-human Fc specific-HRP or anti-human Fc 
specific Dylight 647 fluorescent probe to be used in ELISA or flow cytometric 
analysis respectively. Siglec-7-Fc and secondary antibodies were diluted to 
different concentrations in 1X PBS +1% BSA, in separate tubes. Siglec-7-Fc 
was then mixed with the secondary antibody in a 1:3 ratio (volume/volume) and 
left to incubate for an hour at room temperature (for anti-Fc-HRP conjµlate) and 
on ice (for anti-Fc-Dylight conjµlate). 100µl of this pre-complex was then used 
either for ELISA or to stain 1x10E6 cells for flow cytometry/ confocal microscopy 
staining.  
 
2.13 Confocal Microscopy for detection of GD3 and GM1 
B16 cells were harvested with 1mM EDTA. 1X10E6 cells were spun down and 
washed once with FACS wash buffer. Cells were then resuspended in 100 µl of 
facs buffer, in 96 well (U bottom plate), and then stained with 5 µg/ml of R24 
antibody and 1µl/ml of biotinylated cholera toxin subunit B. Following 30 
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minutes incubation on ice, the cells were washed twice and stained with 2 µl/ml 
of anti-mouse IgG (FITC conjugate) and Streptavidin (HiLyte Fluor 555 
conjugate). Following the washes, cells were fixed with 1% PFA for 30 minutes 
on ice. Cells were washed once with PBS and resuspended in 30-50 µl of 
Vectashield (with DAPI). Resuspended cells were then mounted onto glass 
slide using hydramount mounting media and sealed with varnish.  
Images were collected using the LSM 710 Confocal laser scanning microscope 
using the x40 or x100 oil immersion objectives. Differential interference images 
were collected along with the fluorescence images. Images were then analysed 
using the LSM image software and quantified using Volocity software.  
 
2.14 Dot blots for sialic acid dependent recognition of ICAM-1-Fc  
1cm grids were drawn on nitrocellulose membranes strips (Protran, Whatman). 
Different concentrations of 2 µl of ICAM-Fc (5 µg to 0.1 µg of total protein) were 
spotted onto the center of the grid and allowed to dry for 10-15 minutes at room 
temperature. Dried blots strips are then blocked in 5% milk in TBST (1x TBS + 
0.1% Tween-20). For sialidase treatment of ICAM-1-Fc, blots were incubated in 
acetate buffer (sodium acetate + 1mM calcium chloride) with sialidase at 0.17 
IU/ml dilution for one hour at room temperature. Sialidase was quenched using 
10% FCS in PBS, for 10 minutes.  During this incubation period, Fc pre-
complex was prepared by mixing 1 volume of Siglec-7-Fc (at 5 µg/ml) and 3 
volumes of anti-Fc HRP (1/1000 dilution) in 1%PBA (1xPBS and 1% BSA) and 
incubating for an hour at room temperature.  Blots were incubated with Siglec-7-
Fc pre-complexes, biotinylated anti-human ICAM antibody (clone HA58, 
ebiosciences) or biotinylated Sambucus Niagra Lectin (SNA, Vector labs, B-
1305), for one hour at room temperature (or overnight at 40C). Blots were then 
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washed thrice in TBST. SNA and anti-ICAM blots were then incubated with 
Avidin-HRP (1/1000) in TBST for one hour at room temperature. Blots were 
incubated using ECL reagent for 1 minute, excess removed and exposed to X-
ray film.  
 
2.15 Biochemistry assay and western blotting  
6 well tissue culture plates were coated with 10 µg/ml of protein A, overnight. 
Plates were washed with PBS+0.25%BSA (wash buffer) and blocked with PBS 
+ 5%BSA for 1 hour at room temperature. Plates were coated with 5 µg ml-1 of 
ICAM-Fc (clone 54), overnight. Plates were washed with wash buffer and then 
blocked again with 10%FCS in PBS and left in cold PBS till cells were ready to 
be plated.  
NK92 cells were harvested and resuspended in RPMI 1640 + 10%FCS at 0.2 x 
10E6 cells per ml. Cells were IL2 starved for 2 hours at 370C. Cells were then 
harvested and resuspended in ice-cold adhesion buffer (HBSS (-Ca2++ 2mM 
Mg2+)). Cells were then plated onto cold ICAM-Fc coated plates and centifuged 
at 900 rpm for 30 sec. Plates were then incubated at 370C for different time 
points. Unbound cells were removed from wells into microfuge tubes and 200 ul 
of lysis buffer (Tris.HCl, 150mm NaCl, 0.1%Triton-X-100, pH 8, 1 tablet of 
protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), 2mM sodium 
orthovanadate and 0.1% beta-mercaptoethanol) was added to the wells. The 
unbound cells were spun for 10 minutes at 13,000 rpm, supernatant removed 
and 100 µl lysis buffer added. Both unbound and bound cells from the 
respective cells were mixed. Src inhibitor, PP2, was added at 1250 dilution to 
control cells and incubated for 10 minutes at room temperature before plating 
onto wells.  
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Lysed cells were centifuged at 14,000 rpm for 10 minutes to remove cellular 
debris. Protein concentrations of lysates were estimated using BCA protein 
assay kit (Pierce), as described in section 2.15. Lysates were then mixed with 
NuPage sample loading buffer and NuPage sample reducing agent and boiled 
for 10 minutes at 700C. 15µg of protein were loaded onto 12 well NuPage 4-
12% Bis-tris gels and run at 200 V in NuPage MOPS SDS Running Buffer (x20). 
Gels were then transferred to nitrocellulose membrane (Protran, Whatman) in 
cold 1x Transfer buffer (NuPage Transfer Buffer (x20) and 10% methanol), at 
30V for 90 minutes. Membranes were blocked with 5% marvel in TBST (1X TBS 
+ 0.1% tween-20) for one hour. Blots were stained with the respective primary 
antibodies, overnight. Blots were washed well in TBST (3 times, 10 minutes 
each). A 1:3000 dilution of secondary antibody in 2% milk or BSA were added 
to the blots and incubated for 2 hours at room temperature.  Blots were washed 
in TBST and developed using Immobilon Western Chemiluminescent HRP 
susbtrate (Millipore).  
 
2.16 BCA assay  
BCA assay is the standard method employed to quantify the concentration of 
total protein in cellular lysates. BCA assay kit (Thermo scientific) is used for this 
purpose. The detection range of the kit is between 2 mg/ml and 125 ng/ml 
(when 25 µl of the standard/sample is used). BSA (2mg/ml) is used as the 
standard for the estimation of protein concentration in lysates.  
Both standard and lysate samples were diluted in water. 25 µl of each standard 
and samples (diluted 1:50) were added to 96 well plate in triplicate. Reagent A 
and 1:50 dilution of Reagent B were mixed and 200 µl of this is applied to the 
samples. The plate was then covered in foil and left to incubate for 30 minutes 
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at 370C. The plate was then read at 570nm using a plate reader. Standard 
curve for the samples are plotted as absorbance vs. concentration. Protein 
concentrations of the lysates are extrapolated from the slope of the standard 
curve (Graphpad prism).  
 
2.17 Adhesion assay 
96 well tissue culture grade plate were coated with 1:10 dilution of poly-l-lysine 
(in water), PBS (for blanks) or 10µg ml-1 Protein A and incubated overnight at 4 
0C. Plates were washed with wash buffer (1 X PBS + 0.25% BSA) and blocked 
with 5% BSA in PBS for 1 hour at room temperature. Wells were then coated 
with 5 µg ml-1 of ICAM-Fc in 0.25% BSA in 1xPBS, for 1 hour at room 
temperature. Plates were washed again with wash buffer and blocked with 10% 
FCS in 1xPBS for 2 hours at room temperature and washed with PBS. NK92 
cells were harvested and resuspended at 10E6 per ml in cold binding buffer 
(HBSS +/- MgCl2) and 200µl added to wells. For controls, cells were treated 
with either 10 mM EDTA or PDBU at 20 ng ml-1 in binding buffer, for 15 minutes 
on ice before adding them onto prepared plates. Cells were settled on to wells 
by a pulse spin (30 seconds, 800 rpm). Plates were then incubated for 15 
minutes at 37 0C.  Unbound cells were washed off by inverting plates into a 
container with 4 litre of 1X PBS, supplemented with 0.25mM MgCl2 for 30 -60 
minutes at room temperature. Bound cells were fixed by adding 100 µl of 
methanol and aspirating off after 1 minute. 50 µl of 0.5% Crystal Violet 
(dissolved in 25% methanol) was added to each well, incubated for 10 minutes 
at room temperature and wells were thoroughly washed with PBS. 100 µl of 
methanol was added to each well and plates were read at 570 nm.  
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2.18 Cytotoxicity assay 
Cytotox 96 Non-radioactive assay kit was used to analyze the cytotoxicity of 
effector cells on target cells. Both effector and target cells were split 48 hours 
prior to the assay. Cells were harvested and resuspended in cytotoxicity buffer 
(RPMI 1640 + 1%FCS) at different cell concentrations. Effectors and targets 
were plated out in 200µl of cytotox buffer in 96 well (U-shaped) tissue culture 
plates, centifuged at 250g for 4 minutes and incubated for upto 5 hours. 45 
minutes prior to the termination of the assay, 20µl of lysis buffer (0.1% Triton-X) 
was added to the wells with targets alone. At the end of the assay, plates were 
centifuged again and 50µl of supernatant from each well was transferred to a 96 
well 4 HB Immulon ELISA plate. Assay buffer was prepared according to 
manufacturer’s instructions and 50 µl added to each well. Plates were incubated 
for 30 minutes at room temperature and absorbance was measured at 492 nm 
on plate reader.  Background absorbance was subtracted from each sample 
and percentage cytotoxicity was calculated as follows: 
 
                    (Sample OD – Effector spontaneous release – Target spontaneous release) 
       (Target maximal release – Target spontaneous release) 
 
2.19 Granule polarization assay  
2 x 10E6 Protein A polystyrene particles (6-8 µm) were gently vortexed and 
washed in 1 X PBS twice by centrifuging at 6000 rpm for 5 minutes. Beads were 
then coated with 5µg of ICAM-Fc in 1 X PBS, kept on a vortex at 40C for 1 hour. 
Beads were then washed twice in 1 X PBS and resuspended in 100 µl of HBSS 
(-Ca2+, 2mM Mg2+).  
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18 mm cover slips were coated with Poly-L-Lysine (1/10 dilution in water), over 
night, in 6 well tissue culture plates. Coverslips were then washed off PLL with 
PBS. 0.5X10E6 cells were spun down, resuspended in 100µl of HBSS (-Ca, -
Mg) and spotted on to Poly-L-Lysine coated 18mm cover slip. Cells were left to 
settle on the coverslips by incubating at 370C, 5%CO2, for 1 hour. Following the 
incubation, the buffer on the cover slip was replaced with 100 µl of ICAM-Fc 
coated beads. Coverslips were again left to incubate for one hour at 370C, 
5%CO2. Following this, unbound cells and beads were washed off in 2 ml of 
PBS in a 6 well TC plate. Bound cells were then fixed with 4% 
paraformaldehyde (PFA) for 10 minutes at room temperature. PFA was washed 
off twice in PBS and bound cells were permeabilized with 1xPBS + 0.1% Triton-
X-100 (permeabilization buffer), for 10 minutes at room temperature. Cells were 
then blocked with 10% mouse serum in permeabilization buffer. Cells were then 
stained with 5µg/ml of anti-human perforin (FITC conjugated) in block buffer, 
overnight, in a humidified chamber. Next day, cells were washed twice in 
permeabilization buffer and mounted onto slides using 5 µl of Vectashield 
mounting media (with DAPI).  Mounted coverslips were sealed and left to dry. 
Images were collected using the LSM 710 Confocal laser scanning microscope 
using the x40 or x100 oil immersion objectives. Differential interference images 
were collected along with the fluorescence images.  
 
2.20 Ganglioside assay 
Lysophilized ganlioside stocks were reconstituted at 1 mg/ml using choloroform 
: methanol (1:1) and stored at -200C. The working dilutions were made by 
sonicating ganglioside stocks for 3 minutes in a water bath. The required 
amount was then dissolved in methanol in a glass vial to a concentration of 2 
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µg/ml and was stored at 40C for upto 2 weeks. Ganglioside complexes were 
prepared by sonicating individual gangliosides in the stock vials and then mixing 
them at a 1:1 ratio in a new glass vial. This mixture was then again sonicated 
for 3 minutes. When using liposomes reconstituted with gangliosides (prepared 
as described in section 2.21), gently vortex, add 100µl /well to an ELISA plate 
and incubate at 4ºC overnight to coat. 4HBX Immulon HB ELISA plate was 
coated with 100µl of 2 µg/ml of the respective ganglioside. 100µl of methanol 
was first coated to reduce background contamination. The plate was then dried 
in a hood overnight and transferred to 40C for an hour.  Plates were then 
washed with 0.1% PBA (1X PBS + 0.1% BSA) and dried. Siglec-7-Fc antibody 
pre-complex was prepared by diluting the Fc chimera to 1 µg/ml and goat anti-
human IgG-Fc-HRP TO 1:1000 in 1%PBA (1X PBS + 1%BSA). The two 
dilutions were mixed in 1:3 ratio and incubated for an hour at room temperature.  
100 µl of this pre-complex was then added to the plate and incubated for 2 
hours at 40C. Plate was then washed 3 times with 300 µl of 0.1% PBA. 100 µl of 
TMB substrate was added to the plates and reaction stopped with 50 µl of stop 
solution (3.6% (v/v) of phosphoric acid) and the plate was read at 450nm. 
  
2.21 Preparation of ganglioside reconstituted liposomes 
Liposomes incorporating ganglioside and ganglioside complexes were prepared 
using cholesterol : sphingomyelin : dicetylphosphate : ganglioside 1 (: 
ganglioside 2) in a 5:4:1:1(:1) molar ratio. Blank liposomes (not containing 
ganglioside but containing the other components) were prepared to use in 
negative control wells. The above component lipids were dissolved to 10mg/ml 
in 1:1 chloroform : methanol in a 15ml falcon to give the required molar ratio. 
Dicetylphosphate was kept at a lower concentration (2.5mg/ml) to avoid 
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precipitation. This mixture was then dried under a steady stream of N2 in the 
fume hood, leaving a thin film in the tube which was then resuspended in 5-10 
ml of PBS, pH 7.4 (3-5x final target volume). This mixture was alternatively 
vortexed and sonicated for 15min, releasing the lipid from the walls of the tube 
and producing a uniformly milky solution. It was then alternatively freeze-thawed 
x5 by plunging into liquid N2 and then placing in a water bath at 37oC (to 
produce multi-lamellar vesicles). This was then clarified by centrifulation for 
20min@600g, 1800rpm and pellet discarded. The solution was extruded 9-11x 
throµlh a 0.4µm, using a hand driven extruder, to produce unilamellar vesicles. 
Finally the solution was ultracentifuged for 1 hour @ 110000g, resuspended in 
final required volume of PBS and stored in glass vial.    
 
2.22 Quantitative real-time PCR (qRT-PCR) 
Real time- PCR was used in this project to measure the amount of messenger 
RNA levels of a particular gene in non-transfected cells relative to cells 
transfected with that particular gene.  
Power SYBR green PCR master mix (Applied Biosystems) was used for the 
RT-PCR of the various cDNA samples. The following mix consisting of 12.5 of 
SYBR green, 1 µl each of sense and anti-sense primers, 5 µl of cDNA and 5.5 
µl of RNAase free water was prepared and plated out. Both primer 
concentration and dilutions of cDNA were optimized for each gene.  
The PCR reaction mixture was prepared using 5 μl  of cDNA, 12.5 μl of SYBR 
Green Master mix, 1 μl each of forward and reverse primers and made up to a 
total volume of 25 μl. No Reverse Transcriptase samples were also prepared 
and tested during the PCR run. A StepOne instrument (Applied Biosystems) 
was used to carry out real-time PCR. A total of 40 cycles was run with each 
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cycle set as follows – 15 seconds at 95 0C and 1 minute at 60 0C. Each sample 
was run in triplicate.  
Relative fold change in gene expression in each unknown sample was 
quantified by the comparative ∆∆CT method, normalized to GAPDH (reference 
gene). CT (cycle threshold) values obtained from the PCR runs were averaged 
and analysis conducted as follows. CT of the reference gene was deducted from 
the CT of the target gene to obtain ∆CT,   in each sample. The ∆CT of the 
reference gene was then deducted from ∆CT value of the target gene from each 
sample to obtain ∆∆CT value. This represents the fold change in gene 
expression of the target gene in the sample relative to the calibrator tissue, 
kidney in this case.  
 
2.23 Primers used in generation of clones and qRT-PCR  
Primers used in the cloning of DNA and qRT-PCR are listed in tables 2.4 and 
2.5 respectively.  
Table 2.4 : Primers used in the cloning of DNA into pcDNA 3.1 vector 
Primer Sense sequence (5’ – 3’) Antisense sequence (5’-3’) 
GD3S 
 
CCCAAGCTTGCGATGAGCCCCTGC 
 
GCTCTAGACTAGGAAGTGGGCTGTGGTG 
 
Human 
ICAM-1 
CCCAAGCTTGCGATGGCTCCCAGCAG
CC GCTCTAGATCAGGGAGGCGTGGCTTGTGTGTTC 
Shaded region within primer represents gene specific regions, underlined regions represents 
enzyme restriction sites 
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Table 2.5 : Primers used in qPCR for the analysis of levels of messenger RNA 
Primer Sense sequence (5’-3’) 
Anti-Sense sequence 
(5’-3’) 
GM3S GCTTCAAGCAATGGTAAAAAATGA 
 TTCTGCCACTTGCTTCCAAA 
GM2S AACCGGGTGGCACATCTGGAATTC  CAGAGCAGGAGCCAACACGAAGGA 
GM1S GTCAGCAGCACACAGGGATA CTGGGACGTTGACATACACG 
GD1a CAGCATGGCTACCTTGCCCTACCT GCCGAGGCGCTGTAGTCCTGAATA 
CMAH GGTGGTCAGGATGATTGAAACAGATG TCACCCGGCTATGGATTTCTTC  
 
2.24 Cloning of GD3s into pcDNA 3.1 vector  
mRNA, extracted from mouse brain lysates, was used in the generation of 
GD3s cDNA. Then using the primers for GD3s (table 2.4) cDNA was amplified 
by PCR (figure 2.1, A). Resulting product and vector backbone (pcDNA3.1 
hygromycin) were digested with HindIII and XbaI, ligated, transformed, colonies 
screened and sequenced. Plasmid prep of the resulting clone was analysed by 
restriction enzyme digests as shown in figure (2.1,B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: PCR amplification and cloning of mouse GD3s: 2 µl of cDNA was amplified by 
PCR using 1 µM of primers (annealing temperature of 66.70C). (A) 5 µl of samples before 
1 –  PCR product 
M – 100 bp ladder 
2 –  PCR product after genomic   
DNA digestion 
      1                M             2        bp 
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1.0 
1 – Undigested  
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and after digestion of genomic DNA, were run on 1% agarose gel. (B) Plasmid prep of 
GD3 synthase cloned into pcDNA 3.1 was run on 0.8% agarose gel either undigested, 
single digestion with HindIII or double digested with HindIII and Sal1. 
 
2.25 Cloning of ICAM-1 into pcDNA 3.1 
ICAM-1 was overexpressed in these cells by extracting mRNA from K562 cells.  
This was used to generate cDNA which was then amplified using primers to the 
human ICAM-1 sequence (table 1; figure 2.4, A). Amplified cDNA and vector 
backbone (pcDNA 3.1) were subject to restriction enzyme digests (figure 2.2, B) 
and ligated. Ligation product was transformed into DH5α cells and resulting 
clones screened by restriction digest analysis and DNA sequencing. Plasmid 
DNA maxi prep was prepared using the clone with the right size insert 
	
						
	
	
	
	
	
	
Figure 2.2: PCR and cloning of full length human ICAM-1: (A) PCR reaction mix was set 
up using cDNA, 1 µM sense and antisense primers, KOD buffer and dNTPs. PCR reaction 
was set up as follows- :- Activation – 2 min @ 950C, denaturation – 20 sec @ 950C, 
annealing – 10 sec @ 700C and 730C, extention – 32 sec @ 700C for a total of 35 cycles. 
PCR product was run on a 1.3% agarose gel and purified using Qaigen gel extraction kit. 
(B) 2 µg of PCR product and 2 µg of p CDNA 3.1 plasmid vector were digested with HindIII 
and XbaI for 2 hours at 370C. Digestion products were run on a 1% agarose gel and gel 
extracted. 
  
PCR	product	
						1								2								M	
A	
M – 1Kbp ladder 
1 – ICAM-1 PCR product (Ta – 700C) 
2 – ICAM-1 PCR product (Ta – 7300C) 
3 – pcDNA 3.1 vector  
4 – ICAM-1 PCR product 
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2.26 Cloning of ICAM-1-Fc and ST6Gal1 
Previously cloned ICAM-1-Fc and ST6Gal1 were retransformed into bacterial 
cells (as described in chapter 4, section 4.1.1). Figure 2.3 shows restriction 
enzyme digestion of selected clones of ICAM-1-Fc and ST6Gal1.  
CHO cell were transfected with purified DNA for ICAM-1-Fc and ST6Gal1. 
Selection of stable ICAM-1 producers was achieved by transfecting an empty 
pcDNA 3.1 vector carrying a selection marker for hygromycin resistance. 
Plasmid DNA for the empty vector, ICAM-1-Fc and ST6Gal1 were transfected in 
a ratio of 1:2:2 as described in the methods section. As a control, a separate 
transfection with only plasmid DNA for ICAM-1-Fc was also carried out.  
	
	
	
	
	
	
	
	
 
 
Figure 2.3: Restriction digest analysis of ICAM-1-Fc and α 2,6 sialyltransferase : 1µg of  
ICAM-1-Fc cloned into pCDM8 and ST6Gal1 cDNA cloned into pCDNA 3.1 vector were 
digested with XbaI for 1 hour at 370C. DNA with no enzyme (undigested) was kept as 
control. After incubation, digests were mixed with 6x loading dye and loaded on to 1% 
agarose gel. Gel was run at 100V for 50 minutes. (B) Linear regression curve analysis for 
molecular weight ladder. Log of molecular weight marker is plotted against distance 
travelled by the marker (Rf) 
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2.27 Cloning of Siglec-7 mutants 
Cloning of mutants for Siglec-7 was carried out using PCR based site directed 
mutagenesis (SDM) technique. pcDNA3.1 Siglec-7 was used as the DNA 
template. 50µl of the following mix was prepared for each PCR amplification - 
10x Buffer KOD Hot Start DNA polymerase – 5µl; 25mM MgSO4 – 5 µl; dNTPs 
(2 mM) – 5 µl; PCR grade water; 1 µl of sense primer (10 µM); 1 µl of anti-
sense primer (10 µM); 1 µl of template DNA; 1 µl of KOD Hot Start DNA 
polymerase and 5 µl of DMSO. Primers used are shown in below in table 2.6. 
Reaction was set up as follows: Activation – 2 min @ 950C, denaturation – 20 
sec @ 950C, annealing – 30 sec @ 650C, extension – 10 sec @ 700C for a total 
of 35 cycles. Following PCR, the product was treated with 1 µl of Dpn1 enzyme 
and 1 µl of buffer, in a total volume of 30 µl for 1 hour at 370C. PCR products 
were run on 0.7% agarose gel in 1XTAE (Figure 2.4A) and then purified. 
Purified DNA was then transformed into DH5 α cells. Mutant clones were 
analysed by restriction digest (Figure 2.4, B) to confirm product size and 
putative clones were sequenced.  
 
Table 2.6 Primers used in the SDM of mutants of Siglec-7 
 
Primer Sense sequence (5’-3’) 
 
Anti-sense sequence (5’-3’) 
R124A GGAGATACTTCTTTGCTATGGAGAAAG CTTTCTCCATAGCAAAGAAGTATCTCC 
YIF 
(Y437F) 
AAAGAGAGATCCAGTTTGCACCCCTCAGCTT
TC 
GAAAGCTGAGGGGTGCAAACTGGATCTCTCTTT 
Y2F 
(Y460F) 
AAGCCACCAACAATGAGTTCTCAGAGATCAA
GATCC 
GGATCTTGATCTCTGAGAACTCATTGTTGGTGGCTT 
Sequence in red represents the mutated sites 
 
 
 
 
75	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Cloning of Siglec-7 mutants (A) Plasmid DNA of Siglec-7 in pcDNA3.1 vector 
was used as template to generate the mutant clones using site directed mutagenesis. (B) 
Clones grown in ampicillin resistant plate was then analysed by restriction digest and 
compared to the template Siglec-7 DNA. 
 
 
 
		1							2									3									4							5								6								7							8									9						10
R124A Y1F	 Y2F	
B	
Siglec‐7	
M – 1Kbp ladder 
1 – pcDNA-R124A (post-Dpn1 digest) 
2 – pcDNA R124A (pre-Dpn1 digest) 
3 – pcDNA -Y1F (post-Dpn1 digest) 
4 – pcDNA Y1F (pre-Dpn1 digest) 
5 – pcDNA -Y2F (post-Dpn1 digest) 
6 – pcDNA Y2F (pre-Dpn1 digest) 
 
	
A	
 M         1          2          3        4           5        6
75	
	
	
	
	
	
Chapter 3 
Role of ganglioside complexes in modulating Siglec-7 
recognition of GD3 
 
3.1 Introduction  
There is accumulating evidence that glycolipids do not exist on the cell 
membrane as individual entities but interact with other glycolipids and 
glycoproteins to form new structures that affect recognition by antibodies and 
lectins.  
The basis of this project originated from an interesting study that demonstrated 
how various glycolipid-glycolipid interactions affected the recognition of 
proteins, antibodies and lectins (Rinaldi et al., 2009). This study utilized the 
technique of glycoarrays to spot 20 different glycolipids either individually or in 
combinations creating a grid pattern on PVDF membrane. The membrane was 
then probed with Tetanus Hc-HRP (Tet-Hc-HRP), Cholera toxin subunit B 
(CTB) and recombinant Siglec7-Fc protein. The authors observed complex 
mediated increase and decrease of ligand binding for these different proteins. 
Although Tet-Hc-HRP did not bind individual gangliosides, it showed an 
increased binding to some of the heterodimers. CTB, that binds GM1 with high 
affinity, was unaffected when in complex with other gangliosides. The binding of 
Siglec-7-Fc to its natural ligand GD3 was attenuated in the presence of complex 
sugars such as GM1, GD2, GD1a, GD1b, GT1a, GT1b and GQ1b (Rinaldi et 
al., 2009). The inhibition of Siglec-7-Fc binding to GD3 was independent of 
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whether PVDF membrane or polystyrene ELISA plate was used as the assay 
platform.   
Tumours adopt different mechanisms to evade the recognition and attack by 
immune cells. The classical example of tumour escape mechanism is the down 
regulation of MHC-I to avoid recognition by T cells. Tumours also adopt other 
techniques such as secretion of certain proteins to promote the recruitment of 
regulatory T cells (Tregs), modifying their stromal micro-environment etc (Zindl 
and Chaplin., 2010) (Birkle et al., 2003). Gangliosides shed by tumours also 
have an important role in affecting anti-tumour responses. GD3, a tumour 
associated antigen in melanomas, has long been known for its role in promoting 
the tumourigenic properties of melanomas (reviewed by Furukawa et al., 2008). 
GD3 and GD2 have been shown to interact with integrins and focal adhesion 
kinases (FAK) in melanomas and certain lung cancer cell lines (Cheresh et al., 
1987). Therefore, it is possible that one of the mechanisms adopted by tumours 
like melanomas to escape NK mediated cytotoxicity is the overexpression of 
gangliosides like GD3.  
 
The glycoarray findings by Rinaldi et al., and the knowledge that tumours 
overexpress various ganglioside species provide interesting grounds for 
investigating how tumour associated gangliosides could possibly modulate NK 
cytotoxicity.  A tumour recognition model could be hypothesized as follows. 
Tumours with overexpression of GD3 such as melanomas would be recognized 
by Siglec-7 on NK cells. Strong ligand recognition by this receptor would trigger 
inhibitory signals, which would override signals from potential activating 
receptors, and decrease NK cell mediated natural cytotoxicity (Figure 3.1, target 
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A). However, if a target cell was to expresses sufficient density of complex 
gangliosides such as GM1, then cis-interactions between the two gangliosides 
could occur. This could result in the masking of Siglec-7 epitopes on GD3 
(Figure 3.1, target B). This would affect Siglec-7 recognition of its natural ligand, 
thereby modulating the inhibition mediated by this receptor. Thus increased 
cytotoxicity by the effector cells on this genre of targets could be expected. 
 
 
 
 
 
 
 
 
 
Figure 3.1: Proposed model for the project: Target A, with high expression of GD3, is 
recognized by Siglec-7 on NK cell and leads to decreased killing. GD3 on Target B is 
masked by the expression of GM1 and hence not efficiently recognized by the inhibitory 
receptor, increasing its susceptibility to NK cytotoxicity. GM1         , GD3  
 
Project aims:  
The focus of this project was to investigate if this complex mediated attenuation 
of Siglec-7, seen on glycoarrays using lectin Fc-chimeras, is of significance at a 
cellular level. The broader aim of this project was to investigate the role played 
by such glycolipid cis-interactions in affecting tumour recognition by NK cells. 
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Biochemical and cellular approaches were undertaken towards this goal. Using 
tools like Fc-chimeras and a cellular overexpression model, Siglec-7 recognition 
of GD3 overexpressed in complex with GM1 would be investigated. Depending 
on results obtained from initial studies, primary human NK cells would be used 
to examine the significance of these findings in biological assays.  
 
3.2 Characterization of Siglec-7-Fc 
Unlike protein-protein interactions, protein-glycan interactions are often avidity 
based and multivalent due to the low affinity of protein glycan interactions (Varki 
et al, Essentials of Glycobiology, 1999). In some cases these interactions 
therefore depend on factors such as density of ligands and number of ligand 
recognition sites on the receptor.  
For this project, it was decided to use Siglec-7-Fc chimeras for cellular assays. 
The chimera consists of the entire extracellular domain of the receptor linked by 
disulfide bonds to the Fc and hinge regions of human IgG as shown in the 
figure 3.2. Stable CHO cell clones generated previously in the lab were used for 
the purpose of large scale generation of the Fc-chimera. The Glutamine 
Synthetase (GS) expression system was used in the expression of the Siglec-7-
Fc chimera. This system utilizes the fact that in the absence of external 
glutamine, cell survival depends on the transfected GS gene to produce 
glutamine from glutamate and ammonia. L-MSX was used as a selection agent 
for this purpose. It is commonly used in the production of recombinant proteins 
especially antibodies in CHO cells and others cell lines. It is an inhibitor of the 
GS enzyme and increasing doses of L-MSX results in the efficient amplification 
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of the gene of interest linked to the GS gene. Moreover very high levels of 
protein expression (up to 10 mg/L) can be obtained with this system.  
                   
 
 
 
 
 
Figure 3.2: Schematic representation of (A) Siglec-7-Fc chimera (B) Pre-complex of 
Siglec-7-Fc with a secondary anti-Fc antibody coupled to a fluorescent probe. 
 
3.2.1 Preparation of Siglec-7-Fc 
A stable CHO-K1 cell clone was cultured in GMEM media with 0.5% FCS, 2% 
GSEM and 200 µM of L-MSX. It was also decided to compare the activity of 
Siglec-7-Fc prepared in the presence or absence of serum. For that reason 
cells were also cultured in serum free UCHO media.  
The chimeras were quantified by using an anti-Fc antibody ELISA. Purified 
Sialoadhesin-Fc (Sn-Fc) was used as the protein standard in this ELISA. Figure 
3.3 shows the standard curve used to calculate concentration of Siglec-7-Fc. 
Siglec-7-Fc expressed in GMEM media was calculated to be 16 µg/ml and that 
in UCHO media was 20 µg/ml. 
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Figure 3.3 Standard curve for estimation of Siglec-7-Fc concentration: A 96 well plate 
was coated with 200 µl of 12 µg/ml of anti-human IgG, diluted in carbonate bicarbonate 
buffer. After overnight incubation, the plate was washed x3 with PBA (PBS + 0.25% BSA). 
The plate was blocked with 5% marvel in PBA. After 1 hour blocking at room 
temperature, the plate was washed again and 100 µl of dilutions of standard and 
unknown samples was added. After incubation, the plate was washed again in PBA and 
then 50 µl of alkaline phosphatase conjugated goat anti human IgG in TBA 
(TBS+0.25%BSA). Following 1 hour incubation, the plate was washed with TBA, then 
incubated with 100 µl of PNPP and the coloured product read on an ELISA plate reader 
after 5-10 minutes.  
 
3.2.2 Testing Siglec-7-Fc by RBC solid phase adhesion assay  
Siglec-7-Fc expressed in either GMEM or serum free UCHO media were tested 
for binding of RBCs in an adhesion assay. RBCs express glycoproteins carrying 
sialic acids for example glycophorins. Dilutions of the Siglec-7-Fc chimera were 
coated onto a microtitre plate. RBCs were added to these wells, incubated and 
then unbound cells washed off. Figure 3.4 (A) shows quantification of the 
adhesion of RBCs to Siglec-7-Fc supernatants. To ensure no loss in protein 
functionality after long term storage of chimera at - 800C, the assay was also 
carried out using frozen and thawed proteins (Figure 3.4, B).  
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Figure 3.4: Adhesion of RBCs to Siglec-7-Fc chimera:  Dilutions of Siglec-7-Fc were 
incubated on a plate coated with goat anti-human IgG. Following 1 hour incubation and 
washing with 1X PBS (0.25% BSA), 0.5% (v/v) of RBCs were added to the plate and 
incubated for 1 hour at room temperature. Wells were then washed and bound cells fixed 
with methanol before adding TMB substrate for detection. Error bars represent standard 
deviation between samples (n=3). FT – freeze-thawed 
 
3.3 Siglec-7-Fc recognition of GD3 is inhibited in the presence of GM1 – 
plate based ELISA 
To test the inhibition of Siglec-7 recognition of GD3 by GM1, ganglioside 
ELISAs were carried out using Fc-chimeras, based on the protocol developed 
by Rinaldi et al., 2009. The protocol was further optimized for the best signal to 
noise ratio. GD3 and GM1 gangliosides were diluted in methanol to a working 
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concentration and coated directly onto 96 well microplates. Methanol alone was 
used as the blank in each case. RBC binding to Siglec-Fc-Fc prepared in 
UCHO was higher compared to that prepared in GMEM (Figure 3.4). Hence 
Siglec-7-Fc expressed in UCHO cells was used in these assays. 
 
3.3.1 Titrating Siglec-7-Fc pre-complex on GD3 
Siglec-7-Fc at 3 µg/ml and anti-human Fc-HRP (horse radish peroxidase) 
conjugate at 1 µg/ml were mixed together in different ratios (volume / volume). 
These were used to detect GD3 coated onto plates as shown in figure 3.5. The 
best signal to noise ratio was obtained for the 3:1 ratio. 
 
 
 
 
 
 
 
Figure 3.5: Titration of Siglec-7-Fc precomplexes for the detection of GD3 - Stock of GD3 
was diluted to 2 µg/ml in methanol and plated onto 96-well microtitre plate. After 
overnight incubation, plates were blocked, and then incubated with different 
concentrations of the pre-complexes. After 1 hour incubation, plates were washed and 
detected with TMB substrate. Error bars represent standard deviation between samples 
(n=3).  
 
3.3.2 Ganglioside ELISA to test recognition of GD3 by Siglec-7-Fc 
Next, sensitivity of the Siglec-7-Fc precomplexes in the detection of GD3 was 
examined. GD3 at concentrations ranging from 20 µg to 30 ng were plated and 
Dilutions of Siglec-7-Fc precomplexes 
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detected using Siglec-7-Fc pre-complexes at the optimized ratio of 3:1 (Figure 
3.6). 
 
 
 
 
 
 
 
Figure 3.6: Titrations of GD3 on ganglioside binding assay. Stocks of GD3 were 
sonicated and dilutions prepared in methanol. Microtitre plates were coated with 100 μl 
of GD3 and left to dry overnight. Following blocking with 2% PBA, pre-complex of Siglec-
7-Fc and anti-human IgG HRP conjugate was added to wells and incubated for 4 hours at 
40C. TMB was added as detection substrate and plates read at 450 nm. Error bars 
represent +SEM from two independent experiments. X-axis represents total input 
ganglioside in 100 μL. 
 
3.3.3 Siglec-7-Fc recognition of GD3 in GD3:GM1 complexes 
Siglec-7 inhibition of GD3 recognition by an equal amount of GM1 was first 
analysed. As shown in figure 3.7, GD3 recognition was reduced by more than 
50% when mixed with GM1.  
 
Figure 3.7: GM1 inhibits Siglec-7-Fc recognition of 
GD3. 100 μl of 200 ng each of GD3 and GM1 were 
coated on a microtitre plate, diluted in methanol. 
Assay was carried out as described in figure 3.6.  
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3.3.4 Increasing amounts of GM1 affects recognition of GD3 by Siglec-7-
Fc 
Next, the inhibition of GD3 over a range of GM1 concentrations was tested. 
Different amounts of GM1 (60 to 2000 ng) were mixed with 500 ng of GD3 and  
were plated out for detection by Siglec-7-Fc as shown in figure 3.8. GM1 was 
able to significantly inhibit Siglec-7-Fc recognition of GD3 when used at x0.5, 
x1, x2 or x4 increased amounts of GM1. The ganglioside GT1b was used as a 
positive control while GM1 as negative control in this assay.  
 
 
Figure 3.8: Titration of GM1 for the inhibition of GD3 : To 500 ng of GD3, varying amounts 
of GM1 was added and 100 μl of these complexes were plated out. 500 ng of GM1 was 
used as the negative control and 500 ng of GT1b was used as the positive control for 
detection by Siglec-7-Fc in the assay. Experiments were carried out as detailed in the 
legend of figure 3.6. Statistical test – One-way ANOVA using Dunnet’s post test, 
comparing control group (no-GM1) to all other groups.  Error bars represent SEM from 3 
individual experiments. * - P < 0.5; *** - P < 0.001 
 
3.3.5 GM1 specifically inhibits Siglec-7-Fc recognition of GD3  
Specificity of the inhibition by GM1 was demonstrated by pre-complexing GD3 
with other non-disialylated sugars such as GM3 and lactosyl ceramide (LacCer).  
GM1 (in ng) 
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Figure 3.9: GM1 specifically inhibits Siglec-7-Fc recognition of GD3 : 500 ng of GD3 was 
complexed with varying amounts of GM1 (A), GM3(B) and lactosyl ceramide (LacCer)(C). 
100 μl of each complex was plated out and recognition of GD3 by Siglec-7-Fc examined. 
Experiment carried out as detailed in the legend of figure 3.8. Error bars represent SEM. 
Data is representative of 1 of 3 experiments conducted.  X-axis represents total input of 
ganglioside complexes in 100 μl volume. 
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Figure 3.9 (A) shows that Siglec-7-Fc binding of GD3 is affected by increasing 
amounts of GM1. However, recognition of GD3 when in complex with GM3, 
figure 3.9 (B), or with LacCer, figure 3.9 (C), by Siglec-7-Fc remained 
unaffected. 
 
3.4 Siglec-7-Fc recognition of GD3 is inhibited in the presence of GM1 – 
liposome ELISA  
The lipid layers of liposomes mimic cell membranes. Hence to confirm the 
above findings of the inhibitory effect of GM1 on GD3, the gangliosides were 
reconstituted into liposomes. These were coated out onto microtitre plates and 
detected using Siglec-7-Fc.  
 
3.4.1 Testing of GD3 or GM1 reconstituted liposomes  
Liposomes were prepared using cholesterol, sphingomylein and 
dicetylphosphate. These were then left either blank or reconstituted with 500 ng 
of GD3 or GM1. These liposomes were then plated out and incorporated 
gangliosides detected using Siglec-7-Fc precomplexes. As shown in figure 3.10, 
the lectin specifically recognizes GD3. Blank liposomes were used as a 
negative control.   
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Figure 3.10: Siglec-7-Fc specific recognition of GD3 in liposomes - Liposomes with 
gangliosides were prepared by using cholesterol, sphingomylein, dicetylphosphate 
and the respective gangliosides (described in materials and methods) Liposomes 
,resuspended in PBS, were plated out onto 96-well mictrotitre plates and the assay 
carried out as described in the legend of figure 3.6. Error bars represent standard 
deviation (n=3) and experiment is representative of n=3.  
	
3.4.2 Siglec-7 recognition of GD3 is inhibited by GM1, in liposomes 
  
Binding of Siglec-7-Fc to GD3 was inhibited in the presence of equal amounts 
of GM1 in liposomes (1:1 molar ratio). 
 
 
 
 
 
 
 
 
Figure 3.11: GM1 inhibits Siglec-7 mediated binding of GD3 following reconstitution 
in liposomes – Liposomes were prepared with either GD3 or GM1 or a 1:1 molar ratio 
of GD3 and GM1. Assay was carried out as described in legend of figure 3.10. Assay 
represents experiment from n=2.  
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3.4.3 Siglec-7-Fc and antibody recognition of GD3 is inhibited by GM1 
GD3 was reconstituted into liposomes with increasing molar concentrations of 
GM1. The liposomes were then detected either using Siglec-7-Fc precomplexes 
(Figure 3.12, A), R24 antibody (Figure 3.12, B) and cholera toxin B subunit 
(Figure 3.12, C). R24 detection of GD3 and CTB detection of GM1 was 
optimized using liposomes reconstituted with GD3 or GM1 respectively (data in 
Appendix, A1) 
As shown in plate based ELISA, Siglec-7 recognition of GD3 was significantly 
decreased at all concentrations of GM1 (Figure 3.12, A). CTB detection of GM1 
was unaffected by the presence of GD3 (Figure 3.12, C). However, antibody 
R24 detection of GD3 was reduced by the increasing concentrations of GM1 
(Figure 3.12, B).  
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Figure 3.12: Siglec-7-Fc and R24 antibody recognition of GD3 is inhibited by GM1 in 
liposomes. Assay was carried out as described in legends of figure 3.10 and 3.12. GM1 
was added in increasing molar ratios compared to GD3 ie at 0.5 , 1, 2 and 4 times more 
than GD3 (A) Siglec-7-Fc recognition of GD3 is inhibited by increasing concentrations of 
GM1 (B) Recognition of GD3 by the R24 antibody is also reduced by increasing 
concentrations of GM1. (C) Recognition of GM1 by CTB was unaffected by the presence 
of GD3. Error bars represents SDM (n=3). Experiments using R24 and CTB on the 
recognition of liposomes carrying GD3 and GM1 were carried out only once.  
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3.5 Expression of GM1 on B16 (78) cells 
Having established in both ELISA based and liposome based assays that GM1 
could cis-inhibit GD3 recognition by Siglec-7, I next moved to a biological 
system using a model cell line. For this purpose, the B16 (78) cell line was 
chosen as a model system as it expresses only GM3, the precursor of all 
gangliosides belonging to the a, b and c series in the ganglioside biosynthetic 
pathway (as described in the introduction – figure 1.8) (Hirabayashi et al., 
1985). 
The B16 (78) cell line lacks in expression of GD2 synthase (GD2S) (β 1,4 
galactosyltransferase) which converts GM3 to GM2, and GD3S (α 2,8 
sialyltransferase) which coverts GM3 to GD3 (figure 3.13). However, it 
expresses the GM1 synthase (GM1S) (β 1,3 galactosyl transferase) which 
converts GM2 to GM1. Therefore this cell line was transfected with GM2S and 
GD3S to achieve surface expression of GM1 and GD3. 
 
 
 
 
 
 
Figure 3.13 – Ganglioside profile of the B16 (78) cell line when transfected with GM2S 
and GD3S 
3.5.1 Stable transfection of GD2 synthase  
In order to bring about the expression of GM1, GM2 synthase was transfected 
in this cell line. Expression of GM2 will in turn lead to the expression of GM1. 
GM2S
GM1S GD3S
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The plasmid vector CB6-GM2S-FLAG was a kind gift from Dr. Hugh Willison 
(Glasgow) and was transfected into B16 (78) cells by calcium phosphate 
transfection. Stable clones were generated by limiting dilution (as described in 
materials and methods) and cultured in selection medium with 0.5 mg/ml of 
G418. Transfectants were stained for expression of GM1 using CTB. The 
dilution of CTB to be used was optimized using the HL-60 cell line which 
expresses GM1. Figure 3.14 (A and B) represents a few clones stained with 
biotinylated CTB and Streptavidin-A488 as secondary. Most of the clones had 
similar expression of GM1, with ~50% of the cells showing relatively high 
expression. In a separate experiment, transfectants were also sorted for 
positive and negative fractions by FACS. These fractions were also analysed for 
GM1 expression as shown in figure 3.14, B.   
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Expression of GM1 on B16 (78) GM2 synthase transfectants: 1x 10E6 cells 
were harvested and incubated with 1 µg/ml of CTB for one hour on ice. Cells were then 
washed with 1XPBA (PBS + 0.25% BSA) and incubated with 1/1000 dilution of 
Streptavidin-A488 conjugate for 30 minutes on ice. Cells were washed again in 1X PBA 
A B 
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and analysed by flow cytometry. (A) Expression of GM1 on clonal population of B16(78) 
GM2 synthase transfected cells. (B)  Transfectants were subject to sorting by flow 
cytometry. The positive and negative fractions were stained with CTB for expression of 
GM1.  
 
3.5.2 Confirming the presence of GM2S-FLAG in B16 (78) cells 
In order to confirm the presence of the plasmid GM2S-FLAG in the B16 (78) 
cells transfectants, GM1 positive clones were analysed by western blotting and 
confocal microscopy.  
Figure 3.15 (A), shows western blotting carried out on whole cell lysates from 
three of the GM1 positive clones using anti-FLAG antibody. Also included are 
lysates from positive and negative fractions following a FACS sort of polyclonal 
B16 (78) GM1 cells. The intensity of anti-FLAG staining in each sample 
corresponded with the respective GM1 expression levels as analysed by flow 
cytometry. Wild type cells (lane 1) and negative fraction from FACS sorting 
(lane 4) did not stain positive for anti-FLAG antibody. However enriched fraction 
from the FACS sorting (lane 3) , clones 16 and 19 were positive for anti-FLAG. 
This confirmed the expression of the GM2S-FLAG gene within the 
transfectants. 
Figure 3.15,B is a representative image of confocal microscopy staining 
conducted on B16 (78) GM1 cells with either anti-FLAG (A) or CTB (B). Staining 
of HL-60 (positive control) and B16 (78) (negative control) were also done. Anti-
FLAG antibody showed specific punctate staining within the cell while CTB 
stains GM1 present on the cell surface. It was interesting to note that FLAG 
tagged glycosyltransferase and GM1 expression on the cells were expressed 
independent of each other. This could possibly be related to cell cycle  
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Figure 3.15: GM2S-FLAG is expressed in B16 (78) transfectants: (A) 0.5 X 10E6 cells from 
each sample was used to prepare lysates (described in materials and methods). 20µl of 
each lysate was run on a 4-12% bis-tris gel, in MES buffer. Gels were then transferred to 
nitrocellulose membrane, blocked and incubated with 1:1000 dilution of anti-FLAG or β 
actin antibody. Following overnight incubation, blots were washed and incubated with 
suitable secondary HRP antibody and detected using ECL substrate, following one hour 
incubation at room temperature. (B) 1 x 10E6 cells were fixed with 2% PFA for 10 minutes 
at room temperature (RT), washed and then permeabilized with 0.5% saponin for 10 
1 – B16                                    
2 – B16 GM1+ (clone 16)        
3 – Positive sort fraction 
4 – Negative sort fraction       
5 – B16 GM1+ (clone 19) 
6 – B16 GM1+ (clone 9) 
M- Marker 
Anti-Flag         CTB Anti-Flag + CTB 
A 
B 
 α-Flag  
  1       M         2     3    4     5   6
70 KDa 
 α-β-actin 50 KDa 
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minutes at RT. Cells were then washed with wash solution (1XPBS + 0.2% Tween-20), 
blocked for 30 minutes at RT and then incubated with anti-FLAG (5 ug/ml) or CTB (2 
ug/ml ) for 30 minutes at RT. Cells were then washed and stained with suitable secondary 
antibodies, washed and mounted onto coverslips. Cells were imaged using the LSM 700 
at x 100 magnification and images were analysed using LSM image analysis software. 
The red arrows point to the expression of GM2S-FLAG in the transfectants.  
 
regulation or post-translational modification of this glycosylatransferase. 
However no further experiments were carried to investigate this phenomenon.  
 
3.5.3 Messenger RNA levels of glycosylltransferases  
mRNA expression levels of the different synthases such as GM3S, GM1S, 
GM2S and GD1aS were all analysed by real-time quantitative PCR. Primers 
used are described in the Materials and Methods (table 2.5). Mouse tissues 
(brain, kidney, bone marrow, liver and lung) were used as positive or negative 
controls according to the reported expression levels of these enzymes. B16 (78) 
wild type cells were positive for the transcripts of GM3aS (Figure 3.16, A), 
corresponding to the reported expression of GM3 in these cells (Hirabayashi et 
al., 1985). They were also positive for the expression of GM1S and GD1AS but 
completely lacked mRNA expression of GM2S (Figure 3.16 – B, C, D). The 
GM2S transfected clones 16 and 19 showed differential expression of GM2S 
and GM1S which corresponded with the expression levels of GM1 on these 
cells as analysed by CTB staining (Figure 3.13). Both wild type and GM1 
transfectants also showed weak expression levels of GD1aS mRNA (Figure 
3.16, C) compared to the positive controls. This corresponded to the expression 
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of GD1a on B16 (78) GM1 cells by flow cytometry staining (shown in Appendix, 
A3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Relative fold change in mRNA expression of GM3s, GM2S, GM1s and GD1as 
in B16 (78) cells, plotted with SD values. mRNA was extracted from B16 cells and  
various mouse tissue samples. cDNA was prepared from 1 μg of mRNA and then RT-PCR 
conducted on these samples using optimized primers for the gene of interest. Relative 
fold change in gene expression was quantified by the Comparative ∆∆CT method, using 
GAPDH as normalizer and mouse tissue as the calibrator (taken as 1). Y-axis represents 
the fold change in gene expression, relative to kidney 
 
 GM3S GM2S 
 GM1S  GD1aS 
A B 
C D 
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3.6 Cloning and expression of GD3S in B16 (78) cells 
B16 (78) cells lack in the expression of ST8SIA1/GD3 synthase (GD3S). 
Expression of GD3 on these cells was achieved by transfecting both wild type 
and B16 (78) GM1 transfectants with GD3 synthase.  
 
3.6.1 Stable transfection of GD3 synthase into B16 (78) WT and B16 (78) 
GM1 cells 
mRNA, extracted from mouse brain lysates, was used in the generation of 
GD3S cDNA (as detailed in Materials and Methods, figure 2.1). In order to 
express GD3 on B16 (78) wild type and B16 (78) GM1 transfectants, two 
methods were tried – Ca2+phosphate and polyethylamine transfection reagent 
(PEI). While Ca2+ phosphate transfection gave greater transfection efficiency 
(20%) for the wild type cells, similar transfection efficiencies were seen for B16 
(78) GM1 cells with both methods (Figure 3.17). Transfectants were cultured in 
selection medium for 2 weeks to obtain a polyclonal population of cells 
expressing GD3.  Cells were then stained with a mouse monoclonal anti-GD3 
antibody (R24) (as described in materials and methods), followed by anti-mouse 
PE antibody.  
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Figure 3.17: Transfection efficiency of GD3S into (A) B16 (78) cells and (B) B16 (78) GM1 
cells: Cells were transfected with 30 µg of GD3S plasmid DNA by Ca2+ transfection and 
PEI (as described in Materials and methods). Numbers in the dot blots refer to 
percentage cells transfected by Ca2+ phosphate transfection in the wild type cells and by 
PEI transfection in B16 (78) GM1 cells. For antibody staining, 1x10XE6 cells were 
harvested, stained with 10 µg/ml of R24 antibody, followed by anti-mouse FITC and 
washed and analysed by flow cytometry.  
 
3.7 mRNA expressions of Cytidine monophosphate N-acetyl neuraminic 
acid hydroxylases (CMAH) gene 
The enzyme CMAH is responsible for the conversion of the N-acetyl form of 
sialic acid (NeuAc) into the N-glycolyl form (NeuGc). The expression of the 
glycolyl form of sialic acids could affect recognition of sialylated ligands by 
Siglec-7 and GD3 by the monoclonal antibody, R24.  
Previous studies have shown that the B16 (78) cell line is negative for CMAH. 
To confirm this, messenger RNA levels of the CMAH gene were analysed by 
RT-PCR as described above. Figure 3.18 shows negligible levels of CMAH 
gene expression in this cell line compared to adult mouse liver tissue which 
           A – B16 (78)            B – B16 (78) GM1 
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corresponds well with previous studies conducted on this enzyme (Gabri et al., 
2009).  
 
 
 
 
 
 
 
Figure 3.18: B16 (78) cells lack the expression of CMAH gene: Using primers for CMAH 
(described in appendix), B16 (78) wild type cells, mouse kidney and liver tissues samples 
were quantified for the expression of this gene by RT-PCR, as described in figure 3.16.  
 
3.8 Sialic acid dependent binding of Siglec-7-Fc to B16 GD3 cells 
As discussed in section 3.2, precomplexing the Siglec-7-Fc-chimeras with anti-
Fc antibody increases avidity of the lectin for its glycan ligand and enhances 
binding. Using this method, the recognition of Siglec-7-Fc to GD3 expressed on 
B16 (78) cells was analysed.  
 
3.8.1 Optimization of Siglec-7-Fc pre-complexes –RBC adhesion assay 
Formation of pre-complexes of Siglec-7-Fc with goat anti-human Fc fluorescent 
conjugate was optimized using RBCs. Different concentrations of Siglec-7-Fc 
ranging from 0.1-3 µg/ml of Siglec-7-Fc were mixed with varying concentrations 
of anti-Fc antibody (conjugated to Dylight 649) (0.1 – 3 µg/ml). Binding of the 
different combinations of these precomplexes to RBCs was then analysed by 
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flow cytometry. Based on the initial findings (data not shown), Siglec-7-Fc at 1 
µg/ml and anti-Fc antibody at 3 µg/ml were chosen as the concentrations with  
the best signal : noise ratio. To further optimize the total amount of 
precomplexes added to each sample, the assay was repeated with different 
dilutions of the precomplexes formed at this 1:3 (µg/ml) ratio, as shown in figure 
3.19.   
 
 
 
 
 
 
 
 
Figure 3.19: Optimization of the concentration of Siglec-7-Fc precomplex dilutions: 
Precomplexes were made using 1 µg/ml of Siglec-7-Fc and 3 µg/ml of goat anti-human Fc 
DyLight 649 and left to incubate on ice for one hour. 0.5% (v/v) of RBCs were treated with 
0.17 IU / ml of sialidase for 1 hour at 370C, 8% CO2 in DMEM media. Sialidase was 
quenched and removed by washing cells twice with DMEM + 10% FCS. 100 µl of different 
dilutions of Siglec-7-Fc precomplexes were added onto non-treated and treated RBCs. 
RBCs were incubated for one hour on ice with pre-complexes before washing in facs 
wash buffer and analysing by flow cytometry.  
 
Sialidase treated RBC were used as a negative control in each case. Four fold 
dilution of the 1:3 ratio of Siglec-7-Fc precomplexes was within the dynamic 
range of the flow cytometer. Therefore, it was decided to use this dilution of 
Siglec-7-Fc precomplexes for further cell based assays.   
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3.8.2 Siglec-7-Fc pre-complexes recognize B16 (78) cells in a sialic acid 
dependent manner   
Next, the recognition of GD3 expressed on B16 (78) cells by Siglec-7-Fc 
precomplexes and the R24 antibody was analysed. Figure 3.20 shows binding 
of R24 (A) and Siglec-7-Fc precomplex (B) to wild type and B16 (78) GD3 cells, 
with (+ sialidase) and without sialidase (- sialidase) treatment.  
 
 
 
 
       
 
 
 
Figure 3.20: Recognition of GD3 on B16 (78) cells by Siglec-7-Fc and R24 antibody: B16 
(78) GD3 cells were harvested and sialidase treated as described in section 3.19. Siglec-
7-Fc precomplexes were prepared as described in section 3.19. Sialidase treated 
(+sialidase) and untreated (-sialidase) cells were incubated with either (A) 10 µg/ml of 
R24 antibody or (B) 100 µl of Siglec-7-Fc precomplexes (as described above). Cells were 
stained with anti-mouse FITC antibody, washed  and then analysed by flow cytometry. 
 
R24 bound specifically to GD3 expressing B16 (78) cells, with 80% reduction in 
the intensity following sialidase treatment. Siglec-7-Fc bound GD3 in a sialidase 
dependent manner as there is 90% reduction in binding to sialidase treated 
cells. Siglec-7-Fc also gave a small shift with wild type B16 (78) cells 
suggesting the presence of unknown sialylated ligands on these cells.  
A B
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3.8.3 R24 recognition of GD3 is not inhibited by S7-Fc pre-complexes 
GM1 modulation of Siglec-7 recognition of GD3 would be examined by 
incubating B16 (78) GD3 cells with Siglec-7-Fc precomplexes, R24 antibody 
and CTB. It is possible that binding of Siglec-7 precomplexes to the cells could 
block R24 recognition of GD3. To confirm this, B16 (78) GD3 cells were 
incubated with equal concentrations of R24 and increasing concentrations of 
Siglec-7-Fc pre-complexes. Staining of wild type cells with R24 and Siglec-7-Fc 
precomplexes was used as the negative control. Figure 3.21 represents mean 
fluorescence intensity (MFI) values obtained for the antibody and precomplexes 
staining of each sample. Increasing amounts of Siglec-7-Fc did not block 
recognition of GD3 by R24 antibody. The column in the figure (B) describes the 
concentrations of Siglec-7-Fc and anti-Fc antibody used to make the 
precomplexes. 
  
 
 
 
 
 
 
 
Figure 3.21 R24 recognition of GD3 is not blocked by Siglec-7-Fc precomplexes: B16(78) 
GD3 expressing cells were incubated with increasing concentrations of Siglec-7-Fc 
precomplexes prepared as shown in the column (B) and 10µg/ml of R24 antibody. 
Following incubations and washes cells were stained with anti-mouse FITC and analysed 
by flow cytometry. (A) Graph represents MFI values obtained for Siglec-7-Fc and R24 
antibody in the different samples.  
 
 
Siglec - 7 – Fc 
(μg /ml) 
 
Anti-Fc DyLight 
(μg /ml) 
A 0.1 0.3 
B 0.2 0.6 
C 0.3 0.9 
D 1 3 
E 2 6 
F 3 9 
 A  B 
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3.9 Modulation of Siglec-7 recognition of GD3 by GM1  
A main aim of the project was to analyse the inhibition of GD3 by GM1 on cell 
surfaces and the potential modulation of Siglec-7 recognition of GD3. To 
achieve this, GD3 and GM1 gangliosides were expressed on B16 (78) cells.  
 
3.9.1 Expression of GD3 and GM1 on B16 (78) transfectants 
Figure 3.22 shows expression of GD3 and GM1 on B16 (78) cells, transfected 
with either GD3S (A) or GM2S (B) and cells transfected with both (D). Wild type 
cells were used as a negative control as they lack in expression of both GM1 
and GD3 (C). Staining procedure is detailed in materials and methods.  
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Figure 3.22 – Overexpression of GD3 and GM1 on B16 (78) cells:  B16 (78) wild type cells 
(WT) were transfected with either GD3S or/and GM2S. Transfectants were stained with 10 
µg/ml of R24 antibody  or/and 1 µg/ml of biotinylated CTB. Following incubations with 
either anti-mouse FITC or/and streptavidin PE conjugate, cells were stained with 1/300 
dilution of 7AAD (stock at 0.1 µg/ml) for 10 minutes on ice to identify dead cells before 
analysing them by flow cytometry. (A) WT cells and GD3S transfected cells stained with 
R24 antibody for detection of GD3. (B) WT cells and GM2S transfected cells were stained 
with biotinylated CTB for detection of GM1. WT cells stained with both R24 antibody and 
biotinylated CTB, showing lack in expression of GD3 and GM1 (C) B16(78) cells 
transfected with both GD3S and GM2S, for detection of GD3 and GM1 (D). Numbers in the 
gated population represents percentage of the different subsets of cells.  
 
 
R24 
D
B16 (78)  B16 (78) GD3 GM1 
C 
A B
CTB 
R24 
CTB 
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3.9.2 Siglec-7-Fc precomplex binding of B16 GD3 GM1 cells  
The B16 (78) GD3 GM1 cells were used to analyse the inhibition of Siglec-7-Fc 
recognition of GD3 in the presence of GM1. GD3 and GM1 expressing subsets 
were identified using R24 antibody and CTB. In figure 3.23, the dot plot 
represents B16 (78) cells expressing GD3 and GM1 as defined by R24 antibody 
and CTB. The different subsets of cells with high (H) and low (L) expressions of 
GD3 and GM1 have been boxed out as GD3LGM1L, GD3HGM1L, GD3HGM1H, 
GD3LGM1H. MFI values of GD3 and GM1 are shown in red, next to the dot plot.  
The subsets have been marked, keeping the MFI values for GD3 expression 
constant. The histograms on the right and left side of the dot plot represent 
Siglec-7-Fc staining of each of these subsets of cells.  
In the experiment represented in figure 3.23, Siglec-7-Fc recognition of GD3 on 
GD3HGM1L cells is 1.42 fold higher than GD3HGM1H cells. Similarly, the 
intensity of Siglec-7-Fc staining of GD3LGM1L is 2.45 times higher than the 
staining of GD3LGM1H cells. This data suggests that the presence of high 
density of GM1 and GD3 negatively regulates the recognition of GD3 by Siglec-
7 in a GM1 dependent manner. Analysis of 3 repeats of this experiment showed 
that Siglec-7-Fc binding of GD3HGM1L cells is 1.6 ± 0.08 times higher than 
binding to GD3HGM1H cells. 
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Figure 3.23 – Siglec-7 recognition of GD3 is inhibited by GM1, on B16 (78) cells: (A) Flow 
cytometric analysis of B16(78) GD3 GM1 cells using R24 antibody, biotinylated CTB and 
precomplexes of Siglec-7-Fc with anti-Fc DyLight 649 (carried out as described in 3.19). 
Following staining with anti-mouse FITC and streptavidin PE, cells were washed with 
FACS wash buffer, stained with 7AAD (as described in figure 3.22) and analysed by flow 
cytometry. Histograms represent Siglec-7-Fc staining of the different subsets (marked 
out boxes) of double transfectants identified using R24 antibody and CTB namely 
GD3LGM1L, GD3HGM1L, GD3HGM1H, GD3LGM1H. Numbers within histogram represent MFI 
values of Siglec-7-Fc precomplex staining (B) MFI values of Siglec-7 staining comparing 
GD3HGM1H and GD3HGM1L subsets of cells. Error bars represent standard error of mean 
between 3 experiments. (C) B16 (78) GD3 GM1 cells were stained with biotinylated CTB, 
CTB R24 Siglec-7-FC 
CTB + R24 R24 + Siglec-7-FC Merge 
C
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R24 mAb and precomplexes of Siglec-7-Fc and anti-Fc DyLight 649 (as described in 
above). Cells were washed, incubated with suitable concentration streptavidin-555 and 
anti-mouse FITC respectivley washed, fixed with 2% PFA before mounting onto cover 
slips. Images were taken on the LSM 700, at x40 magnification and analysed using the 
LSM image analysis software. White arrows in the images point to the binding of Siglec-
7-Fc to GD3HGM1L cells; Red arrows represent R24 and CTB binding to GD3HGM1H cells. 
 
3.10 Minimal GD3 GM1 co-localization on double transfectants 
From the above described flow cytometry data, it was evident that only a small 
percentage of the B16 (78) cells have high expression of both GM1 and GD3. 
To confer masking of the GD3 epitope, both GM1 and GD3 would have to be 
co-localized on the same micro-domains. Therefore the percentage of cells 
showing GD3 and GM1 co-localization was quantitatively assessed using 
confocal microscopy staining.  
R24 and CTB stained wild type and GD3, GM1 B16 (78) expressing cells were 
fixed and imaged using the LSM 700. Imaged cells were quantified using the 
Volocity software and cells were divided in two groups - (A) number of cells 
expressing both GD3 and GM1 and (B) number of GD3 GM1 positive cells 
having patches of GD3 GM1 co-localization. Table 3.3 represents percentage of 
each group calculated from a total of 739 cells from 18 images analysed. Only 
3% of the total number of cells had patches of GD3 GM1 co-localization. Bar 
chart (Figure 3.24) represents the distribution of cells from each group for the 
individual images.   
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Table 3.1:  Quantification of B16 (78) cells expressing both GD3 and GM1 and cells 
carrying patches of GD3 GM1 co-localization 
 
	
Figure 3.24: Distribution of GD3 and GM1 on B16 (78) cells : Histogram represents the 
number of cells from each image of double transfected B16 (78) cells expressing GD3 
and GM1 and the number of cells showing patches of co-localization of the two 
gangliosides.  
Figure 3.25 shows representative images of wild type (A) and double 
transfectants (B, C and D). Figure 3.25, D is a 3D projection of the cell shown in 
figure 3.25 (C). The images clearly demonstrate that the majority of GD3 and 
GM1 exist independent of each other, in separate spatial microdomains on the 
cell membrane. 
Total number of cells 
analysed 
Cells expressing 
both GD3 and GM1 
Cells having patches of co-
localization of GD3 and GM1 
739 56 25 
% of the total number of 
cells analysed 
 
7% 
 
3% 
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Figure 3.25: GM1 and GD3 are expressed laterally segregated of each other on B16(78) 
cells - Confocal microscopy analysis of GD3 and GM1 on B16 (78) transfectant cells: B16 
(78) wild type and transfectant cells were harvested, stained with CTB and R24 antibody, 
followed by their secondary antibodies – Streptavidin-555 and anti-mouse FITC as 
    (A) 
B16 (78) 
    (B) 
B16 (78) 
GD3 GM1 
    (C) 
B16 (78) 
GD3 GM1 
    (D) 
3D view of  
  B16 (78) 
GD3 GM1 
CTB      R24    Merge 
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described in figure 3.23. Cells were then fixed with 4% PFA and mounted onto cover 
slips. Images were collected at 100x magnification using the LSM 700. Image analysis 
was carried out using Zeiss LSM Image browser. White arrows represent patches of co-
localization of GD3 and GM1. Red arrows represent non-co-localized GD3 and GM1. 
Images are from experiment representative of n=3.  
 
3.11 Cholesterol depletion of lipid rafts 
The complex nature of gangliosides and their expression patterns can make 
them “invisible” to certain methods of detection. Extraction of gangliosides from 
cells has been reported not to correlate with their immuno staining (Nakakuma 
et al., 1992). This is because the epitopes are not exposed for optimal binding 
by the antibody being used. In such cases, the ganglioside is known to be 
“cryptic”. This is a well reported phenomenon and organization of these 
gangliosides in lipid rafts is attributed to be responsible for their cryptic nature 
(Lloyd et al., 1992; Greenshields et al., 2009).  
To confirm that GD3 and GM1 were not forming complexes on the B16 (78) cell 
line, it was decided to disrupt lipid rafts by depleting the cells of cholesterol. 
Methyl beta cyclodextrin (MβCD) is a cholesterol sequestering reagent that is 
routinely used in disrupting lipid rafts (Greenshields et al., 2009). Depleting 
cholesterol from cell membranes would be expected to dissociate any potential 
GD3 GM1 ganglioside complexes and release cryptic GD3. The efficiency of 
MβCD treatment can be analyzed by measuring the cholesterol released 
following the treatment (Greenshields et al., 2009). 
 
 
 
111	
	
	
	
	
	
3.11.1 Titration of effective concentration of MβCD 
Firstly, the effect of lipid raft disruption by MβCD on ligand recognition of Siglec-
7-Fc was analyzed using B16 (78) GD3 cell line. As shown in figure 3.26, 
increasing concentrations of MβCD reduced the binding of Siglec-7-Fc 
precomplexes to these cells. Therefore this technique was used as a 
quantitative measure of raft disruption in the experiments conducted here. 
From the histogram of Geo Mean Intensities (Figure 3.26, B), it can be seen 
that, a concentration of 10 µM resulted in a reduction of > 90% of Siglec-7-Fc 
binding. There was also a decrease in the percentage of live cells at higher 
concentrations of MβCD, as measured by 7AAD staining (Figure 3.26, C). 
Based on these findings, it was decided to use 1 µM of MβCD for further 
experiments.  
                      
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 Optimizing MβCD concentration for lipid raft dissociation: 1 x10E6 B16 (78) 
cells were harvested and treated with different concentrations of MβCD for 30 minutes at 
370C, in serum-free media. Cells were washed with ice-cold serum-free media and 
CB 
A
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incubated with (A) and (B) Siglec-7-Fc precomplexes as described earlier (B) with 7AAD 
as described in figure 3.22. Washed cells were analysed using flow cytometry  
 
3.11.2 Effect of MBCD on R24 and CTB binding to B16 cells 
MβCD treated cells were analysed for binding of Siglec-7-Fc, R24 and CTB to 
double transfected B16 (78) cells.  While Siglec-7-Fc binding of B16 (78) GD3 
cells was significantly reduced following treatment with MβCD, there was no 
effect on B16 (78) GD3 GM1 cells (Figure 3.27, A). Similarly the binding of R24 
was not affected in the double transfectants following cholesterol treatment 
(Figure 3.27,B). These results suggest an absence of cryptic GD3 on B16 (78) 
GD3 GM1 cells. Hence disruption of lipid rafts had no effect on either Siglec-7-
Fc or antibody R24 binding. CTB binding to these three populations of cells are 
shown in Figure 3.27 (C).  
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Figure 3.27: Absence of cryptic GD3 on B16 (78) GD3 GM1 cells: B16 (78) cells were 
harvested and treated with or without 1 µM MβCD as described in figure 3.26. Cells were 
washed and incubated with R24 antibody, CTB or Siglec-7-Fc precomplexes. Following 
incubation with either anti-mouse PE or Streptavidin conjugate, cells were washed with 
facs wash buffer, stained with 7AAD and analysed by flow cytometry. Error bars 
represent standard deviation between samples (n=3). Experiment shown is 
representative of n=2. 
C 
B 
A 
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3.12 Discussion  
Rinaldi et al., 2009 showed that on PVDF arrays, Siglec-7-Fc recognition of 
GD3 was significantly inhibited when this disialic acid containing ganglioside 
was in complex with structurally more complex gangliosides such as GM1. The 
aim of this project was to evaluate the biological significance of these findings in 
a biological system and to examine the role of such glycolipid complexes in 
immune cell receptor modulation. 
Initial assays conducted here were aimed at re-confirming findings of the 
glycoarray data (Rinaldi et al., 2009). Recombinant Siglec-7-Fc, generated by 
CHO cells in UCHO media, was precomplexed to anti-Fc antibody to enable 
avidity based binding of the lectin to its glycol ligand (Figure 3.2). Precomplexes 
were specifically able to recognize GD3 coated on microtitre plates, over a 
range of concentrations (20 µg to 30 ng) (Figure 3.6). Siglec-7-Fc was also able 
to recognize GD3 incorporated into liposomes (Figure 3.10). The masking effect 
of GD3 by GM1 was seen when the gangliosides were either coated directly 
onto plates or when they were incorporated into liposomes (Figure 3.9 and 
3.11).  
These findings suggested that irrespective of the assay format, a structurally 
more complex ganglioside is able to inhibit Siglec-7 recognition of GD3. This 
has been named as “complex attenuated” effect (Rinaldi et al., 2009). This 
could be attributed to either steric hindrance by a structurally more complex 
ganglioside such as GM1 or formation of a neo structure when the two sugars 
are in close proximity. Both these mechanisms could potentially block Siglec-7 
recognition of its natural ligand.  
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Gangliosides are overexpressed in many cancers and play important roles in 
cell adhesion, motility, etc. Overexpression of gangliosides on tumour surfaces 
may lead to their clustering in microdomains such as rafts. Structural 
determinants and underlying glycosidic linkages affect lectin recognition of their 
carbohydrate ligand. Hence in tumours, overexpression and clustering could 
affect lectin and antibody recognition of these tumour associated antigens 
(TAA) and impact tumour associated immunity.  
The monoclonal antibody, R24 and toxin CTB were used in parallel wth Siglec-
7-Fc precomplexes to confirm the presence of GD3 and GM1 incorporated into 
liposomes. Interestingly, increasing concentrations of GM1 also inhibited R24 
antibody recognition of GD3 (Figure 3.12). At 4 times higher amounts of GM1, 
there was complete inhibition of R24 binding. It is possible that the terminal 
NeuAcα2-8NeuAc structure on GD3 is masked by GM1, which blocks 
recognition by the R24 antibody. However, no experiments were undertaken to 
investigate this finding further.  
R24 antibody is known to have strong preference for the disialic acid epitope 
NeuAcα2-8NeuAcα2-3Gal, found on GD3, GD1b, GQ1b (Tai et al., 1998)(Avril 
et al., 2006). In a study by Greenshields et al., (2009), antibody recognition was 
shown to be affected by ganglioside complexes. GM2, GD1a and GD1b were 
found to negatively affect the recognition of an anti-GM1 antibody for GM1 by 
masking the non-reducing galactose and internal sialic acid epitope on GM1 
(Greenshields et al., 2009). In their study, similar results were also obtained 
when PC12 rat neuroendocrine cells were overexpressed with GD1a and GM1. 
However in these experiments, GM1 binding by CTB or another clonally 
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different GM1 antibody was unaffected. These results were explained by the 
low affinity of the antibody for its epitope compared to CTB.  
For examining the biological significance of the inhibition imposed by GM1, a 
mouse melanoma cell line, B16 (78), was genetically modified to over express 
both GM1 and GD3. The expression of GM1 and GD3 was confirmed using 
cholera toxin subunit B (CTB) and R24 antibody in flow cytometry analysis 
(Figure 3.22). Transfection of GM2S in these cells resulted in clonally restricted 
expression of GM1 (Figure 3.14) whereas >98% of cells stained positive for 
GD3 when transfected with GD3S. R24 mAb binding to these cells was GD3 
mediated as no binding of wild type cells was seen (Figure 3.20, A). Similar 
findings have been reported for the P815 GD3 transfected cells (Nicoll et al., 
2003).  
Glycosyltransferases are responsible for the biosynthesis of gangliosides. 
These enzymes are transcriptionally regulated and their expression determines 
ganglioside repertoires at the cell surface (Ruan et al., 1992). Abnormal 
glycosylation patterns on tumour cells can be directly related to the relative 
levels of these glycosyltransferases. Ganglioside composition of cells is not only 
regulated by the levels of the different glycosyltransferases but also depends on 
the relative ratio between them. Some neuroblastoma cell lines express high 
levels of GD2 but low levels of GD3. This has been related to low levels of 
GD3S and comparatively higher levels of GM2S (Ruan et al., 1999).  
In the B16 (78) cells double transfected with GM2S and GD3S, only between 5 
and 20% of the cells co-expressed GD3 and GM1. The percentage of these 
double positive cells decreased while cells were maintained in culture. The 
remaining subsets within this population of cells were predominantly GD3 
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positive or negative for both GD3 and GM1. Only 10% of the cells were positive 
for GM1.  
Transcript levels of the enzymes involved in the biosynthesis of GD3 and GM1 
were analysed by quantitative real-time PCR and correlated to ganglioside 
profiles in B16 (78) cells. The wild type cells were positive for expression of 
transcripts for GM3s, GM1s and GD1as (Figure 3.16). mRNA levels of GM2s in 
B16 (78) GM1 clones 16 and 19 corresponded to the expression of GM1 on 
these cells. A possible role of cell cycle regulation of this glycosyltransferase 
(GM2S) was suspected. Further experiments in this direction are required. 
Another possible explanation for this phenomenon is the rapid conversion of 
GM1 into the next ganglioside in the biosynthetic pathway, GD1a. However, 
when GM2S transfected cells were stained with anti-GD1a antibody (MOG35), 
< 1% cells stained positive (shown in Appendix, Figure A3). The mRNA level of 
GD1as was examined by RT-PCR (Figure 3.16,D) and found to be comparable 
to mouse liver cells which are reported to have low transcript levels of this 
enzyme.  
The limited expression of GM1 might also be regulated by other factors such as 
the level of GM1s which catalyses the conversion of GM2 to GM1. The mRNA 
levels of GM1s in the transfectants were compared to expression levels in 
mouse brain tissue. Transcript levels were found to be 20 fold less in the clone 
with the maximal expression of GM1 (Clone 16) and 38 fold less in the clone 
with weak expression of GM1 (clone 19) (Figure 3.16, C). Based on these data, 
it is possible to infer that low levels of GM1s in these cells limit the conversion of 
all of the cellular pool of GM2 into GM1. Expression of GM2 would have to be 
analysed by means of antibody staining.  
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In the double transfectants, both GM2S and GD3S would be expected to 
compete for the substrate GM3 and convert it to either GM2 or GD3 
respectively. While GD3 expression depended only on GD3S, GM1 expression 
depended on both recombinant GM2S and endogenous GM1s. Weak 
expression of GM1s could therefore limit the expression of GM1 in these cells. 
Moreover ganglioside composition of melanoma cells are known to be typically 
GM3=GD3 and less commonly GM3=GD3=GM2=GM1 (Ruan et al., 1999). The 
pattern of ganglioside expression in this mouse melanoma double transfectant 
cells is in line with these previous studies and may explain the higher 
percentage of double transfected cells only expressing GD3. Co-expression of 
both GD3 and GM1 is present in only a very small subset in the double 
transfectant population. 
Siglec-7-Fc bound the wild type cells weakly and gave a strong shift in 
fluorescence intensity with B16 (78) GD3 cells (Figure 3.20, B). At least 80% of 
increased binding of Siglec-7-Fc to B16 (78) GD3 cells compared to wild type 
cells can be attributed to GD3 expression. 
Pre-complexing of an Fc chimera can lead to the formation of large complexes 
(Figure 3.2). Therefore the possible blocking of R24 recognition of GD3 by the 
Siglec-7-Fc precomplexes was examined (Figure 3.21). Interestingly, the R24 
antibody recognition of its disialic acid epitope on GD3 was not affected by 
increasing amounts of Siglec-7-Fc precomplexes. High affinity of R24 mAb for 
its ligand could overcome the avidity based binding of the lectin precomplexes 
to GD3. The main aim of the project was to examine the blocking effect of GM1 
on the recognition of GD3 by Siglec-7-Fc.  Therefore experiment to analyse the 
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effect of Siglec-7-Fc recognition of GD3, in the presence of saturating amounts 
of R24 antibody was not carried out.  
The biological significance of the masking effect of GD3 by GM1 (as seen in the 
plate based assays) was analysed by Siglec-7-Fc staining of the double 
transfectant population (Figure 3.23). The presence of four subsets within this 
transfectant population made the assay internally well controlled.  Siglec-7-Fc 
precomplexes binding of GD3HGM1H expressing cells was significantly weaker 
than GD3HGM1L cells. These results correlate with the ELISA based assays 
using ganglioside complexes directly coated onto plates or incorporated into 
liposomes. Confocal microscopy staining using Siglec-7-Fc precomplexes also 
showed a similar bias for Siglec-7-Fc recognition of GD3 not co-localized with 
GM1.  
Confocal microscopy staining also showed that in cells with expression of both 
GD3 and GM1, the gangliosides were laterally segregated. Only 7% of the 
double transfectants had dual expression of both GD3 and GM1 on their cell 
surface and only 3% of the total cells had patches of co-localization of the two 
gangliosides (Figure 3.24). For GM1 masking of the sialic acid epitope on GD3, 
co-localization of the two gangliosides on the same lipid raft would be a pre-
requisite. The lack of co-existence of these gangliosides on the same 
microdomain could have implications on the interaction of these two species of 
gangliosides and thereby hinder cis-interactions. Thus it would be difficult to 
assess the biological significance of this finding using primary NK cells.  
To confirm the absence of masked/cryptic GD3 on these transfectants, 
cholesterol depletion studies using MβCD were undertaken. Although Siglec-7-
Fc binding to B16 GD3 cells was significantly affected following MβCD 
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treatment, there was no change seen in the binding of Siglec-7-Fc to double 
transfectants which implies that possibly only a very small percentage of GD3 
and GM1 exist within the same microdomains (Figure 3.27). Cholesterol 
depletion had also no effect on R24 binding to the double transfected cells. This 
reconfirms the absence of any cryptic GD3 when over expressed on these cells.  
In parallel with the work on the B16 (78) melanoma cell line, co-expression of 
GD3 and GM1 was also attempted on another cell, the MDA-MB-231. These 
human breast cancer cells are negative for GD3 expression but expresses 
gangliosides belonging to the a-series of the ganglioside biosynthetic pathway 
ie GM2 and GM1. This cell line was therefore transfected with pCDNA 3.1- 
GD3S plasmid and clones expressing different levels of GD3 and GM1 were 
obtained. However on examining these transfectants by confocal microscopy, a 
similar pattern of lateral segregation of GD3 and GM1 was observed (data not 
shown).  
Lateral segregation of gangliosides on cell surface depends on various factors. 
While my studies were underway, Dong et al., (2010) reported that GD3 and 
GM1 have distinct distribution patterns when co-expressed on human breast 
cancer cell lines. Using multiple reaction monitoring (MRM) analysis, GD3 was 
proposed to distribute onto glycolipid enriched microdomains (GEM/lipid rafts) 
and non-GEM domains based on the fatty acid composition of these molecules 
and degree of saturation of the fatty acid chains. The ability of GM1 and GD3 to 
cluster independently of each other in membrane rafts with minimal co-
localization has also been previously demonstrated. However these 
experiments were conducted on artificial monolayers and healthy rat neuronal 
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cells (Vyas et al., 2001). Therefore their findings cannot be extrapolated to 
ganglioside expression on tumours. 
Gangliosides are complex molecules. While their large hydrophilic 
oligosaccharide head groups protrude out into the extracellular milieu, their 
hydrophobic ceramide backbone is embedded within the lipid layers of the cell 
membrane. Their expression, distribution and organization in lipid domains on 
the cell surface are dependent on various factors (Sonnino et al., 2007). 
It is possible that on the B16 (78) cell line too, differences in structure and 
composition of the over-expressed gangliosides favours their lateral 
segregation into separate membrane microdomains. Interactions of these 
molecules with other protein and lipid components of the cell membrane might 
be another factor affecting their distribution on the cell membrane. The cis-
interactions between GD3 and GM1 was hypothesized to alter NK cell 
cytotoxicity. It would be therefore interesting to analyze if such interactions 
occur on non-transformed cells as well as primary tumours.  
The role of GD3 in modulating the role of Siglec-7 in NK cells is discussed in 
chapters 4 and 5.  
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Chapter 4 
Role of Siglec-7 in modulating LFA-1 recognition on NK cells  
 
4.1 Introduction 
Siglec-7 is evolutionarily related to the mouse neutrophil siglec, Siglec-E (as 
described in the introduction, page 26). Recent findings from our lab suggested 
a regulatory role for Siglec-E in integrin (CD11b) signalling (McMillan et al., 
2013). Their results also showed a constitutive association of Siglec-E with 
SHP-1 and its role in regulating β2 integrin activation of Syk tyrosine kinase and 
p38. These findings would imply an evolutionarily conserved function of Siglec-
7 in negatively regulating integrin functions.  
The aim of this project was to investigate the role of the NK cell inhibitory 
receptor, Siglec-7 in regulating β2 integrin mediated functions. A brief overview 
on intergrin biology in leukocytes will be detailed here before explaining the 
specific aims of this part of the project.  
Integrins are heterodimeric cell – surface adhesion proteins expressed on all 
leukocytes and are important in aiding leukocyte migration both in normal 
physiology and during inflammation (Hogg et al., 2002),(Harburger and 
Calderwood, 2009). Leukocytes commonly express the following β2 integrins – 
Leukocyte Function Associate Antigen-1 (αLβ2), Mac-1(αMβ2) and the Very 
Late Antigen-4 (α4β1) belonging to the β1 family. ICAM-1, a cell surface 
adhesion molecule, is the preferred ligand for adhesion receptors such as LFA-
1 and Mac-1 (Marlin and Springer., 1987)(Lawson and Wolf.,2009). Integrin 
activation results in cellular responses such as survival, respiratory burst, 
cytokine production, complement mediated phagocytosis, cellular polarization 
and degranulation (Abram and Lowell, 2009). These heterodimeric 
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transmembrane proteins consist of an α and a β subunit. Integrins are tightly 
regulated under normal physiological conditions and therefore do not mediate 
cell-cell or cell – extracellular matrix interactions. Upon receiving signals from 
chemokines and other cellular receptors, integrins go from a completely 
inactive, bent conformation through an intermediate affinity state to a high 
affinity, open conformation. This is known as the “inside-out” signalling. (Abram 
and Lowell, 2009;Hogg, Patzak and Willenbrock, 2011). Along with the above 
mentioned conformational changes, integrins also undergo clustering in lipid 
rafts for enhancing their avidity for ligands.  
 “Outside in” signalling follows clustering of integrins and conversion of the 
intermediate form of LFA-1 to the high affinity form and tightening adhesion with 
ligands. The cellular responses that follow outside-in signalling are varied in 
different cell types of leukocytes. Outside in signalling of integrins can also be 
bought about by the addition of divalent cations and by antibody crosslinking 
(Yan, Fumagalli and Berton, 1995). (Hogg et al., 2003). Figure 4.1 (A) is a 
schematic representation of some of the key molecules involved in the integrin 
signalling cascade in leukocytes (Adapted from Hogg, Patzak and Willenbrock., 
2011).  
Similar to its role on T-cells and B-cells, LFA-1 plays an important role in 
adhesion and co-activation of NK cells (Kurzinger et al., 1981). Its role in NK 
cells has been detailed in chapter 1 (pages 12-13 ). Functions and downstream 
signalling of LFA-1 in NK cells have been studied using NK cell lines and 
primary NK cells (Barber et al., 2004)(Perez et al., 2004). Depending on the 
experimental strategy involved, these studies have used either ICAM-1 
expressed as Fc-chimeras and coated on beads, plates etc or target cells that 
express ICAM-1.  
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Figure 4.1 (A): Outside-in signalling of LFA-1 : (a) Following inside out signalling Vav-1, 
talin, possibly kindlin3, RAP1 and RAPL associate with LFA-1 at the cell membrane (b) 
Src and Syk family members associate with LFA-1 and get phosphorylated following 
binding of LFA-1 to ICAM-1. Phosphorylated ZAP70 then phosphorylates Vav1 causing 
talin release from the Vav1-talin complex. (c) Binding of talin to the β-subunit of LFA-1 
and RAPL to the α-subunit results in the final conversion of LFA-1 into the high-affinity 
conformation. PtdIns(4,5)P2, phosphatidylinositol-4,5-bisphosphate; RAPL - regulator of 
adhesion and cell polarization enriched in lymphoid tissue. Adapted from Hogg, Patzak 
and Willenbrock., 2011) 
 
Based on the findings of Siglec-E in the negative regulation of CD11b in 
neutrophils, the following two models were proposed for the possible role of 
Siglec-7 in NK cells. Model A (Figure 4.1, B) suggests that Siglec-7 recognizes 
glycosylated ICAM-1 (or other sialylated molecules in the vicinity) and dampens 
signalling triggered by activated LFA-1. According to model B (Figure 4.1,B), 
constitutive association of Siglec-7 with receptors like LFA-1 is sufficient to 
dampen the downstream signalling generated by LFA-1 following ligand 
recognition.  
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Figure 4.1 (B): Proposed model of Siglec-7 inhibition of LFA-1 signalling. In model A, 
Siglec-7 recognition of the glycosylated ICAM-1 results in negative regulation of LFA-1 
mediated signalling. In model B, Siglec-7 is constitutively cis-associated with LFA-1. 
Activation of LFA-1 following ligand binding is sufficent for Siglec-7 to exert its inhibitory 
functions on LFA-1 signalling.  
 
Project Aims:  
The aims of this project were to investigate the potential role of Siglec-7 in 
modulating integrin functions in the context of NK cell biology by:  
1) Examining LFA-1 mediated functions such as adhesion and perforin 
polarization in the presence and absence of siglec-7 expression. 
2) Investigating downstream signalling events mediated by LFA-1 following 
ligand binding in the presence and absence of siglec-7 expression 
Towards these goals an NK cell line and purified recombinant ICAM-1-Fc was 
used in this project. Preliminary cytotoxicity assays involving LFA-1 and ICAM-1 
are presented in Chapter 5. 
Downstream 
signalling 
  Model B 
Siglec‐7       Activated LFA‐1 
Glycosylated 
ICAM‐1 
Downstream 
signalling 
  Model A 
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ICAM-1 consists of 5 Ig-like domains (D1-D5), a transmembrane domain and a 
short cytoplasmic tail. ICAM-1 is heavily glycosylated in its D2, D3 and D4 
domains carrying 4, 2 and 2 predicted sites of N-linked glycosylation 
respectively as shown in Figure 4.2, A. LFA-1 interacts with the D1 of ICAM-1 
via its insertion (I) domain (Jun et al., 2001;Landis et al., 1994). Under 
physiological conditions, ICAM-1 is expressed at low levels on endothelial cells 
and lymphocytes but its expression is upregulated in various pathological 
conditions by inflammatory cytokines for eg: asthma, atherosclerosis and 
tumours (Hubbard and Rothlein., 2000)(Roland et al., 2007). 
 
 
 
 
 
 
        
 
 
 
Figure 4.2: Schematic representation of (A) ICAM-1 with N-glycosylation sites (shown as 
red spheres) (B) Recombinant dimeric ICAM-1 linked to the Fc region of IgG 
ICAM-1-Fc chimeras are useful tools in aiding the study of receptor-ligand 
function. Structurally, they consist of dimers of the five extracellular Ig domains 
of ICAM-1 linked to the hinge region and Fc fragment of human IgG (Figure 
4.2,B). 
The functional role of receptors is studied by over-expressing or blocking the 
receptor of interest (blocking antibodies or gene silencing) in either primary cells 
B 
ICAM-1 dimer 
Fc region of IgG
Hinge region of IgG 
A 
N-glycosylated extracellular domains of 
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or cell lines. Here, over-expression of Siglec-7 in an NK cell line was the chosen 
method.  
NK cell lines are routinely used as model systems in studying the biological 
functions of NK cell receptors, screening drug candidates that will modulate NK 
functions etc (Yusa and Campell., 2003)(Wang et al., 2012). Some examples of 
human NK cell lines include NK92, NKL, KHGY-1, NK3.3. While most of these 
cell lines have excellent cytotoxicity towards NK target cells, their receptor 
profiles vary considerably (Gong et al., 1994)(Yagita et al., 2000) (Kornbluth et 
al., 1982).  
Having almost no expression of any of the inhibitory KIR receptors, the NK92 
cell line exhibits potent cellular cytotoxicity mediated by perforin and granzymes 
(Gong, Maki and Klingemann, 1994) (Lutz and Kurago, 1999). This is an IL-2 
dependent cell line and hence requires an external supply of IL-2 for survival, 
proliferation and effector functions (Tam et al., 1999). NK92 are known to 
express adhesion molecules other than CD11a such as CD2, CD11c and CD28 
(Zheng et al., 2009). 
 
4.2 Generation and characterization of ICAM-1-Fc 
Chinese hamster ovary (CHO) cells are the most commonly used cell line for 
the large scale production of antibodies and recombinant proteins due to the 
stable, long term and mammalian glycosylation patterns which can be attained 
(Hossler, Khattak and Li, 2009). Here, CHO cells were chosen for the 
expression of the ICAM-1-Fc chimera. Wild type CHO cells are not known to 
express the α 2,6 sialyltransferase, ST6Gal1, since they only produce N-glycan 
sugar chains carrying the NeuAc α 2,3 Galβ1,4GlcNA-R (Lee, Roth and 
Paulson, 1989). Therefore to increase the probability of the ICAM-1-Fc having 
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N-linked glycosylation with NeuAc α 2,6 Galβ1 pattern, thereby also favouring 
recognition by Siglec-7, it was decided to co-transfect these cells with the 
enzyme ST6Gal1.  
 
4.2.1 Cloning of ICAM-1-Fc and ST6Gal1  
Previously constructed ICAM-1-Fc and ST6Gal1 clones, kindly provided by Dr 
D. Simmons and Dr S. Kelm respectively were used. ICAM-Fc cloned into 
pCDM8 vector was retransformed into K12 MC1061/P3 strain of ultracompetent 
E.coli cells while the ST6Gal1 cloned into pCDNA 3.1 (neomycin resistance) 
was retransformed into DH5α cells (detailed in the Materials and Methods 
section – Section 2.26).  
 
4.2.2 Transfection of ICAM-Fc and α 2,6 sialyltransferase plasmids into 
CHO cells  
Supernatants were collected after one week and an ELISA conducted on them 
to confirm the presence of ICAM-1-Fc and α 2,6 linkages using anti-ICAM-1 
antibody and Sambucus niagra agglutinin (SNA) respectively (Figure 4.3). The 
lectin SNA has a strong preference for Neu5Ac α 2,6 Gal sequences (Naoto 
Shibuya et al., 1996). Single cell cloning of transfected CHO cells was 
performed by limiting dilution as described in the methods section. Cloning by 
limiting dilution follows the Poisson probability distribution, according to which a 
clonal frequency of 33% would have > 90% chance of being clonal (Kojima et 
al., 1988). 
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Figure 4.3: ELISA to confirm the transfection of ICAM-1-Fc and ST6Gal1 in non-clonal 
CHO cells. 96 well plates were coated with anti-Fc IgG, blocked and plated with different 
dilutions of supernatant of transfected CHO cells. Plates were then incubated with 
biotinylated anti-ICAM antibody or SNA and detected with streptavidin alkaline 
phosphatase and pNPP substrate.  Bars represent the different preparations of ICAM-1-
Fc with and without ST6GalI and media alone which was used as blank in the assay.  
 
On this basis, an anti-Fc ELISA was conducted to test for selected clones 
(Figure 4.4,A). Only 2 clones from the ICAM-1-Fc transfection and 6 clones 
from the ICAM-1-Fc + ST6Gal1 double transfection tested positive for anti-Fc 
antibody. These clones were then subjected to anti-ICAM-1 and SNA ELISAs 
(Figure 4.4, B and C). Clone 17 from the ICAM-1-Fc transfection alone was 
positive for ICAM-1 and negative for SNA binding while clones 54 and 58 from 
the double transfection were strongly positive for both ICAM-1and SNA binding. 
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Figure 4.4: CHO cells transfectants express ICAM-1-Fc - ELISA was carried out to 
characterize supernatant from CHO cell clones expressing ICAM-1-Fc and ST6Gal1. 
ELISA was carried out on supernatants from different clones to detect (A) Fc (B) 
ICAM-1 (C) α 2,6 linkages. 96 well plates were coated with anti-Fc IgG, blocked and 
1/15 dilution of supernants of clones that grew in selection media were added and 
incubated for 1 hour at room temperature. Plates were then incubated with 
biotinylated anti-ICAM-1 antibody or biotinylated SNA for one hour at room 
temperature. Washed plates were incubated with Streptavidin alkaline phosphatase 
(1:1000) and 100 µl of pNPP substrate was added and plates read at 405nm. For Fc 
detection, plates were incubated with 100 µl of anti-human Fc-alkaline conjugate 
(n=2). Error bars represents standard deviation (n=3). 
A ) Anti-Fc ELISA 
B ) Anti-ICAM ELISA 
C ) SNA ELISA 
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4.2.3 Purification of ICAM-Fc supernatants 
Both Protein A and G bind most human IgG subclasses with high affinity and 
are therefore routinely used in the purification of Fc chimeras, antibodies and 
other recombinant proteins. The purification of ICAM-1-Fc was initially 
undertaken using protein G Sepharose column. However the yields were low 
and the flow through contained substantial levels of unbound Fc chimera as 
determined by ELISA (data not shown).  
Hence it was decided to re-run the supernatants through a protein A Sepharose 
column. Elutions were measured using the Nanodrop (readings given in table 
1). Table 4.1, A, shows details of ICAM-1-Fc supernatant quantified using 
ELISA from the different CHO cell harvests and table 4.1, B, gives protein 
concentrations as determined by Nanodrop readings before and after buffer 
exchange. 
Table 4.1 A: ELISA Quantification of ICAM-1-Fc supernatant from CHO cell harvest 
 
ICAM-Fc 
clones 
Elution 1 
(mg per 
ml) 
Elution 2 
(mg per 
ml) 
Total Protein 
mg/2ml 
After spin 
concentration 
(mg/ml) 
Total protein 
(µg) 
            
Clone 17 0.95 0.04 0.99 1.35 1200 
Clone 54 1.09 0.13 1.22 1.30 1300 
Clone 58 0.67 0.09 0.76 0.90 900 
            
Table 4.1 B: Protein quantified by Nanodrop after ICAM-1-Fc purfication using Protein A 
column 
 
 
  Clone 17   Clone 54   Clone 58   
  
Concentration 
(mg/ml) 
Total 
protein  
(µg)  
Concentration 
(mg/ml) 
Total 
protein 
(µg)  
Concentration 
(mg/ml) 
Total 
protein 
(µg)  
Harvest 1 1.22 612.43 1.59 792.53 1.02 507.86 
Harvest 2 1.26 628.31 1.53 765.96 1.03 512.80 
Harvest 3 1.59 794.94 1.35 675.64 1.29 647.25 
Harvest 4 1.72 858.21 1.65 826.26 1.41 704.60 
Harvest 5 0.97 487.33 1.53 764.24     
  1.35 3381.22 1.53 3824.63 1.19 2372.50 
Volume of 
supernatant   2.5 L   2.5L   2L 
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4.2.4 SDS page analysis of purified proteins 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is the 
most convenient method of separating proteins according to the molecular 
weight and analyzing their purity. The use of a reducing agent in the samples 
breaks down intramolecular disulfide bonds.  
3 µg of each ICAM-1-Fc protein, non-reduced and reduced, were run on a 
gradient polyacrylamide gel under constant voltage (Figure 4.5, A). Figure 4.5 
(B) shows linear regression analysis curve plotted using relative migration 
distance (Rf) vs the known molecular weights (MW) of the ladder.  
The calculated molecular weights (MW) of the ICAM-1-Fc under reducing 
conditions are as follows – clones 17 and 54 – 109.58 KDa and clone 58 – 
105.3 KDa. The molecular weight of the non-reduced Fc proteins could not be 
extrapolated from the standard curve as the proteins migrated outside the range 
of the molecular weights of the marker but was approximately 200 KDa, the 
expected size. The gel also confirmed a purity of > 95%.  
An ELISA using the lectin SNA to confirm the presence of α 2,6 sialic acid 
linkages of the ICAM-1-Fc (clone 54) was carried out (Figure 4.6). The results 
confirmed that the two clones (54 and 58) which were transfected with ICAM-1-  
-Fc and ST6Gal1 were strongly positive for SNA binding in a concentration 
dependent fashion while clone 17 which was not transfected with ST6Gal1 did 
not bind the lectin. 
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Figure 4.5: SDS-PAGE analysis of purified ICAM-1-Fc supernatant purified using protein 
A column. 3 µg of each of the purified supernatants from clones 17, 54 and 58 were 
prepared in loading dye, without or with reducing agent. Samples were boiled for 5 
minutes at 100 0C and then ran on 4-12% Bis-Tris gel at 200V for 35 minutes. Gel was  
washed with water and stained with Nupage Simply Blue Safe stain for 1 hour at room 
temperature. Gel was then destained with water and imaged. (B) Linear regression curve 
for molecular weight marker used in SDS-PAGE analysis.  
 
 
 
 
 
 
Figure 4.6: ELISA for the detection of α 2, 6 sialylation using biotinylated SNA. 96 well 
plates were coated with anti-Fc IgG, blocked and different concentrations of purified 
ICAM-Fc proteins were added and incubated for 1 hour at room temperature.  Plates were 
washed 3 times with PBA (0.25% BSA) and then incubated with biotinylated SNA (10 
µg/ml) for 1 hour at room temperature. Washes were repeated after incubation and plates 
were coated with Streptavidin alkaline phosphatase (1:1000) in TBA (0.25% BSA). After 
washes in TBA (0.25% BSA), 100 µl of pNPP substrate was added and plates read at 
405nm.  
 
KDa
   1       2        3        M         1       2       3
    ReducedNon-reduced
180
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80
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2 – Clone 54 
3 – Clone 58 
M – Nupage MW     
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B
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4.3 Sialic acid dependent binding of S7-Fc to ICAM-Fc – Dot Blots 
Binding of Siglec-7-Fc-precomplexes to ICAM-1-Fc chimeras was attempted in 
an ELISA format. However, the precomplexes failed to detect any ligands. This 
was thought to be due to the relatively low coating density of the Fc chimeras 
on a 96-well plate that do not provide sufficent multivalency for pre-complexed 
Siglec-7-Fc binding. Hence the chimeras were analysed for Siglec-7-Fc binding 
using dot blots in which high protein density can be achieved. This technique is 
a convenient method to identify and analyse proteins and study protein-ligand 
interactions. In parallel, the anti-ICAM-1 antibody and SNA lectin would also be 
used to confirm the presence of ICAM-1 and α 2,6 linkages on ICAM-1. 
 
4.3.1 Recognition of GD3 by Siglec-7-Fc precomplexes 
Siglec-7-Fc recognition of sialylated ligands on dot blots was optimized using 
ganglioside GD3 spotted onto PVDF membranes. Figure 4.7 (A –D) shows the 
optimization data using different concentrations of Siglec-7-Fc and Anti-Fc-HRP 
(Table 2). 5 µg/ml of Siglec-7-Fc and 1:1000 dilution of the anti-human Fc-HRP 
gave the best signal to noise ratio. 
 
 
 
 
 
 
            Table 4.2 
 
Figure 4.7: Dot blots for the optimization of Siglec-7-Fc precomplexes: 1 µg, 0.1 µg , 0.03 
µg and 0.01 µg of GD3 (diluted in methanol) were spotted onto PVDF strips, dried for one 
 Siglec-7-Fc Anti-Fc-
HRP 
A 5 µg/ml 1:1000 
B 5 µg/ml 1:3000 
C 1 µg/ml 1:1000 
D 1 µg/ml 1:3000 
C
D
A 
B 
       1          0.1          0.03           0.01    
 µg
     1       0.1     0.03       0.01      blank
       1       0.1          0.03           0.01   
    1      0.1        0.03     0.01   blank  µg
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hour and then blocked with 5% milk. Blots were then quenched with 10% FCS. Titrations 
of Siglec-7-Fc and anti-Fc-HRP were used (as shown in column) to prepare precomplexes 
by mixing them in 1:3 (volume/volume). Precomplexes were added onto blocked 
membrane and then left to incubate overnight at 40C. Blots were then washed thoroughly 
in 1XTBS + 0.1% Tween-20 and then detected using ECL substrate. Methanol only was 
spotted on as negative control (blank). 
 
4.3.2 Sialic acid dependent recogntion of ICAM-Fc by Siglec-7-Fc and 
antibodies 
Titrations of ICAM-1-Fc (clone 17 and 54) were spotted in duplicates on 
nitrocellulose membranes and treated with or without sialidase. Blots were then 
incubated with either Sigec-7-Fc precomplexed to anti-Fc antibody, anti-ICAM-1 
antibody or SNA lectin (Figure 4.8, B). Titrations of GD3 spotted onto PVDF 
membranes were used as a positive control for Siglec-7-Fc binding (Figure 4.8, 
A). 
Siglec-7-Fc precomplexes bound strongly to ICAM-1-Fc from both clones and 
this was partially reduced following sialidase treatment (Figure 4.8, C). The anti-
ICAM-1 antibody  
also recognized both clones but also showed some reduction following sialidase 
treatment (Figure 4.8, D). SNA binding to both clones was significantly reduced 
following sialidase treatment (Figure 4.8, E). The bar charts in Figure 4.8 
represents the average signal obtained from duplicate samples in each case.  
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Figure 4.8: Detection of ICAM-Fc by Siglec7, Anti-ICAM-1 antibody and SNA using dot 
blots: (A) Different concentrations of GD3 were spotted onto PVDF membrane and 
incubated with Siglec-7-Fc precomplexes as described in figure 4.7. (B) Different 
concentrations of ICAM-1-Fc (with and without α 2,6 sialylation) were spotted onto 
nitrocellulose membrane in duplicates, dried for one hour and then blocked with 5% milk. 
Sialidase treatments of blots were carried out by incubating blots in 0.17 IU/ml of 
+ Sialidase    - Sialidase 
M         2        1         0.5       0.1    0.3   M       2          1         0.5       0.1    0.3   
Quantification of dot blot signals
Clone 54 
Clone 17 
Clone 54 
Clone 54 
Clone 17 
Clone 17 
ICAM-Fc 
in µg 
- Sialidase    + Sialidase  
C      1      0.5      0.25     0.1 C      1       0.5     0.25     0.1
( C ) Siglec-7-Fc 
 ( D ) Anti-ICAM-1 Antibody 
( E ) SNA 
A 
GD3 in µg 
B 
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sialidase in sodium acetate buffer for one hour at 370C. Blots were then quenched with 
10% FCS and then incubated with (C) Siglec-7-Fc precomplexes (as described in figure 
4.6), (D) Anti-ICAM-1 antibody and (E) SNA, overnight at 40C. Blots were then washed in 
TBST and incubated for an hour with Avidin-HRP (1:5000). Blots were washed again and 
detection carried out using ECL substrate. Experiment is representative of n=2.  
 
 
4.4 Characterization of NK92 cell line and PBMC 
NK92 cell line was a kind gift from Dr. Eric Vivier (CIML, Marsielle). Culture 
conditions were optimized as to the media, IL-2 requirements and cell 
concentrations (detailed in the Materials and Methods sections). 
 
4.4.1 Expression of CD56, Siglec-7 and LFA-1 on NK92 cell line 
NK92 cells are known to be positive for CD56 bright, CD2, CD11a, CD54 and 
negative for CD3, CD16, Mac-1 and for KIRs (Gong et al., 1994; Komatsu F and 
Kajiwara M., 1998). 
Using suitable antibodies and isotype controls, expression levels of CD56, 
Siglec-7 and LFA-1 on NK92 cells were compared to those of IL-2 activated 
human peripheral blood mononuclear cells (PBMCs). Cells were stained with 
suitable antibodies or isotype controls and analysed by flow cytometry. As 
shown in figure 4.9, both NK92 and IL-2 activated PBMC were positive for 
CD56 (A). While PBMC have CD56 dim and CD56 bright populations, NK92 cells 
are only positive CD56 bright. CD56+CD3- PBMCs were also positive for Siglec-7 
(B) while NK92 was negative for this receptor. Finally as reported, NK92 also 
stained positive for LFA-1(C) (Zheng et al., 2009). 
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Figure 4.9 : Flow cytometry characterization of NK92 cell line - IL-2 cultured PBMCs 
(gated on CD3 negative population) for the detection of CD56-FITC , Siglec-7 expression 
or relevant isotype controls. 1X10E6 cells were stained with anti-CD56 antibody (A) or 
sheep  polyclonal anti-Siglec-7 antibody (B), diluted in wash buffer (blue histograms). 
Relevant isotype control for CD56 and pre-immune sheep sera were used (red filled 
histograms) Samples were incubated for 30 minutes on ice. Cells were then washed x3 
with wash buffer and then stained with anti-sheep secondary antibody for 30 minutes on 
ice. (C) NK92 cells were also stained with anti-LFA-1-FITC (green line) and relevant 
isotype control (orange filled histogram). Following washes in wash buffer, cells were 
fixed with 1% PFA and then analysed by flow cytometry. 
 
PBMC NK92
CD56
A 
B
C
LFA-1
 Siglec-7 
NK92  
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4.4.2 Siglec-7 mRNA levels in NK92 cell line 
In order to confirm the absence of Siglec-7 expression in this cell line, mRNA 
levels were quantified using RT-PCR. Primers used for this are shown in Table 
2.5, in the Materials and Methods. The method used for quantification was the 
∆∆Ct method in which the mRNA level of the target gene of interest is 
normalized to levels of GAPDH in the cell. Figure 4.10 shows fold change in 
Siglec-7 mRNA expression levels in NK92 cells compared to PBMCs. These 
results confirmed that NK92 cells have no transcripts for Siglec-7. Hence these 
tally with what was observed by flow cytometry.  
    Figure 4.10 SIglec-7 messenger RNA expression levels 
in NK92 cells: cDNA prepared from 1 µg of PBMC and 
NK92 m RNA. RT-PCR was conducted on these samples 
using optimized primers for Siglec-7 and GAPDH.  
Relative fold change in gene expression was quantified 
by the Comparative ∆∆CT method, using GAPDH as 
normalizer and NK92 as the calibrator (taken as 1). 
cDNA from PBMCs were used as the positive control. Y-
axis represents the fold change in gene expression, 
relative to PBMC. 
 
4.4.3 Generation of Siglec-7 expression vector and mutants  
Based on the above findings, it was decided to transfect these cells with vectors 
carrying full length cDNA for Siglec-7 and its mutant forms. A previously cloned 
Siglec-7 cDNA in the pcDNA 3.1 vector (neomycin selection) (clone 14) was 
used for this purpose. The vector sequence was confirmed by plasmid DNA 
sequencing using the T7 forward and reverse primers. This plasmid vector was 
then re-transformed into DH5 α cells and a single clone was used in the 
preparation of purified DNA.  
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This DNA prep was also then used to make Siglec-7 mutants by site directed 
mutagenesis using primers described in Table 2.4 (Materials and Methods). 
Siglec-7 mutants included:  
a) Sugar binding mutant, R124A in which the Arginine at position 124 is 
mutated to an Alanine (A). The mutation of this residue to an Alanine (A) is 
known to reduce sialic acid dependent binding of Siglec-7(Angata and Varki, 
2000). b) Tyrosine mutations in the ITIM and ITIM-like motifs in the cytoplasmic 
domains, Y1F(YY437F) and Y2F(Y460F) respectively. The membrane proximal 
ITIM has been shown to be important in inhibitory signalling mediated by Siglec-
7 (Avril et al., 2004). 
The cloning of these mutants has been detailed in the Materials and Methods 
section (Section 2.27). Mutant clones were sequenced to confirm the presence 
of the desired mutations (data not shown). 
 
4.4.4 Over-expression of Siglec-7 and mutants in NK92 cell line   
In previous studies NK92 cells have been transfected with success in different 
ways. For this project, a number of methods were attempted for transfecting this 
cell line such as the transfection reagent Lipofectamine (Zhang et al., 2004) and 
use of retroviral and lentiviral systems (Savan et al., 2009). While these 
methods gave very minimal levels of transfection, as assessed by flow 
cytometry staining of Siglec-7, nucleofection with a commercially available kit 
had better efficiency. Following nucleofection, transfected cells were cultured in 
selection media for two weeks before cloning plates were set up using the 
limiting dilution method as discussed in Materials and Methods, 2.4.3.  Clones 
were allowed to grow in selection media for a month before they were analysed 
by flow cytometry using anti-Siglec-7 mAb (supernatant 7.7a) as shown in 
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Figure 4.11, A. Clones with low, medium and high expression of Siglec-7 were 
cultured in flasks before freezing 2-3 vials of each clone.  
 
 
    
 
          
 
 
 
 
 
 
 
 
Figure 4.11: Overexpression of Siglec-7 in NK92 cell lines : WT NK92 cell line was 
electroporated  with  4 µg of Siglec-7/ R124A/ Y1F or Y2F plasmid DNA. (A) WT and 
Siglec-7 cells (polyclonal or clonal) were stained with 1/5 dilution of mouse monoclonal 
anti-Siglec-7 antibody (7.7a) in wash buffer and incubated for 30 minutes on ice. Cells 
were then washed x3 in wash buffer and stained with 1/200 of anti-mouse PE. Cells were 
washed again in wash buffer, fixed with 1% PFA and then analysed by flow cytometry. 
(B) Same was repeated for the Siglec-7-R124A/Y1F/Y2F mutant polyclonal population. (C) 
WT and Siglec-7 (Clone 14) was also stained with anti-LFA-1 antibody and isotype 
control. 
 
A 
B 
C
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Siglec-7 mutants (R124A, Y1F and Y2F) were also nucleofected into NK92 wild 
type cells and cultured in selection media. Both polyclonal populations and 
clones derived from limiting dilution of the NK92 expressing mutants were 
analysed by flow cytometry staining and aliquots frozen (Figure 4.11, B). 
One constant problem that was faced in maintaining Siglec-7 (or mutants) 
expressing NK92 cells was the loss of expression over a period of time in 
culture.  This made it difficult to have uniform and high expression of the 
receptor prior to biological assays. Hence FACS sorting was used to select for 
high expressers.  
Since the core of this project involved studying the biological effects of integrin 
signalling, expression of LFA-1 on Siglec-7 expressing NK92 cells was also 
examined (Figure 4.11, C). Staining of the wild type and transfected cells with 
an anti-LFA-1 antibody and suitable isotype control showed that the expression 
of Siglec-7 in the NK92 cells did not affect LFA-1 levels. 
 
4.4.5 Expression of Siglec-5 and 9 on NK92 cell line 
Primary NK cells are known to express Siglec-7 and to a lesser extent, Siglec-9 
while neutrophils express Siglec-5 and -9. In order to rule out the possible 
expression of other Siglecs on NK92 cells, antibody staining and flow cytometric 
analysis was carried out. While human neutrophils stained positive for Siglecs-5 
and -9 (Figure 4.12, A), NK92 cells were devoid of these members of the Siglec 
family (Figure 4.12, B). 
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Figure 4.12: NK92 cells do not express Siglec-5 or Siglec-9 : Human neutrophils (A) and 
NK92 cells (B) were stained with anti-Siglec 5, 9(Kalli) and 7(7.7a) mouse monoclonal 
antibodies for 30 minutes on ice, diluted 2.5x in wash buffer. Cells were washed in wash 
buffer and then stained with 1/200 dilution of anti-mouse PE for 30 minutes on ice. 
Following x3 washing with wash buffer, cells were fixed with 1%PFA and analysed by 
flow cytometry. Cells stained with secondary alone was used as negative control 
 
4.5 Adhesion of wild type and Siglec-7 expressing NK92 cells to ICAM-Fc 
Adhesion assay have been used for studying the role of LFA-1 in neutrophils, 
macrophages, platelets and lymphocytes. The use of ICAM-1-Fc chimeras 
coated onto plates is a commonly used method of assessing LFA-1 mediated 
adhesion (Dransfield et al., 1992).  
 
4.5.1 Siglec-7 negatively affects adhesion of NK92 cells to ICAM-1-Fc 
Purified ICAM-1-Fc (clone 54 – carrying α 2,6 sialic acid linkages) was coated 
on plates to which NK92 cells (± Siglec-7) were added and incubated. Unbound 
cells were washed off and the bound cells were analysed using crystal violet (as 
A 
B
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detailed in Materials and Methods). Divalent cations such as Mg2+ are known 
to activate integrins and help them attain their fully active confirmation. In the 
adhesion assay described here, varying concentrations of Mg2+ has been used 
to activate integrins. Figure 4.13 represents OD values obtained for wild type 
and Siglec-7 expressing NK92 cells when activated with or without Mg2+ and 
added on to wells coated with ICAM-1-Fc. Integrin mediated adhesion to ICAM-
1-Fc was absent when the cation was chelated using EDTA or when human IgG 
was used instead of ICAM-1-Fc. Phorbol esters such as Phorbol 12,13 
dibutyrate (PDBU) are known to cause inside out activation of integrins. Hence 
cells treated with PDBU were used as positive control. Cells added to wells 
coated with poly-L-lysine (PLL) were used as another internal control to obtain 
maximal adhesion of cells. 
 In all cases, the binding of wild type NK92 cells to ICAM-1-Fc in the presence 
of Mg2+ was significantly higher than that of Siglec-7 expressing NK92 cells. In 
order to keep within the physiological levels of Mg2+, concentrations between 
0.1 and 5 mM were chosen. Cells added onto PLL coated wells were also 
resuspended in 1mM Mg2+. 
Adhesion of WT and Siglec-7 cells to different preparations of ICAM-1-Fc was 
also compared (shown in appendix).  
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Figure 4.13: Siglec-7 reduces adhesion of NK92 cells to ICAM-1-Fc coated wells : (A) 96 
well tissue culture plates were coated with 10 µg/ml of protein A or 0.01% of poly-L-
Lysine (PLL), overnight. Plates were coated with 5 µg/ml of ICAM-Fc or human IgG in 
PBS.  2 x 10E5 NK92 WT or NK92 Siglec-7 (C14) were resuspended in 1XHBSS (-Ca2+) 
with different concentrations of +Mg2+. For control groups, cells were either treated with 
10 µM of EDTA or 20 ng/ml of PDBU for 10 minutes on ice. Cells were added to wells, 
spun down and incubated for 30 minutes at 370C. Unbound cells were then removed from 
the plate by gravity wash and bound cells were fixed, stained and plates read at 570 nm. 
Cells added to PLL coated plate was used as control to obtain maximal binding of cells. 
(B) Adhesion of NK92 WT and Siglec-7 (C14) cells onto ICAM-1-Fc coated wells from 3 
different experiments (conducted on 3 different days), in the presence of 1 mM Mg2+, is 
compared. Error bars represent standard error of mean.  
 
 A 
 B 
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4.5.2 Sialic acid independent adhesion of NK92 Siglec-7 cells to ICAM-1-Fc 
The adhesion assays conducted (Figure 4.13) using wild type and Siglec-7 
expressing NK92 cells suggests a negative regulatory role of this receptor in 
modulating LFA-1 mediated adhesion of the cells to ICAM-1-Fc coated on 
plates. In order to understand the role of sialic acid linkages present on ICAM-1-
Fc in influencing the binding of Siglec-7, ICAM-1-Fc coated plates were treated 
either with or without sialidase (in acetate buffer). The conditions used for the 
treatment of the coated plates were optimized previously in this lab. 
NK92 cells (+/- Siglec-7) were added to the sialidase treated plates, unbound 
cells removed and adhesion measured. In this assay, along with Siglec-7 
expressing clone 14 (S7(C14)) that was used in the previous assay, another 
independent clone that had > 90% receptor expression was also used, clone A 
(CA).  
At 1 mM concentration of Mg2+, both Siglec-7 clones had significantly reduced 
adhesion to ICAM-1-Fc compared to wild type cells (Figure 4.14, A). 
Interestingly, this was not reversed following sialidase treatment of the LFA-1 
ligand. The adhesion of wild type cells, was, however increased following 
sialidase treatment. This could be due to the removal of negatively charged 
sialic acids from the ligand, increasing adhesion of cells (Figure 4.14, B) 
A sugar binding Siglec-7 mutant, R124A, was also used in these experiments to 
investigate the role of sialic acids recognition in this assay. The R124A mutation 
did not reverse the binding of the transfectants to that of wild type cells (Figure 
4.14, A). The above data suggests that Siglec-7 is able to regulate LFA-1 
mediated adhesion in the absence of sialylated ligands.  
Two further experiments reconfirming the sialidase independent effect on the 
adhesion of wild type, Siglec-7 and R124A mutants was carried out using two 
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different ICAM-1-Fc preparations. Results obtained are similar to that shown in 
Figure 4.14 and is shown in appendix.  
 
 
  
Figure 4.14: Sialic acid independent adhesion of NK92 WT or NK92 Siglec-7 (C14 and CA) 
cells to ICAM-1-Fc : Procedure was carried out as described in figure 4.13. ICAM-1-Fc 
coated plates were treated with 0.17 IU/ml of sialidase for 1 hour at 37 0C. Sialidase 
treatment was quenched using 10%FCS. Cells were then washed with RPMI with 10% 
FCS and resuspended in 1XHBSS (-Ca2+, +Mg2+). EDTA treated cells were used as 
negative control. NK92 cells expressing the mutant R124A were only plated in duplicates 
on the sialidase treated plate and hence level of significance was not analysed.  
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4.6 Siglec-7 modulates Src kinase phosphorylation following LFA-1 
binding of ICAM-1-Fc 
In NK cells, LFA-1 has been shown to affect activation of kinases and factors 
such as Vav-1 resulting in the actin cytoskeletal reorganization and polarization 
of perforin granules (Riteau et al., 2003; EM Mace et al., 2010). 
In an attempt to study signalling pathways triggered in the NK92 cell line 
downstream of LFA-1, pan and phospho antibodies were used to examine the 
phosphorylation status of different down stream molecules in whole cell lysates.  
 
4.6.1 Optimization of divalent cation concentration  
As discussed earlier, divalent cations are needed to change conformations of 
integrins such as LFA-1 from a closed low affinity to an open high affinity state. 
Because different cations have varied effects on integrin conformations, 
divalent cation concentrations were optimized using wild type NK92 cells. Assay 
buffers containing either Mg2+ or Mn2+ were tested. Clone 54, ICAM-1-Fc fusion 
(+ α 2,6 sialic acid linkages) was used for all biochemistry assays. Cells 
resuspended in the assay buffer but not plated onto ICAM-1 were used as 
negative controls. Cells treated with pervanadate (PV), a protein tyrosine 
phosphatase inhibitor, were used as positive controls in these experiments 
(McMillan et al., 2013). Whole cell lysates were measured for protein 
concentration and used for western blotting. Blots were then analysed using 
pan and phospho antibodies for different downstream molecules. Figure 4.15 
shows the phosphorylation status of some of the key molecules known to be 
important in LFA-1 mediated signalling in NK cells such as Src, Syk, Akt, Erk1/2 
and p38 MAPK. A time dependent increase in phosphorylation was only seen in 
the case of pY416 Src and pS473 Akt. The phospho Src antibody recognizes  
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Figure 4.15: Optimizing divalent cation concentration for LFA-1 mediated activation of 
intracellular signalling molecules: 6 well tissue culture plates were coated with 10 µg/ml 
of Protein A, blocked with 5% BSA and then coated with 5 µg/ml of ICAM-1. Plates were 
again blocked with 10% FCS and stored in PBS at 40C. NK92 cells were harvested and 
incubated in complete media without IL-2 for 4 hours at 370C. Cells were then spun down, 
resuspended in 1xHBSS with different concentrations of Mn2+ or Mg2+. Cells were added 
 0 minutes 
Lanes 
1 – 2 mM Mg2+ 
2 - 5 mM Mg2+ 
3 – 2 mM Mn2+ 
M – Marker 
pYSrc416 
T-Src 
pY525/526 
Syk  
pY323 Syk 
T-Syk 
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pT180/Y182 p38 
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          KDa 
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to plates, spun down at 900 rpm for 30 seconds and incubated for 0 and 20 minutes. Both 
bound and unbound cells were then lysed in lysis buffer, lysate cleared by centrifµgation 
and 15 µg ran on 4-12% bis-tris SDS PAGE gel. Gels were then transferred to 
nitrocellulose membrane , blots blocked and stained with rabbit or mouse primary 
antibodies with overnight incubation. Following washes in TBST, blots were incubated in 
sheep anti-rabbit-HRP antibodies. Blots were washed and developed using ECL 
chemiluniscent substrate. T=Total; p = Phospho; PV – Pervanadate 
 
phosphorylated Src and cross reacts with other members of the Src family such 
as Lck, Lyn, Fyn, Yes, Hck when phosphorylated at tyrosine 416.  Src 
phosphorylation at Tyr 416 and Akt at Ser 473 showed minimal basal levels of 
phosphorylation both in suspension and at the 0 minute time point. This then 
increased by 20 minutes in both cases. There was no phosphorylation observed 
for pY323 on Syk and pT202/Y204 on Erk1/2. Syk tryrosine 525/526 and 
pT180/Y182 p38 MAPK showed very minimal increase in phosphorylation in an 
integrin dependent manner over the time course. 
 
4.6.2 Role of Siglec-7 in modulating LFA-1 mediated signalling via Src 
kinase in NK92 cells 
2x10E6 wild type and Siglec-7 expressing NK92 cells (clone 14) were 
resuspended in assay buffer and plated onto wells coated with ICAM-1-Fc 
(clone 54). A time course experiment was carried at 0, 5 and 20 minutes. Wells 
coated with no ICAM-1-Fc was used as negative control (for 20 minutes). 
Western blotting was conducted using whole cell lysates. Figure 4.16 (A and B) 
shows whole cell lysates probed for pY416 Src from two different experiments. 
Since the total Src antibody gave multiple bands (Figure 4.15), GAPDH was 
used in these experiments to probe for total amount of protein in each of the 
whole cell lysates. Cells treated with PP2, a Src kinase inhibitor, were used as 
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negative control in these experiments. Suspension cells and cells treated with 
PP2, showed low levels of pY416-Src phosphorylation (Figure 4.16,A). Panel A 
and B represents two independent experiments showing an increase in pY416-
Src phosphorylation in wild type NK92 cells which was reduced by 2 fold in 
Siglec-7 expressing NK92 cells by 20 minutes.  
 
 
 
       
 
      
 
       
 
 
 
 
       
 
Figure 4.16: Siglec-7 negatively modulates LFA-1 mediated Src kinase signaling in NK92 
cells: (A) and (B) are results from two experiments comparing LFA-1 mediated Src kinase 
phosphorylation between wild type NK92 and Siglec-7 expressing NK92 (C14) cells.   
Whole cell lysates were blotted for pYSrc416 and GAPDH. Experiments were conducted 
as described in figure 4.15. Cells treated with PP2, a Src kinase inhibitor, were used as 
the negative control while PV treated cells served as the positive control. (C) and (D) Bar 
charts represent densitometry of Src phosphorylation signals from each experiment 
shown in (A) and (B). PV – Pervanadate 
 
A 
B 
NK92 S7(C14)
NK92 (WT) NK92 S7 (C14)
NK92 (WT) Quantitation of 
phosphorylation signals to 
the total amount of protein
D 
C 
      Experiment 1 
      Experiment 2 
152 
 
Although a time dependent increase in phosphorylation of Src is seen in panel 
A, this is less evident in panel B. Figure 4.16, C and D represents densitometry 
conducted on the signals obtained and is represented as the ratio intensity of 
phosphorylation of Src to total protein as measured by GAPDH. 
Data on pSer473Akt from one experiment also showed an increase in the 
phosphorylation levels in wild type NK92 cells, devoid of Siglec-7 (figure shown 
in Appendix, figure A5). However, in a repeat experiment conducted, there was 
no difference between the two cell types.  
 
4.7 Role of Siglec-7 in modulating integrin mediated polarization of 
perforin in NK92 cells 
Another functional readout for LFA-1 is the polarization of perforin granules 
(March et al., 2011). ICAM-1-Fc coated to Protein A beads was used for this 
purpose. The coating of ICAM-1-Fc to the beads was optimized by flow 
cytometry staining using anti-ICAM-1 antibodies as shown in figure 4.17.  
 
 
 
 
 
 
Figure 4.17: Coating of Protein A beads with ICAM-1-Fc: Protein A beads were sonicated 
for 6 cycles, each cycle lasting 30 seconds. 1x10E6 beads were then pipetted out and 
washed in 200 µl of 1XPBS (twice). Beads were then incubated with or without 5 ug of 
ICAM-1-Fc protein (clone 54), on a spin rotor at 40C for 30 minutes. Unbound protein was 
washed off in PBS. Beads were then blocked with 10% mouse serum for 30 minutes on 
ice and then stained with 0.5 µg of anti-ICAM-1 antibody (30 minutes on ice) followed by 
1/500 dilution of streptavidin-APC. The beads were then analysed by flow cytometry. 
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NK92 wild type (WT) cells and NK92 Siglec-7 expressing clone (C14) were 
incubated with ICAM-1-Fc coated beads, stained for perforin and examined by 
confocal microscopy as shown in figure 4.18, A. Protein A beads coated with 
human IgG and cells treated with PP2 inhibitor were used as negative controls 
in the experiment.  
For distinguishing polarized cells from unpolarized cells, each cell in contact 
with a bead was arbitrarily divided in half. If the cell had perforin staining 
localized in that half of the cell which was in contact with the bead, it was 
considered to be polarized (Figure 4.18, A). Based on this classification, z-stack 
images (100x magnification and zoom 1) from all samples were analysed using 
the image analysis software, Volocity. Figure 4.18 B, are representative images 
from the different samples. White arrows point to polarized cells while red 
arrows point to non-polarized cells. Fisher’s exact test, comparing WT cells to 
the remaining treatment groups (Figure 4.18, C) shows that the proportion of 
polarized cells to non-polarized cells in the WT sample group is significantly 
higher compared to PP2 treated or the NK92 Siglec-7(C14) cells. Figure 4.18, 
D, represents the percentage of polarized conjugates in the different groups.  
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Figure 4.18: Siglec-7 expression on NK92 cells negatively affects LFA-1 mediated 
perforin polarization – (A) Schematic diagram of bead : cell conjugate, with polarized 
(above) and non-polarized (below) perforin granules. (B) Protein A beads were 
conjugated with ICAM-1-Fc as described in figure 4.18. 0.5 X 10E6 WT and Siglec-7 
expressing clone (C14) were treated with or without PP2 inhibitor. The cells were 
resuspended in 1X HBSS and plated onto poly-L-Lysine coated 18mm coverslips and left 
to settle for 1 hour at 370C. Buffer on the cells were replaced with 1 X 10E6 beads coated 
with either ICAM-1-Fc or human IgG and resuspended in 5 mM Mg2+, were added on to 
the cells and left to incubate for 1 hour at 370C. Coverslips were washed in PBS + 1% 
BSA, fixed with 4% paraformaldehyde for 15 minutes at room temperature (RT) and 
permeabilized with PBS + 0.1% triton for 15 minutes at RT. Cells were then blocked with 
10% mouse serum for 30 minutes at RT and incubated with 20 μg/ml of anti-perforin 
(FITC conjugated) in block buffer, overnight at 40C. Coverslips were washed and 
mounted using Vectashield (with DAPI). Images were acquired using the LSM 700, X100 
magnification and zoom 1. For z-stacks, slices of 1 μm thickness were collected for each 
image. White arrows – polarized cells; Red arrows – non-polarized cells. (C) Table 4.3 - 
   Polarized		
cells	
Non‐
polarized	
cells	
Fisher’s	
test		
(P	value)	
WT	 91  74    
WT	+	
PP2	
21  44  0.0021 
S7	
(C14)	
40  83  0.0002 
S7	
(C14)	
+	PP1	
19  29  0.0121 
C D
E 
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showing the number of polarized and non-polarized conjugates in each sample group 
and statistical analysis using the Fisher’s exact test. (D) Bar chart representing the 
percentage of polarized conjugates formed in each sample group (E) Mean intensity of 
perforin in the polarized half of the bead : cell conjugates were normalized to the mean 
intensity of staining in the whole cell. N represents the number of bead : cell conjugates 
examined for this analysis.  Experiment represents n=1.  
 
Further analysis was also carried out comparing the perforin staining intensities 
of the cells conjugated to beads in the different groups. For this purpose, mean 
intensity value of perforin staining in the polarized half of the cell was 
normalized to the mean intensity value in the whole of the cell. Normalized 
ratios for the different groups are shown in figure 4.18, E. The intensity 
measurement also shows a significant decrease in intensity in the PP2 treated 
cells and the C14 cells compared to the WT cells. Taken together, these data 
suggests a role for Siglec-7 in negatively regulating LFA-1 mediated perforin 
polarization in NK92 cells. 
The isotype control for the anti-perforin antibody used gave high background 
(data not shown). This could be either because the dynamic range of the anti-
perforin antibody is small or could be the result of high autofluoresence. Hence 
further optimization using another fluorescent conjugated antibody which will 
give an improved signal to noise ratio will be needed.  
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4.8 Discussion 
This part of the project was based on the recent findings from our lab that highly 
related murine Siglec-E could modulate β2 integrin signalling in neutrophils. 
Therefore the main aim was to investigate whether Siglec-7 shared similar 
functions in regulating integrin functions in NK cells. Indeed the data presented 
here shows a role for Siglec-7 in modulating integrin signalling and functions.  
 
Since the ICAM-1-Fc chimeras, used as LFA-1 ligands, were generated in wild 
type CHO cells, a predominantly α-2,3 sialylation of the expressed recombinant 
protein was expected. In order to bias the linkages on the glycosylated ICAM-1-
Fc to NeuAc α-2,6 βGal1, CHO cells were transfected with plasmid DNA for the 
sialyltransferase, ST6Gal1. Overexpressed ST6Gal1 in these cells would be 
expected to compete with the endogenous ST3Gal1 and bias the sialic acid 
linkages on the expressed protein.  
In characterization of the ICAM-1-Fc protein, ELISAs conducted on the ICAM-1-
Fc chimera’s (Figure 4.4) showed that while supernatant from clone 17 
(transfected with only ICAM-1-Fc) was negative for SNA binding, supernatants 
from clones 54 and 58 (transfected with ICAM-1-Fc and ST6Gal1) bound SNA. 
However, the lectin based ELISA is only qualitative and hence does not confirm 
the absence of α-2,3 linkages on the clones 54 and 58. Further invitro assays 
using purified sialyltransferase ST6Gal1 would be needed to quantitatively 
assess the α-2, 6 linkages on these chimeras. The lectin MAL I is known for its 
specificity for NeuAc α-2,3 Galβ 1,4 GlcNAc linkages (Knibbs et al., 1991). 
Binding of this lectin to RBCs in a sialic acid dependent manner using a flow 
cytometry based assay confirmed that the lectin was functional (data not 
shown). However, it failed to recognize the ICAM-1-Fc chimeras on ELISA 
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based assays (data not shown). This could be due to unfavourable ligand 
density or presentation on polystyrene ELISA plates, for MAL I recognition. 
Dot blots carried out to determine recognition of these chimeras by Siglec-7-Fc 
precomplexes showed an increased avidity of this lectin precomplex for both 
clones 17 and 54 of ICAM-1-Fc (Figure 4.8, A). This fits well with the known fact 
that Siglec-7 can weakly bind sialic acids that are present not only in α-2,6 but 
also α-2,3 glycosidic linkages (McMillan and Crocker, 2008). However, the 
binding to the clone 54 was 1.5 - 2.3 fold higher compared to clone 17. 
Although sialidase treatment reduced the recognition of Siglec-7-Fc, it was not 
completely abolished suggesting the ability of the receptor to bind ligands 
independent of sialic acids.  
The lectin SNA bound clone 54 on dot blots in a sialic acid dependent manner, 
but it also bound clone 17 (Figure 4.8, E). This finding is interesting and is 
contradictory to the ELISA data. A possible explanation for this could be high 
ligand density and assay format, favouring lectin recognition of sialic acids in α-
2,3 linkages when spotted onto nitrocellulose membrane. However the signal 
intensity was independent of ligand concentration which could also indicate 
possible non-specific binding by the pre-complexes.  
In the case of the antibody however, following sialidase treatment, there was 
some reduction in binding to the ICAM-1-Fc clones (Figure 4.8, D). This could 
be either from loss of protein or underlying linkages needed for antibody 
recognition. Therefore, these experiments would need to be optimized further to 
make firm conclusions on Siglec-7 recognition of the ICAM-1-Fc clones, in a 
sialic acid dependent manner. 
NK92, an NK cell line was used in this project as a model system to investigate 
the role of Siglec-7 in modulating integrin functions by the two models proposed 
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in figure 4.1 B. This cell line lacks the expression of Siglec-7 as shown by 
antibody staining (Figure 4.9) and mRNA expression levels (Figures 4.10). 
Therefore Siglec-7 and its mutants were over-expressed in this cell line (Figure 
4.11). LFA-1 expression levels remained unaffected in both the wild type and 
transfectant cells (4.11, C).  
Adhesion assays carried out using wild type and Siglec-7 expressing NK92 cells 
on ICAM-1-Fc coated plates demonstrated the possible regulatory role of 
Siglec-7 in modulating outside-in signalling of integrins. At all concentrations of 
Mg2+, there was a significant difference in adhesion between wild type NK92 
cells and Siglec-7 transfectants, S7(C14)(Figure 4.13). The role of divalent 
cations in strengthening outside in signalling of integrins has been extensively 
studied with respect to T cells (Labadia et al., 1998) (Cabanas and Hogg, 1993) 
(Dransfieldet al., 1992). Mg2+ has been shown to bind the extracellular domain 
of LFA-1, change its confirmation to high affinity, upregulate expression of the 
m24 antibody epitope on LFA-1 and increase adhesion of T cells to immobilized 
ICAM-1 (Porter et al., 2002). Outside-in signalling leads to clustering of LFA-1 
and cytoskeletal rearrangements via proteins such as Talin that are associated 
with it (Smith et al., 2005) (Cairo, Mirchev and Golan, 2006) (Bakker et al., 
2012). In NK cells, Siglec-7 could be modulating LFA-1 by regulating either the 
conversion of inactive LFA-1 into the high affinity confirmation induced by Mg2+ 
or affecting other events downstream of outside-in signalling such as LFA-1 
clustering. Further experiments such as antibody staining of the high affinity 
confirmation state of LFA-1, use of inhibitors to cytoskeletal rearrangement such 
as Cytochalasin D and blocking antibodies to LFA-1 would be needed to clearly 
identify the mechanism involved.  
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Interestingly both sialidase treatment of the ICAM-1-Fc and sugar binding 
mutant (R124A) were not able to reverse the Siglec-7 inhibition of adhesion 
(Figure 4.14). It is therefore tempting to consider a sialic acid independent 
binding of Siglec-7 to the glycosylated ICAM-1. These results are contrary to the 
known requirement of sialic acid in ligand recognition by Siglec-7. However due 
to time constraints these experiments could not be repeated. Confirming 
effective sialidase treatment of ICAM-1-Fc coated onto the wells would require a 
positive control such as the sialidase-sensitive Siglec-7 RBC adhesion assay or 
direct biochemical analysis of the ICAM-1-Fc protein. The data obtained to date, 
however, would support model B (Figure 4.1 B) wherein a constitutive 
association of Siglec-7 with β2 integrins is hypothesized, which could negatively 
regulate integrin activation and signalling independently of sialic acid-dependent 
binding.  This could occur through co-localization of Siglec-7 with activated LFA-
1 into so called ‘lipid rafts’ on NK cells.  
 
“Outside-in” integrin signalling results in the strengthening of integrin mediated 
adhesion by bringing about cytoskeletal changes and assembly of a number of 
signalling molecules to the point of adhesion (Totani et al., 2006, Hogg et al., 
2011).  In an attempt to define LFA-1 mediated downstream signalling events 
that could be affected by Siglec-7, a biochemical approach was adopted. LFA-1 
on NK92 cells were stimulated via “outside-in” signalling using ICAM-1-Fc 
coated onto plates. Using western blotting of whole cell lysates of wild type 
NK92 cells bound to the ICAM-1-Fc plates, time dependent increase in 
phosphorylation of Src kinase, Syk, Akt, p38 MAPK and Erk1/2 MAPK was 
examined. 
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Binding of ICAM-1-Fc to NK cells triggered activation of only Src kinases and 
Akt in a time dependent manner (Figure 4.15). No time dependent integrin 
mediated activation of Syk, p38, MAPK and ERK1/2 MAPK was observed.  
Src-family protein tyrosine kinases (SFK) consists of nine structurally related 
nonreceptor tyrosine kinases with ubiquitous cell expression – B cells (Blk, Fgr, 
Lyn), T cells (Lck), NK cells (Lck), Myeloid cells (Fgr, Hck,Lyn), ubiquitous (Fyn, 
Src, Yes, Yrk) (Parsons and Parsons., 2004). Figure 4.19, A, represents the 
domain structure common to members of this family. SFKs like many other 
receptor tyrosine kinases (RTKs) are in a state of auto-inhibtion with the SH2 
domain interacting with a phosphorylated tyrosine residue of the kinase region 
and the SH3 domain interacting with the linker region (Blume-Jensen and 
Hunter., 2001). Ligand binding to the SH2 or the SH3 domains or the 
dephosphorylation of the C-terminal tyrosine (by CD45 or SHP-2) releases 
these kinases from its inhibitory state. This results in the auto-phosphorylation 
of a key tyrosine residue in the activation loop of its kinase domain leading to a 
highly active enzymatic state (Figure 4.19) (Ingley., 2012). The main role of this 
family of kinases is the regulation of cell signalling of membrane receptors. 
Hence they have been implicated in numerous fundamental cellular processes 
such as growth, survival, migration etc. Many detailed reviews of this family of 
kinases with regards to their roles in B-cells and T-cells can be found – Lowell., 
2011, Gauld and Cambier., 2004, Palacios and Weiss., 2004.  
In NK cells,  Src kinase activation is one of the proximal steps in both integrin 
mediated signalling as well as signalling mediated by other activation receptors 
(Mocsai et al., 2002)(Totani et al., 2006). The SFK are responsible for the 
phosphorylation of various downstream kinases and adaptor molecules (Vivier, 
Nunes and Vely, 2004). The use of specific pharmacological inhibitors such as 
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PP1 demonstrated the importance of Src kinases in the early activation of Vav-1 
following LFA-1 recognition of ICAM-1 expressed on insect target cells (Riteau, 
Barber and Long., 2003). Src kinases such as Fyn and Lck, have been clearly 
implicated in activation of several downstream signalling molecules, NK natural 
cytotoxicity as well as ADCC mediated by activating receptors (Augugliaro P et 
al., 2003)(Cone et al., 1993), (Pignata et al., 1993) (Adrian T Ting et al., 
1995)(Claudia CS Chini et al., 2000). Ligand induced phosphorylation of 
CRACC (CD2-like receptor-activating cytotoxic cell), an NK activating receptor, 
by the adaptor EAT-2 has been shown to be negatively affected by 
pharmocological inhibitors, such as PP2 (Tassi and Colonna., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: (A) Diagrammatic representation of the modular structure common to the 
members of the Src-protein family kinases (SFKs). (B) Auto-inhibited and active 
confirmations of SFK. Tyrosine sites shown with respect to Lyn (adapted from Steve 
Martin., 2001). 
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Although there is no direct evidence on the nature of the SFK member present 
in the NK92 cell line, there are reports where blocking these tyrosine kinases by 
using inhibitors like PP2 affects cytoxicity and downstream signalling (Ruckrich 
and Steinle., 2013) (Choi and Mitchison., 2013)(Bambard et al., 2009). Recently 
the phosphorylation of the hemi-ITAM of the NK activating receptor NKp80 was 
found to be affected by blocking Src kinases using PP2, in the NK92 cell line 
(Ruckrich and Steinle., 2013).  
 
Syk kinase plays an important role in integrin signalling in neutrophils, and 
macrophages via ITAM containing adaptors DAP12 and FcRγ (Mocsai, Ruland 
and Tybulewicz, 2010). Using primary NK cells and immunoprecipitation studies 
with relevant antibodies one report demonstrated that LFA-1 signalling in 
human NK cells activates TCR-ζ, Syk kinase and PLC-γ, induced granule 
polarization and cause accumulation of the microtubule organization centre 
(MTOC) at the target effector immunological centre (March and Long, 2011).  
In the experiments conducted here using NK92 cells, there was no 
phosphorylation of Syk at Y323 observed and while phosphorylation of 
pY525/526 Syk was present, there was only a minimal increase over time 
(Figure 4.15). The absence of pY323 Syk was unexpected since this residue is 
the equivalent of the mouse Y317 Syk that has been shown to be activated by 
CD11b binding of fibrinogen in mouse neutrophils (McMillan et al., 2013). The 
phosphorylation observed at Y525/526 could be basal as there was only 
minimal over time. So, it is possible that in this cell line, signalling via LFA-1 
could either involve phosphorylation of another tyrosine site on Syk or bypass 
Syk kinase completely.  
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p38 MAPK is activated in an integrin dependent manner in different cell types 
such as primary NK cells and neutrophils (Mocsai et al., 2002) (Mainiero et al., 
2000). Here, the NK92 cells showed a constitutively high basal level of 
phosphorylation of p38 (Figure 4.15). There was no increase in phosphorylation 
over time. One explanation for the high basal phosphorylation status of p38 
could be the IL-2 mediated signalling in this cell line. However, IL-2 has been 
shown not to activate p38 in primary human NK cells (Yu et al., 2000). 
Moreover the NK92 cells used in these assays were cultured in IL-2 cytokine 
but were rested for four hours prior to plating out on ICAM-1 coated plates.  
 
The absence of phosphorylation of ERK1/2 (as examined using 2 different 
antibodies) following integrin engagement in these experiments was also 
unexpected. Zhen et al., 2009 demonstrated that blocking of NK92 adhesion to 
target K562 cells by using anti-CD11a antibodies, greatly reduced Erk1/2 
phosphorylation at Thr202/Tyr204 (Zhenget al., 2009).  
Our lab has demonstrated a negative role for Siglec-E in outside-in signalling, 
leading to Src kinase dependent Syk kinase activation. This increase in 
phosphorylation of Syk kinase (Y317) and p38 MAPK when Siglec-E knock-out 
mouse bone marrow cells were plated onto CD11b ligand, fibrinogen, was sialic 
acid dependent suggesting that Siglec-E recognition of sialic acids present on 
fibrinogen negatively regulated CD11b signalling (McMillan et al., 2013). 
 
Here, comparing integrin mediated Src kinase phosphorylation between wild 
type NK92 cells and NK92 expressing Siglec-7, a 2-fold reduction in the signal 
intensity was observed at the 5 and 20 minute time points (Figure 4.16). The 
Src inhibitor PP2 completely abolished LFA-1 mediated activation of Src kinase 
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in both cell types. These results suggest that Siglec-7 is capable of negatively 
regulating the recruitment and/or activation of Src kinases and thereby dampen 
LFA-1 signalling following ICAM-1 recognition.  
In one experiment, there was a significant reduction in phosphorylation of Akt 
Serine473 in Siglec-7 transfectants at 5 and 20 minute time points (Figure A5, 
Appendix). But this was not observed in a repeat experiment. This could be due 
to experimental factors and possibly protein degradation. Akt has been linked to 
Syk via a Syk-P13K-Rac1 pathway in IL-2 activated NK92 cells. The authors 
utilized both kinase assays as well biochemical validation of the relevant Akt 
phosphorylation sites in NK92 cells and NK92 transfected with kinase deficient 
Syk (Jian et al., 2003). 
LFA-1 has been shown to affect perforin polarization in NK cells when in contact 
with targets expressing ICAM-1 (March and Long., 2011). Here, using ICAM-Fc 
coated beads, Siglec-7 was shown to inhibit LFA-1 mediated perforin 
polarization in NK92 cells (Figure 4.18). These results parallel studies which 
show that inhibitory receptors (CD94-NKG2A and LLT1) are capable of blocking 
LFA-1/ICAM-1 induced perforin polarization in primary human NK cells (Das 
and Long., 2010). 
Recombinant ICAM-1-Fc (clone 54) used in the biochemical and perforin 
polarization assays was co-expressed with ST6GalI in order to favour N-linked 
glycosylation terminating with α-2,6 rather than α-2,3 sialic acid linkages, the 
former being preferred by Siglec-7. This chimera therefore serves as a ligand 
for LFA-1 and a potential counter receptor for Siglec-7. However data from dot 
blot assays (Figure 4.8) and adhesion assays (Figure 4.14) are suggestive of 
sialic acid independent recognition of ligands by Siglec-7 
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Recently, Siglec-G, an inhibitory receptor of macrophages, was shown to 
negatively regulate RIG-I dependent induction of type 1 IFN in response to RNA 
viral infection. This was however independent of sialic acid binding. Expression 
of Siglec-G allowed recruitment of SHP-2, RIG-1 and the ubiquitin ligase, Cbl. 
This promoted the ubiquitination of RIG-I and therefore degradation (Chen et 
al., 2013). 
Collectively, the data shown here imply a strong role for the inhibitory receptor, 
Siglec-7, in regulating LFA-1 functions in NK cells.  One possibility is that 
Siglec-7 is able to modulate LFA-1 receptor functions by means of constitutive 
cis-association with LFA-1 in microdomains, as shown in model B (Figure 4.1 
B). Based on the results obtained, a proposed model of Sigec-7 regulation of 
LFA-1, in a sialic acid independent manner, is shown in figure 4.20.  
. 
 
 
 
 
 
 
 
 
Figure 4.20: Siglec-7 modulates LFA-1 signalling, in a sialic acid independent manner: 
(A) Outside-in signalling of LFA-1 results in receptor clustering, recruitment of kinases 
such as Src and polarization of perforin in NK cells. (B) Cis-interactions between LFA-1 
and Siglec-7 results in inhibition of these LFA-1 mediated events, possibly by the 
recruitment of SHP-1.  
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Siglec-5 and Siglec-E, have been shown to signal independent of their ITIM 
motif’s and are weakly associated with SHP-1 (Avril et al., 2005; McMillan et al., 
2013). Therefore experiments examining the recruitment of or constitutive 
association of SHP-1 phosphatase with the ITIMs of Siglec-7 in these cells 
would also be needed to determine the exact mechanism by which Siglec-7 is 
able to modulate LFA-1. Also, a definitive role of sialic acid recognition in these 
assays has not been established.  Further experiments using ICAM-1-Fc 
lacking in α-2,6 sialylation (clone 17) to investigate trans sialic acid interactions 
of Siglec-7 would be needed. The use of targets expressing ligands for LFA-1 
would also strengthen the data obtained here. Towards this goal, genetically 
modified B16 mouse melanoma cells expressing human ICAM-1 could be used.  
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Chapter 5 
Evaluating Siglec-7 functions in regulating NK cell cytotoxicity 
 
5.1 Introduction 
NK effector functions are tightly regulated by many activatory, inhibitory and co-
stimulatory receptors (E.O.Long et al., 2013). They recognize targets by a 
complex system of numerous, but well integrated receptor-ligand interactions. 
To evaluate the role of individual NK cell receptors, a standard approach 
adopted is the expression of its ligands on defined target cells or 
overexpression of the receptor on NK cell lines. Xenogenic species are 
sometimes better suited as targets because of the mismatch in KIR-MHC 
recognition, which removes inhibitory signals that could be triggered upon target 
cell recognition. A good example of a well established xenogeneic target used 
in the study of many of the NK receptors, especially LFA-1, is the Drosophila 
Schneider 2 (SC2) cell line (Barber et al., 2004. Cyril Fauriat., 2009; Schleinitz 
et al., 2008).  
Siglec-7 has been shown to be in a “masked” state at the cell surface by 
interacting with the numerous sialylated glycans in cis (Avril et al., 2006). These 
cis-interactions between sialylated glycoproteins/glycolipids and Siglec-7 are 
thought to be important in the maintaining the receptor in quiescent state. 
Sialidase treatment of cells removes the sialic acids from the cell surface 
thereby “unmasking” Siglec-7. This helps promote trans interaction between 
Siglec-7 on NK cells and sialic acid ligands expressed on target cells to 
increase the potency of siglec-dependent inhibitory functions (Nicoll et al., 
2003). Figure 5.1 is a schematic representation of this process.  
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Figure 5.1: Cis and trans interactions of Siglec-7: Siglec-7 expressed on NK cells are 
masked by cis-interactions between numerous sialic acid containing counter-receptors 
on the cell surface. On sialidase treatment, these cis-interactions are lost and the 
receptor is free to mediate trans interactions with targets expressing sialylated ligands. 
This is known as the unmasking of the receptor.  
 
Nicoll et al transfected the P815 mouse mastocytoma cell line with GD3S and 
used the GD3 expressing cells as a model to demonstrate the inhibitory role of 
Siglec-7. IL-2 activated PBMC were either sialidase treated or not treated and 
used in cytotoxicity assays against P815 GD3 targets. They were able to show 
that the P815 target cells became more sensitive to killing by NK cells when the 
effectors were treated with sialidase (Nicoll et al., 2003). An interesting finding 
from these experiments was that in the absence of sialidase treatment of 
PBMCs, P815 GD3 cells were more sensitive to cytotoxicity than P815 wild type 
cells. This phenomenon was explained by the possible presence of an 
activating receptor on NK cells that recognize GD3 as a ligand.  
For this project however the B16 (78) cell line was chosen as a model system. 
The initial aim was to reconfirm the inhibitory role of Siglec-7 using B16 (78) 
cells as targets and then investigate the effect of overexpressing gangliosides 
GD3 and GM1 on killing susceptibility as discussed in Chapter 3. 
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Aims:  
Although the initial goal of this project was to assess the biological significance 
of ganglioside complexes in modulating Siglec-7-dependent NK cytotoxicity, 
results from chapter 3 showed that over-expression of GD3 and GM1 in  the 
B16 (78) cell line did not lead to efficient formation of ganglioside complexes. 
Hence measuring modulation of NK cell function in this context was not 
considered a worthwhile aim.  
Instead, it was decided to investigate the role of Siglec-7 in regulating NK cell 
biology as follows: 
1. Role of GD3 in modulating Siglec-7 recognition – This was studied using IL-2 
activated PBMCs and a genetically modified NK cell line. 
2. Regulating integrin functions - Data shown in chapter 4 are strongly 
suggestive of a role of this inhibitory receptor in affecting integrin mediated 
adhesion and polarization of perforin granules. A biological outcome of this 
finding was then investigated and preliminary experiments by means of 
cytotoxicity assays carried out on targets expressing ICAM-1.  
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5.2 Role of Siglec-7 in regulating effector functions of CD56+ primary NK 
cells via GD3 expression on target cells 
 
PBMC isolated by ficoll gradient of blood from different donors were used in 
these assays. PBMCs were cultured for 4 days in IL-2.  
 
5.2.1 Modulation of NK cell mediated cytotoxicity in a sialic acid 
dependent manner 
Cytotoxicity of human PBMCs against target cells was measured using an 
ELISA based assay, which measures lactate dehydrogenase (LDH) release 
from target cells. The number of targets required for detection of LDH was 
optimized for each cell line. Targets cells included B16 (78) wild type cells, B16 
(78) cells overexpressing GD3 and the K562 cell line which served as the 
positive control as it is known to be highly susceptible to killing by NK cells.  
Figure 5.2 (A) represents the percentage cytotoxicity of IL-2 activated PBMC (±) 
sialidase treatment on B16 (78) ± GD3 and K562 control cells. Cytotoxicity of 
the B16 (78) GD3 cells was reduced compared to wild type control cells. 
Sialidase treatment of the effector cells reduced lysis of both B16 (78) ± GD3 
cells to effector cytotoxicity (Figure 5.2, B).  
One of the methods that have facilitated investigation of ligand binding 
specificity of the various Siglecs is the use of  sialoside-polyacrylamide (PAA) 
probes.  These multivalent platforms can have sialic acid in different linkages, 
covalently attached to the PAA polymer and is biotinylated to enable easy 
detection.  
The efficiency of sialidase treatment in the cytotoxicity assays conducted here 
was confirmed by examining binding of sialidase treated CD3-CD56+ PBMCs to  
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Figure 5.2: Increased sensitivity of B16 ± GD3 cells to cytotoxicity by human PBMCs: 
Human PBMCs, cultured in IL-2 for 4 days, were treated without (A) or with sialidase (B) 
(0.17 IU/ml) for 1 hour at 370C in DMEM and quenched with 10% FCS. 1x104 B16 and B16 
GD3 expressing targerts were added to the PBMCs at different cell concentrations and 
incubated for 4 hours at 370C. Following the incubation period, 50 µl of the supernatant 
was used to measure LDH release using assay substrate. Data was normalized to 
effector and target spontaneous release and percentage cytotoxicity calculated 
according to equation given in materials and methods. Error bars represent standard 
deviation between samples (n=3) and experiment is representative of n=5 (C) Siglec-7 is 
masked on PBMCs – Sialidase treatment of PBMC  was used to unmask Siglec-7 and 
promote binding to sialylated ligands. Following sialidase treatment (or not) PBMCs were 
incubated with biotinylated α 2,8 - PAA probes.  Cells were then stained with anti-CD3 
and anti-CD56 antibodies and analysed by flow cytometry. The dot blot represents 
B
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greater binding of salidase treated (blue dots) human PBMCs to biotinylated disialylated 
probes  compared to non-sialidase treated PBMCs (red dots). Experiment is 
representative of n=5 (D) Siglec-7 recognition of GD3 down regulates TNF-α response of 
PBMCs to B16 GD3 cells. Targets and effectors were incubated for 24 hours and 100 µl of 
supernatant was collected at 6 hour and 24 hour time point. TNF-α ELISA kit was used to 
detect TNF-α in the culture supernatants. Error bars represent standard deviation 
between samples (n=4). 
 
biotinylated PAA probe carrying sialic acids in α 2,8 linkages (shown in figure 
5.2, C). 49% of the sialidase treated CD56+ PBMCs bound the sugar probes. 
Binding of these cells to lactosyl-ceramide PAA probes was found to be 
negative (data not shown). 
The cytokine response of IL-2 activated PBMCs to B16 (78) ± GD3 target was 
also analysed by measuring TNF-α release by ELISA, in a separate experiment. 
There was a 2-fold reduction in the amount of TNF- α released at 24 hours 
when effectors were in contact with B16 (78) GD3 targets as compared to wild 
type B16 (78) cells (shown in figure 5.2, D). 
 
5.2.2 Clonal expression of GD3 modulates NK cell mediated cytotoxicity 
 
The data shown above suggests that GD3 expression on target cells affects NK 
cell cytotoxicity. To explore the possible role of Siglec-7 in these assays, 
cytotoxicity assays were performed using B16 clones expressing different levels 
of GD3 and cytotoxicity correlated to the expression levels of GD3. 
For this purpose, GD3 expressing B16 (78) clones were generated by limiting 
dilution as described previously. Clones were analyzed by flow cytometry 
(Figure 5.3, A). Clones with high, medium and low expression levels of GD3 
were subject to cytotoxicity using IL-2 cultured non-sialidase treated PBMCs as 
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described above. Figure 5.3, B shows the %ge lysis of B16 (78) cells 
expressing different levels of GD3, compared to the wild type B16 (78) cells. 
Clones 3 and 6 with the highest expression of GD3 had significantly reduced 
cytotoxicity compared to clone 7, which had 5 fold less expression of GD3. The 
cytotoxicity of clone 7 was comparable to the wild type B16 (78) cells, which 
lacked in GD3 expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Susceptibility of B16(78) clones expressing different levels of GD3 to 
cytotoxicity of PBMC: B16 (78) cells, transfected with GD3S were cloned by limiting 
dilution. (A) B16 (78) wild type cells and GD3 expressing clones were stained with anti-
GD3 antibody (R24) for 30 minutes on ice. Cells were then washed and stained with anti-
mouse FITC antibody for 30 minutes on ice. Washed cells were then analyzed by flow 
cytometry. (B) B16 (78) cells were also subjected to cytotoxicity by IL-2 activated PBMC 
as explained in figure 5.2. Error bars represent standard deviation between samples 
(n=3). 
A
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5.2.3 Blocking of RBC adhesion by Siglec-7 antibodies 
The aim of these experiments was to investigate if anti-siglec-7 antibody could 
reverse GD3-dependent suppression of killing. Sheep polyclonal anti Siglec-7 
serum, mouse monoclonal antibody (clone 7.7A) and sheep polyclonal Fab 
fragments to Siglec-7 were used in the cytotoxicity assays. In chapter 4, both 
sheep polyclonal anti-Siglec-7 serum and the mouse monoclonal antibody 
(clone 7.7a) have been used to specifically identify Siglec-7 positive cells. RBCs 
adhere to Siglec-7-Fc coated on to anti-Fc coated plates (as described in 
chapter 3). The binding of RBCs to Siglec-7-Fc coated plates was blocked by 
the incubating the plate with dilutions of sheep antisera, mouse monoclonal 
antibody tissue culture supernatant (clone 7.7a) or different concentrations of 
Fab fragments. The polyclonal sheep antiserum efficiently blocked RBC 
adhesion over a range of dilutions (Figure 5.4, A). Pre-immune sheep serum 
was used as a negative control and did not inhibit RBC adhesion. Monoclonal 
antibody, clone 7.7a, only reduced adhesion when used as neat supernatant 
(Figure 5.4, B). 
At concentrations ranging between 20 µg/ml and 1 µg/ml, Siglec-7 Fab antibody 
fragment also significantly blocked the adhesion of RBCs to Siglec-7-Fc (Figure 
5.4, C). Adhesion was sialic acid dependent as sialidase treated RBCs failed to 
bind to Siglec-7-Fc (Figure 5.4, C). 
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Figure 5.4: Siglec-7 antibodies block RBC adhesion: 96 well plates were coated with 100 
μl of 12 μg/ml of goat anti-human IgG in bicarbonate buffer (p H 9.6). After overnight 
incubation, plates were blocked with 5% marvel in 1 X PBS. Following x3 washes in PBA, 
wells were coated with 100 µl of Siglec-7-Fc (@ 7 μg/ml) and incubated for 1 hour at 370C. 
Plates were then incubated with different dilutions of the Siglec-7 polyclonal antiserum 
(A), monoclonal antibody (B) or different concentrations of Fab fragments (C) and 
incubated at 370C for 30 minutes. 100 μl of prepared RBCs were added and incubated for 
1 hour room temperature. Plates were washed using an orbital shaker to remove 
unbound RBC, cells fixed with methanol and 100 µl of TMB substrate added and 
incubated for 30 minutes at room temperature. The reaction was stopped using 100 μl of 
sulfuric acid and plates read at 450nm. Error bars represent standard deviations (n=3).  
 
5.2.4 Antibodies do not block Siglec-7 mediated inhibition of cytotoxicity  
 
The above tested antibodies were then used in cytotoxicity assays to determine 
if they block Siglec-7 mediated inhibition of cytotoxicity against GD3 expressing 
B16 target cells. IL-2 activated PBMCs were used as effectors in cytotoxicity 
A B 
C 
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assays as described in section 5.2.1. Polyclonal antiserum (1/1000 dilution), 
undiluted monoclonal antibody supernatant or Fab fragments (10 µg/ml) were 
incubated with effectors for 15 minutes at room temperature prior to addition of 
target cells. Neither the polyclonal Siglec-7 antibody (figure 5.5, A) nor the 
monoclonal antibody (figure 5.5, B) could reverse the inhibition of Siglec-7 
mediated cytotoxicity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Antibodies do not block inhibition of NK cytotoxicity by Siglec-7: Cytotoxicity 
assay using IL-2 activated PBMCs and B16 (78) ± GD3 were carried out as described in 
figure 5.2 using (A) Siglec-7 polyclonal antibody @ 1/1000 dilution (B) Siglec-7 
monoclonal antibody, clone 7.7A and (C) Siglec-7 Fab fragment @ 10 µg/ml. Fc receptors 
on PBMCs were blocked with human serum for 15 minutes prior to addition of 
antibodies. Error bars represent standard deviation (n=3) and experiment is 
representative of n=3.  
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The Fab fragment gave a very modest increase in lysis of B16 (78) GD3 cells at 
9:1 effector : target ratio (figure 5.5, C). However, in this assay the B16 (78) 
GD3 cells were only slightly protected compared to the B16 (78) WT cells. The 
assays were repeated with the different antibodies and gave similar results.  
 
5.2.5 Cytotoxicity of human melanoma cell line (SK-MEL-28) 
 
Another approach adopted to investigate the inhibitory role of GD3 via ligand 
avidity for Siglec-7 was the use of a different target cell population, SK-MEL-28, 
with endogenously high expression of GD3.  
IL-2 activated PBMC were incubated with either wild type or sialidase treated 
targets. Sialidase treatment of cells was confirmed by anti-GD3 antibody 
staining which showed a striking loss (figure 5.6, C). Upon removal of α 2,8 
linkages by sialidase treatment, SK-MEL28 cells became more susceptible to 
PBMC mediated killing (figure 5.6, B). 
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Figure 5.6: Sensitivity of SK-MEL-28 cells to NK cytotoxicity is decreased following 
sialidase treatment of cells. (A) Schematic shows Siglec-7 on effector NK cells recognize 
sialic acid ligands on target cells and inhibits cytotoxicity. However upon sialidase 
treatment of targets, the sialylated ligands are removed and Siglec-7 engages with cis- 
ligands, resulting in increased lysis of the targets (B) SK-MEL-28 cells +/- sialidase 
treatment were subject to lysis by IL-2 activated PBMCs as described in 5.2 (C) SK-MEL-
28 cells used in the cytotoxicity assay were stained for GD3 using R24 antibody before 
and after sialidase treatment. Error bars represent standard deviation (n=3). Data 
represents experiment from n = 1. 
 
5.3 Role of Siglec-7 in regulating cytotoxic functions of activating 
receptors via recognition of GD3  
The above cytotoxicity data suggest the potential inhibitory role of Siglec-7 in 
inhibiting NK cytotoxicity of GD3 expressing B16 (78) and SK-MEL-28 cells.  
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To further establish these findings, an NK cell line, NK92, deficient in Siglec-7 
expression was used as effector population. NK92 is known to express 
activating receptors such as – NKp46, NKp30, NKG2D, 2B4 and CD28 (Maki et 
al., 2001). This cell line has been characterized in Chapter 4 with regards to 
Siglec-7 expression. 
 
5.3.1 Expression of GD3 on the K562 cell line 
 
The prototype K562 target cell line, which is highly sensitive to killing by both 
primary NK cells and NK cells lines, was used.  
K562 cells were analysed for expression of GD3 using the mouse anti-GD3 
antibody (R24). The cell line was negative for the expression of GD3. Hence 
this cell line was transfected with cDNA for GD3S and overexpression of GD3 
achieved as shown by flow cytometry staining in figure 5.7.  
  
 
 
 
 
Figure 5.7: Flow cytometry staining of K562 cells for expression of GD3 : K562 cells were 
transfected with GD3S and expression of GD3 analysed using anti-GD3 antibody (R24). 
Histogram in red – wild type K562 cells ; Histogram in blue – K562 cells transfected with 
GD3S.  
 
 
 
 
Anti-GD3 antibody 
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5.3.2 Siglec-7-Fc precomplex recognition of GD3 expressed on K562 ± 
GD3 
Siglec-7 recognition of GD3 expressed on the K562 cells was analysed using 
Siglec-7-Fc precomplexes (figure 5.8). The pre-complexes bound strongly to 
both K562 wild type cells and GD3 expressing cells. Upon sialidase treatment of 
the cells, there was only a moderate decrease in the binding of these 
precomplexes. This is suggestive of the Siglec-7 precomplexes binding to the 
cells in a sialic acid independent manner. These results also suggest that this 
cell line, in contrast to the B16 (78) wild type cells, has a sialylation pattern that 
favours Siglec-7 recognition, independent of GD3. 
 
 
 
 
 
 
 
Figure 5.8 Siglec-7-Fc precomplexes bind K562 ± GD3 cells in a sialidase dependent 
manner. Precomplexes were prepared as described in chapter 4 and added to sialidase 
treated and non-treated K562 (A) and K562 GD3 (B) cells for 1 hour on ice. Cells were 
then analysed by flow cytometry. The mean fluoresence intensity of each sample is 
represented in the box below. 
 
5.3.3 Siglec-7 modulates the cytotoxicity of K562 GD3 cells  
K562 ± GD3 cells were then used as targets in cytotoxicity assays comparing 
killing mediated by NK92 ± Siglec-7. The expression of GD3 on K562 cells did 
not affect their sensitivity to killing by either the wild type NK92 cells (Figure 
BA
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5.9,B) or the Siglec-7 expressing NK92 cells (figure 5.9, C). However sensitivity 
of both the wild type K562 and GD3 expressing K562 cells to Siglec-7 
expressing NK92 clone was significantly lower than to the wild type NK92 cells 
(Figure 5.9, D and E).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Siglec-7 modulates NK92 cytotoxicity of K562 GD3 expressing cells: 
Cytotoxicity assays were carried out as detailed in figure 1.2. (A) Schematic showing the 
expression of Siglec-7 favours trans interactions between glycans on target cells and 
reduces cytotoxicity of sensitive targets. (B) NK92 and (C) NK92 Siglec-7 cells (C14) were 
incubated with either K562 wild type cells or K562 GD3 cells. (D) K562 cells and (E) K562 
GD3 cells were tested for their sensitivity to NK92 and NK92 S7 (C14) cells. Experiment is 
representative of n=2.  
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5.3.4  Sialidase treatment affects cytotoxicity of NK92 S7 expressing cells 
In a separate experiment, sialidase treatment of effector cells, to unmask 
Siglec-7, was examined on K562 target cells, expressing GD3.  
Sialidase treatment of the wild type cells reduces cytotoxicity of target cells 
(figure 5.10, B) however this effect is more significant (at all effector to target 
ratios) in Siglec -7 expressing NK92 cells (Figure .510, C). The cytotoxicity of 
Siglec-7 expressing NK92 cells (clone 14) was significantly lower at all effector 
to target concentrations, compared to sialidase non-treated and treated wild 
type cells (Figure 5.10, D and E).  
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Figure 5.10 – Unmasked Siglec-7 show increased inhibition of cytotoxicity towards K562 
GD3 cells – Cytotoxicity assays were carried out as described in figure 5.2 using K562 
GD3 cells (A) Schematic showing how sialidase treatment affects Siglec-7 unmasking. 
Comparing cytotoxicity of sialidase untreated and treated (B) NK92 wild type cells (C) 
and Siglec 7 expressing NK92 cells – S7 (C14). Comparing cytotoxicity of NK92 and 
S7(C14) cells (D) before sialidase treatment (E) after sialidase treatment. Experiment is 
representative of n=1.  
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5.4 Siglec-7 affects LFA-1 mediated cytotoxicity 
Unlike T cells and B cells, LFA-1 in NK cells has an important role in adhesion 
and provides for early cytotoxicity signals (Barber, Faure and Long, 2004).  It 
also acts in concert with other activating receptors to bring about actin 
cytoskeletal re-organization and perforin granule polarization. Long et al., 2004 
showed that LFA-1 is sufficient to cause lysis of insect cells in an ICAM-1 
dependent manner by IL-2 activated cells and this is affected by KIR inhibitory 
signals.  
Data described in chapter 4 using ICAM-1-Fc chimera showed that Siglec-7 
plays a negative role in LFA-1 dependent adhesion of NK92 cells and that 
integrin dependent signalling was intercepted at the proximal stages of the 
signalling cascade. The biological significance of these findings can be 
examined by means of NK cytotoxicity assays where LFA-1 is known to play a 
role. Towards this, the NK92 effector cells were used as a model system to 
investigate the role of Siglec-7 in affecting LFA-1 cytotoxicity functions in a 
biological setting. 
 
5.4.1 B16 cells lack ICAM-1 expression 
Unlike human melanoma cells (Nakayama et al., 1997) the mouse B16 cell line 
is not known to express ICAM-1 under ordinary culture conditions. This was re-
confirmed by flow cytometry staining, using an anti-mouse ICAM-1 antibody or 
isotype and mouse neutrophils as positive control (figure 5.11). Consistent with 
published reports, the B16 (78) cells had no expression of mouse ICAM-1 
(Nakayama, J et al., 1997). 
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Figure 5.11: B16(78) cell line does not express ICAM-1 : Mouse splenocytes (A) and B16 
mouse melanoma cells (B) were stained with 0.125 µg of anti-mouse ICAM-1 PE (blue 
histogram) antibody or isotype control (red filled histogram) in FACS buffer for 30 
minutes on ice. Cells were then washed with FACS buffer, fixed with 1% PBA and 
analysed by flow cytometry. 
 
5.4.2 Expression of human ICAM-1 on ± B16 GD3 cells 
mRNA for human ICAM-1 was extracted from K562 cells and used to generate 
cDNA using suitable primers (described in materials and methods). ICAM-1 
cDNA was then cloned into pcDNA 3.1 vector and purified plasmid DNA was 
transfected into B16 ± GD3 cells. After 2 weeks of culturing cells in selection 
media (hygromycin - @ 0.4 mg/ml), polyclonal cells stably expressing ICAM 
were analyzed by flow cytometry staining using antibodies to human ICAM-1. 
Cells were then subject to 1-2 rounds of MACS sorting to substantially enhance 
the percentage of ICAM-1 expressing cells.  
Figure 5.12 shows the expression levels of both ICAM-1 (A) and GD3 (B) on the 
different populations of B16 (78) transfectants following MACS sorting. Wild 
type B16 (78) which do not express either GD3 or ICAM-1 was used as a 
negative control. 
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Figure 5.12:  Expression of GD3 and ICAM-1 on B16 cell line: B16 wild type cell line and 
B16 GD3 expressing cell line were transfected with pCDNA3.1-ICAM-1. Cells were stained 
either with (A) anti-GD3 antibody (R24) or (B) with anti-ICAM-1 antibody for 30 minutes on 
ice. Following washes in FACS buffer, cells were stained with 1/200 dilution of anti-
mouse PE or 1/500 dilution of streptavidin-APC. Cells were washed and fixed with 1% 
PFA and then analysed by flow cytometry. 
 
5.4.3 SNA and Siglec-7-Fc precomplex binding to B16 ± ICAM cells 
 
In chapter 3, Siglec-7-Fc precomplexes bound minimally to B16(78) wild type 
cells. Upon transfection of GD3 synthase, there was significantly stronger 
binding of the complexes in a sialic acid dependent manner. These results  
suggested that wild type B16 (78) cells express predominantly glycans with 
terminal sialic acids in mostly α 2,3 or α 2,6 linkages for example GM3 
glycolipids that are the less preferred ligands for Siglec-7.  
B16 cells overexpressing ICAM-1 were analysed using the lectin SNA and 
Siglec-7-Fc precomplexes. The binding of the lectin SNA would help reveal the 
A B 
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presence of sialic acids in α 2,6 linkages on cell surface glycoproteins and 
glycolipids that could act as putative Siglec-7 counter receptors . 
Figure 5.13, A shows the binding of SNA lectin to B16 (78), B16 ICAM-1 and 
B16 GD3 ICAM cells with and without sialidase treatment. The lectin bound 
strongly to wild type cells and transfectants. Figure 5.13, B, shows the binding 
of Siglec-7-Fc precomplexes to these three populations of cells. Interestingly, 
there was no difference in the binding of these precomplexes to either the B16 
(78) wild type or ICAM-1 positive cells. Stronger binding of the complexes to 
GD3 expressing cells was observed.  
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Figure 5.13 – Comparing binding of SNA and Siglec-7-Fc-precomplexes to B16, B16 GD3 
and B16 GD3 ICAM cells. (A) Cells were harvested and treated with sialidase (0.17 IU/ml) 
in DMEM for 1 hour at 370C. Cells were then washed with DMEM + 10% FCS. Biotinylated 
SNA at 5 µg/ml was added to the samples for 30 minutes on ice. Following incubation, 
cells were washed in FACS buffer and then stained with 1/500 dilution of streptavidin-
APC. Cells were washed and fixed with 1% PFA before analysing by flow cytometry. (B) 
Siglec-7-Fc (@ 1 µg/ml) precomplexes with anti-human Fc IgG (@3 µg/ml) was prepared 
in HBSS, for 1 hour on ice. 100 µl of complex was added to each cell sample and left to 
incubate for an hour on ice. Cells were then washed with FACS buffer and fixed with 1% 
PFA before analysing by flow cytometry 
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5.4.4 ICAM-1 expression increases sensitivity of B16 (78) targets to NK92 
effectors 
NK92 cells mediate cytotoxicity against a range of primary human target cells 
and cell lines. However the cytotoxic effect of these cells on the B16(78) cells 
has not been studied previously to the best of my knowledge. Initial 4 hour 
cytotoxicity assays using the NK92:B16(78) effector-target system showed that 
these target cells are highly resistant to the cytotoxic action of this effector cell 
line (data not shown).  
Therefore it was decided to first test if the over-expression of ICAM-1 on these 
target cells would improve their sensitivity to NK92 killing by means of LFA-
1/ICAM-1 interactions. To improve the signal to noise ratio, the assay time was 
extended to 5 hours. Figure 5.14 demonstrates a modest improvement in the 
senstivity of B16 (78) ICAM-1 and B16 (78) GD3 ICAM-1 cells to these effectors 
compared to wild type B16 (78) cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: B16(78) ICAM-1 expressing cells are sensitive to NK cytotoxicity:  B16 (+/- 
GD3) and B16 (+/-ICAM-1) were subject to cytotoxicity assay using NK92 effector cells as 
described in figure 4.17. K562 cells were used as a positive control in the experiment. 
Error bars represent standard deviation with n=4. Data represents experiment from n = 1.  
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5.4.5 Differential killing of B16 GD3 ICAM by NK92 and C14 cells 
 
Using B16 (78) GD3 ICAM cells as targets, cytotoxic effects of wild type NK92 
cells and Siglec-7 expressing NK92 (Clone 14) cells were examined. Sialidase 
treatment of both effector populations was carried out to unmask Siglec-7. 
Figure 5.15, A shows that both untreated effector populations were comparable 
in their cytotoxicity of these targets. However upon sialidase treatment, there 
was a significant reduction in target lysis by Siglec-7 expressing clone (C14) 
(Figure 5.15, B).  
Siglec-7 expression was also tested by flow cytometry staining in both sialidase 
treated and untreated effectors (Figure 5.15, C). Sialidase treatment had no 
effect on the expression levels of Siglec-7 on these cells.  
To confirm effectiveness of the sialidase treatment, effectors were incubated 
with biotinylated α 2,8 sialic acid PAA probes (Figure 5.15, D) and biotinylated 
LacCer PAA probes (Figure 5.15, E). While untreated and treated wild type 
NK92 cells were negative for binding of α 2,8 PAA probes, clone 14 (C14) cells 
bound strongly to the probe following sialidase treatment. All groups of cells 
were negative for binding to LacCer probes. Data represents experiment from n 
= 1. 
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Figure 5.15: B16(78) GD3 ICAM target cells are less sensitive to the cytotoxic action of 
sialidase treated NK92 Siglec-7 cells :  Assay was carried out as described in figure 4.17 
using (A) non-sialidase treated effector cells and (B) sialidase treated effector cells. 
Targets and effectors were incubated for 5 hours and error bars represent standard 
deviation between samples (n=4). Effector cells using in the experiment were stained for 
Siglec-7 expression (C) and biotinylated sugar binding (D) as described in figures. 
Binding of effector cells to biotinylated LacCer PAA (E) was used as negative control. 
A B
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5.5 Discussion 
The data generated in the experiments described here point to the role of 
Siglec-7 in regulating NK cytotoxicity against tumour targets via 1) recognition of 
GD3 expressed on target cells and 2) dampening integrin mediated cytotoxicity 
signals.  
GD3 in modulating the inhibitory functions of Siglec-7: 
At the outset of this PhD project, the primary aim was to investigate the role of 
heteromeric complexes of GD3 and GM1 gangliosides in affecting Siglec-7 
recognition and thereby modulation of NK cytotoxicity. The B16 (78) cell line 
was chosen for this purpose as it only expresses the precursor of all other 
ganglioside species ie GM3 and therefore could be genetically modified to 
overexpress glycosyltransferases leading to the synthesis of gangliosides GD3 
and GM1.  However, due to the lack of formation of GD3:GM1 complexes on 
the surface of these target cells, it was decided to shift focus on the role of GD3 
expression on tumour cells in affecting NK cell functions , specifically 
cytotoxicity. The initial cytotoxicity assays were focused on reconfirming findings 
of Nicoll et al., with respect to GD3 in the B16 (78) mouse melanoma cell line 
(discussed in introduction to this chapter). In the cytotoxicity assays conducted 
using B16 (78) vs. the B16 (78) GD3 target cells, there was a clear inhibition in 
the lysis of targets (Figure 5.2) by non-sialidase treated IL-2 activated PBMCS. 
These findings are interesting as they question the previous finding of the 
presence of a GD3 recognizing activating receptor on activated NK cells. 
Additionally if this is a Siglec-7 dependent effect, these results suggest that 
Siglec-7 is unmasked under the conditions used and is therefore capable of 
ligand recognition in trans. One possible explanation for this reduction in lysis 
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would be the over-coming of cis-interactions of Siglec-7 by endogenous 
sialylated ligands on the cell surface by high affinity ligands in trans. Strong 
inhibitory signals generated by Siglec-7 in the NK effector cells would increase 
the threshold required by activating receptors thereby reducing overall 
cytotoxicity of GD3 expressing targets. Indeed this phenomenon has been 
demonstrated for the B-cell expressing Siglec-2, CD22. In the presence of high 
affinity ligands, CD22 overcomes its threshold for cis-binding and is able to bind 
ligands in trans (Collins et al., 2006). 
As shown in figure 5.2, sialidase treatment of PBMCs inhibited NK cell killing of 
B16 (78) GD3 targets but it also reduced the lysis of wild type B16 (78) cells. 
Sialidase treatment of effectors removes endogenous cis interactions and 
exposes the ligand binding site of Siglec-7. But it is also possible that this 
treatment affects glycosylation patterns of NK activating receptors and alters 
overall NK cytotoxicity (as has been shown for NKp44 (Hershkovitz et al., 
2009)). Sialidases catalyze the cleavage of sialic acids from oligosaccharides 
presented by glycoproteins and glycolipids at the cell surface. For the 
cytotoxicity assays conducted here, sialidase from Vibrio cholerae (type III) was 
used. This sialidase has broad specificity and will catalyze cleavage of sialic 
acids in α 2,3- < α 2,6- < α 2,8- linkages (Chokawala et al., 2007).  
The abundance of sialic acids on cell surfaces provides cells with their negative 
charge and contributes to many properties of cell-cell interactions (Varki and 
Gagneux, 2012). Therefore sialidase treatment of cells, to remove surface sialic 
acids, would decrease the overall negative charge on the cell, affect cell-cell 
interactions and possibly increase non-specific interactions (Zhang and Varki., 
2004). Removal of sialic acids by sialidases was shown to expose the ligand 
binding site of β1-integrins and dramatically increased the adhesion of cells to 
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fibrinogen (Pretzlaff et al., 2000). Sialidase treatment of B cells has also been 
shown to play a role in modulating B cell : T cell interactions (Bagriacik and 
Miller., 1999).  
The use of Siglec-7 antibodies in the cytotoxicity assays did not reverse the 
inhibitory effects of Siglec-7 (Figure 5.5). However these antibodies were able 
to block RBC adhesion to Siglec-7-Fc coated plates (Figure 5.4). The epitopes 
on Siglec-7 recognized by these antibodies have not been defined. Although 
the RBC adhesion assays suggests a blocking role for these antibodies, the 
possible effect of steric hindrance by the IgG molecules cannot be overlooked. 
In cellular assays, these antibodies could have little role in blocking the sugar 
binding site on Siglec-7. Ligation of anti-CD33 and cross-linking of Siglec-7 
antibodies have been shown to inhibit the proliferation of acute myeloid 
leukemic cells (Balaian, Zhong and Ball, 2003;Vitale et al., 2001). Antibodies or 
glycan ligand-based cargo are also known to trigger receptor endocytosis in 
some members of the siglec family such as CD22 (B cell receptor), Siglec-F 
and Siglec-H (Shan and Press, 1995; Zhang et al., 2006; Tateno et al., 2007) 
(O’Reilly et al., 2011).  Endocytosis leads to either recycling of the receptor 
back onto the surface (eg., CD22) or lysosomal degradation (eg., Siglec-F) 
(Stoddart et al., 2005). Polyclonal Siglec-7 antibody conjugated to nano-
particles has also been reported to internalize Siglec-7 (Scott et al., 2008). A 
recycling pathway is not yet known for Siglec-7. But it is possible that the anti-
Siglec-7 antibodies trigger rapid internalization and recycling of the receptor. 
This would result in the receptor being in a constant state of equilibrium on the 
cell surface and actively engaging in trans ligand interactions. This would partly 
explain why the antibodies were not able to reverse the inhibitory effects of 
Siglec-7 in the cytotoxicity assays conducted here.  
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To further define the inhibitory role of Siglec-7 in regulating NK cell mediated 
killing, CD107a release from CD3-CD56+ effectors following incubation with 
targets was measured as well as direct measure of killing using 7AAD staining 
as a marker for cell death was performed (data not shown). Data from both 
these assays demonstrated clear inhibition of NK mediated cytotoxicity when 
B16 (78) targets expressing GD3 was used. 
Therefore it is reasonable to conclude that the availability of higher affinity 
Siglec-7 ligands such as disialylated GD3 on target cells is enough to over 
come cis-masking of Siglec-7 on NK cells and facilitate trans interactions in the 
absence of sialidase treatment. These interactions are sufficient to increase the 
threshold needed by NK activating receptors, resulting in decreased target cell 
lysis.  
 
Another novel approach taken towards the goal of identifying the role of GD3 in 
modulating NK cell functions was the use of an NK cell line, deficient in Siglec-
7. This cell line would help directly investigate the role played by this receptor in 
NK cell biology. The K562 leukemic cell line was chosen as a suitable target, as 
it is highly sensitive to both primary NK cells as well as the NK92 cell line. 
Interestingly it also lacked expression of the ganglioside GD3 (Figure 5.7). and 
was therefore manipulated to overexpress GD3. Binding of Siglec-7-Fc 
precomplexes on wild type K562 and GD3 expressing K562 cells gave very 
high shift in fluoresence intensities, implying presence of sialylated ligands on 
these cells. However these cells are known to express the Fc receptor, FcγRIIB, 
which could contribute to the high binding of these pre-complexes (Littaua et al., 
1990). The nature of sialylated ligands on K562 cells or their linkages are not 
known and would require further investigation using either antibody or lectin 
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staining and analysis of messenger RNA levels of the different 
glycosyltransferases. 
In cytotoxicity assays, NK92 Siglec-7 expressing cells showed a significant 
reduction in cytotoxicity of both K562 and K562 GD3 cells compared to wild 
type NK92 over a range of effector : target ratios (Figure 5.9). Unmasking 
Siglec-7 on these effectors by sialidase treatment enhanced the inhibition of 
lysis of K562 GD3 targets (Figure 5.10). These results are significant as they 
suggest that in the presence of targets that have expression of sialylated 
ligands in high density, Siglec-7 undergoes unmasking from cis-interactions and 
is able to bind ligands in trans. This results in generation of inhibitory signals 
which is capable of over-riding cytotoxicity signals initiated by activating 
receptors against this sensitive target. However sialidase treatment of wild type 
NK92 cells also led to decreased cytotoxicity of K562 GD3 cells. This is 
suggestive of the dual effects of sialidase treatment – a specific one which 
results in unmasking of Siglec-7 and a more non-specific effect resulting in 
decreased cytotoxicity.  
These results are consistent with the data obtained using PBMCs on B16 (78) 
GD3 expressing targets but are different to results from the P185 model used 
previously in the lab. In the latter model, Siglec-7 on PBMCs had to be 
unmasked by sialidase treatment in order to recognize ligands in trans and 
exhibit inhibitory role. In the B16 (78) and K562 cell lines, unmasking the 
receptor was not a prerequisite for effective inhibitory responses. These 
differences could possibly arise from the differences in the cell line models used 
as well as density and presentation of ligands on the target cells.  
As detailed in the introduction (Chapter 1), GD3 is aberrantly over expressed in 
tumours such as melanomas and acute lymphoblastic leukemias. Over-
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expression of GD3 is known to facilitate various tumourigenic properties such 
as cell proliferation, invasion and metastasis (Cheresh et al., 1986;Zeng et al., 
2000) (Hamamura et al., 2005). Breast cancer MDA-MB-231 cells over-
expressing GD3 were shown to proliferate, independent of serum (Cazet et al., 
2009). Constitutive activation of tyrosine kinases Erk1/2 and PI3K/Akt were 
shown to be responsible for this phenotype (Cazet et al., 2010). Recent reports 
from Furukawa’s group have also tried to dissect the mechanisms relating to the 
altered phenotype of melanoma cell lines transfected with GD3S (discussed in 
introduction) (Hamamura et al., 2008;Ohkawa et al., 2010;Ohkawa et al., 2008). 
Put together these data underscores the role of GD3 in enhancing the 
malignant properties of tumours. GD3 has also been suggested as a possible 
inhibitor of NK cytotoxicity (Furukawa,K., 2008) (Bergelson et al., 1989). Based 
on these reports, the overexpression of GD3 on the K562 tumour cells could be 
expected to alter their susceptibility to NK cytotoxicity. However GD3 
expression on K562 cells did not increase the resistance of these targets to NK 
cell lysis, in a Siglec-7 independent manner (Figure 5.9).  
 
Integrin dependent modulation of NK cytotoxicity by Siglec-7: 
LFA-1 is an important adhesion receptor for NK cells but also provide important 
signals required for natural cytotoxicity and ADCC. Initial studies on this 
receptor showed that LFA-1 contributed to early NK cytotoxicity signals (Barber 
et al., 2004). The cytotoxicity signals were shown to result in tyrosine 
phosphorylation of Vav-1, in a Src kinase dependent manner (Riteau et al., 
2003). However, further studies revealed that LFA-1 signalling is important for 
NK cell granule polarization but not degranulation (March and Long., 
2011)(Gross et al., 2010).  
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In chapter 4, results suggesting the regulatory role of Siglec-7 (expressed on 
NK92 cells) in affecting LFA-1 mediated functions such as adhesion, signalling 
and perforin polarization have been demonstrated. The data also showed a 
minimal role of sialic acid recognition in Siglec-7 activation. A model where 
constitutive cis-association of Siglec-7 with LFA-1 is sufficent to elicit its 
inhibitory roles was suggested as a mechanism (Figure 4.20,B).  
The aim of this part of the project was to investigate if LFA-1 mediated cytotoxic 
action of IL-2 activated NK92 cells was affected by the over-expression of the 
inhibitory receptor Siglec-7 in these effector cells. The B16 (78) cell line was 
chosen as the target as they lack in ICAM-1 expression (Figure 5.11). Based on 
the model suggested in chapter 4, the B16(78) targets were modified to either 
express only ICAM-1 or co-express ICAM-1 and GD3 (figure 5.12). This 
approach would help examine if (1) Siglec-7 can affect cytotoxicity signals 
generated by LFA-1 by its constitutive association with the receptor (2) Siglec-7 
requires the presence of a higher affinity glycan ligand such as GD3 in trans in 
order to regulate LFA-1 responses.  
 
Siglec-7-Fc binding of ICAM-1 transfected B16 (78) cells showed no increased 
binding over wild type B16(78) cells. These cells were however bound the lectin 
SNA in a sialic acid dependent manner suggesting the expression of glycans 
carrying sialic acids in α 2,6 linkages (Figure 5.13). Expression of ICAM-1 on 
B16 (78) and B16 (78) GD3 cells caused a modest increase in their sensitivity 
to NK92 cytotoxicity compared to the wild type B16 (78) cells (Figure 5.14). 
Since wild type cells, lacking in ICAM-1 expression, were not sensitive to NK92 
effectors, any increase in cytotoxicity of ICAM-1 positive targets was attributed 
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to a LFA-1/ICAM-1 mediated interactions. The use of anti-LFA-1 blocking 
antibodies to confirm the role of LFA-1 in this model system was not attempted. 
In a preliminary experiment carried out, sensitivity of B16 (78) ICAM-1 GD3 
expressing cells to both NK92 and NK92 Siglec-7 (S7(C14)) effectors was 
examined (Figure 5.15, A). The sensitivity of these targets was reduced 
significantly following the sialidase treatment of effector cells (Figure 5.15, B). 
The “masked” status of Siglec-7 on NK92 cells was confirmed with the help of 
suitable sialylated PAA probes, before and after sialidase treatment (Figure 
5.15, C and D). These preliminary results are consistent with the notion that 
trans interactions of Siglec-7 with high affinity ligands such as GD3 or other 
disialylated glycolipids or glycoproteins can alter NK cytotoxicity responses.  
The ganglioside disialosyl globopentaosylceramide (DSGb5), containing 
internally branched α 2,6 sialic acids, is a ligand for Siglec-7 (Kawasaki et al., 
2010). Highly metastatic renal carcinoma cells, expressing DSGb5, was found 
to be resistant to NK cell cytotoxicity (Kawasakiet al., 2010).  
However, using ICAM-1-Fc coated on to plates or beads, a constitutive cis-
association between Siglec-7 and LFA-1, was demonstrated (Chapter 4). This 
cis- association was sufficient for Siglec-7 to mediate its inhibitory effects on 
LFA-1 signalling. Therefore the biological implication of these findings would 
require the use of ICAM-1 expressing target cells. Towards this experiments 
examining the sensitivity of B16 (78) ICAM-1 cells to NK92 cells, with and 
without Siglec-7 expression, will be needed.  
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Chapter 6  
 
Discussion  
 
 
The overall aim of this project was to dissect the role of the inhibitory receptor, 
Siglec-7, in NK cell recognition and killing of tumours via interactions with 
glycans. Healthy cells undergo aberrant changes in their ganglioside expression 
profiles during tumour transformation. They switch on the expression of 
complex gangliosides which are characteristically expressed during 
embryogenesis, for instance GD3 in cancers of neuroectodermal origin. These 
changes are known to support their survival and propagation.  
The role of GD3 in enhancing tumour survival has been well demonstrated by 
using the human breast cancer cell line, MB-MDA-231, by Delannoy and group. 
Overexpression of GD3 on this cell line confers the cell with unusual growth 
properties (Cazet et al., 2009). Previous findings from our lab have shown that 
GD3 expression protects tumour cells from NK recognition (Nicoll et al., 2003). 
Thus it can be thought that the specific up-regulation of GD3 on tumours 
provide them with two main advantages – (1) survival (2) evasion of immune 
recognition. Recent evidence from glycolipid arrays consisting of combinations 
of gangliosides showed a clear modulation of Siglec-7 recognition of GD3 when 
present with structurally more complex gangliosides such as GM1 (Rinaldi et 
al., 2009). The implications of these findings in a biological setting would be the 
following:  
(1) cis-interactions between GD3 and complex gangliosides such as GM1 on 
tumour surfaces could render the GD3 cryptic  
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(2) These interactions could alter Siglec-7 recognition and enhance NK cell 
killing  
(3) These interactions can serve as potential novel mechanism of assessing 
tumour prognosis by screening for gangliosides  
Although a previous study demonstrated that GD3 and GM1 do not exist on the 
same microdomains (Vyas et al., 2005), this was done using artificial 
monolayers and a single cell type, namely primary rat neuronal cells. Therefore 
in the present study it was felt important to perform an analysis of these 
gangliosides overexpressed  in a tumour cell line  
Flow cytometric analysis of the B16 (78) model cell line using Siglec-7-Fc 
proteins demonstrated decreased recognition of GD3 on cells with high 
expression of both GD3 and GM1. However, confocal microscopy analysis of 
these cells revealed that less than 3% of cells had patches of co-localization of 
GD3 and GM1. Lipid raft dissociation studies confirmed the absence of any 
cryptic GD3 on these cells.  A breast cancer cell line was also genetically 
manipulated to over-express GD3. Confocal microscopy analysis of these cells  
confirmed that the two gangliosides existed on separate microdomains on the 
cell membrane. While my work was in progress, Dong et al reported similar 
findings in a breast cancer cell line (Dong et al., 2012). Their investigation into 
the molecular mechanism of this phenomenon showed that saturation levels 
and fatty acid composition of these gangliosides affected their accumulation in 
different microdomains. The inference from these findings is that cis-interactions 
between gangliosides are not favoured in model cell lines by means of genetic 
manipulation. However, it is possible that in primary tumours, such cis-
interactions are formed and could contribute to tumour cell clearance by NK 
cells. The preferred segregation of gangliosides in membrane microdomains 
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could be a method of evasion adopted by tumour cells to escape NK cell 
surveillance. One of the main areas of research in the field of tumour cell 
biology is to understand the mechanisms involved in tumour cell escape from 
immunosurveillance. Therefore exploring such ganglioside cis-interactions in 
the context of primary tumours would be of potential benefit. 
 
The second part of this project was to attempt to study the potential 
mechanisms by which Siglec-7 inhibits NK cell functions. We initiated the study 
by revisiting the role of the ganglioside ligand, GD3, in modulating the functions 
of this receptor. Here, we used two different effector systems and two different 
target models to confirm these findings. Indeed, Siglec-7 recognition of GD3 
expressed on target cells resulted in the decrease of NK cell cytotoxic functions. 
These results were in line with the previous study from our lab (Nicoll et al., 
2003). Most of the Siglecs are masked on cell surfaces and therefore require 
unmasking to interact with ligands in trans. Nicoll et al., also showed the same 
to be true for Siglec-7 in cytotoxicity assays involving GD3 expressing targets.  
Unmasking of the receptor expressed on the NK92 cell line was not a 
prerequisite for Siglec-7 recognition of ligand in trans. The receptor was able to 
overcome cis interactions with endogenous low affinity ligands and recognize 
ligands in trans. These results are interesting as they imply that NK responses 
can be effectively modulated by Siglec-7 recognition of high affinity ligands 
expressed on certain tumours, without the need for receptor unmasking. This 
may be a novel mechanism by which tumours affect immune cells. Therefore, 
Siglec-7 may be a potential target for antibody therapy in the treatment of 
certain classes of tumours with expression of high affinity ligands.  
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CD33 related Siglecs are broadly expressed on innate immune cells and their 
primary function is the tight regulation of immune responses. However sialylated 
pathogens seem to have evolved to take advantage of this function. The CD33 
related Siglecs form a large gene cluster on the chromosome 19 and is thought 
to have originated by major inverse duplication of a small cluster of genes, over 
millions of years (Cao and Crocker, 2011). This cluster is well conserved in 
mammals. During the course of evolution, large scale gene deletion formed the 
rodent CD33r Siglec cluster from which the primate cluster is thought to have 
evolved (Cao et al., 2009). The latter cluster expanded as a result of gene 
duplication and is continually evolving (Varki and Angata, 2006). This expansion 
also led the formation of receptors with activating roles such as Siglec-14 and 
Siglec-16. However, specific de-selective pressure has led these receptors to 
become non-functional pseudogenes.  Unlike primates, the rodent CD33r Siglec 
cluster is not evolving. This rapidly expanding repertoire of CD33r Siglecs in 
primates could be thought of as an evolutionary process to keep up with the 
different pathogens. Rodent NK cells do not have an equivalent of primate 
Siglec-7 that specifically recognizes disialic acids. This would imply that Siglec-
7 on primate NK cells must have clear functional roles as an inhibitory receptor 
that justify its expression on NK cells, for example in the self-recognition of the 
cells of the nervous system. Neuronal cells lack MHC-I molecules and have 
been shown to be sensitive to direct killing by NK cells. (Backstrom et al., 2000). 
The recognition of disialylated gangliosides, expressed in abundance on 
neuronal cells, by Siglec-7, could protect them from NK mediated lysis (Nicoll et 
al., 2003).  
During the course of this project, new evidence on the regulatory role of Siglec-
E in controlling neutrophil responses via integrin signaling was published by our 
206	
	
	
laboratory (McMillan et al, 2013). Siglec-7 and Siglec-9 in primates are 
evolutionarily highly related to the rodent Siglec-E and are considered 
‘functional orthologues’. It was thought possible that the regulatory role of 
Siglec-E in integrin signaling could be a conserved feature of these highly 
related siglecs. To investigate this for Siglec-7, an NK cell line deficient in the 
expression of Siglec-7 was used. Results showed that Siglec-7 expressing NK 
effector cells have the reduced ability to adhere to ICAM-1-Fc as well as to 
bring about polarization of perforin granules upon contact with ICAM-1-Fc 
coated beads. In an attempt to dissect the signaling mechanisms involved in 
this regulation, biochemical studies were able to identify Src kinase as a 
potential substrate of this inhibitory signalling pathway. Similar experiments, 
using target cells expressing ligands for LFA-1, would be needed to reconfirm 
these findings.  
Vav-1, an important regulator of NK cytotoxicity, has been identified as one of 
the substrates of SHP-1 phosphatase activity. However these reports have 
made use of immunoprecipitation and a pan antibody against tryrosine 
phosphorylation. In this project, Vav-1 phosphorylation status in western blotting 
experiments was examined using an anti-phospho-Vav-1 antibody. Although 
blots are suggestive of the decreased phosphorylation of this guanine 
nucleotide exchange factor, further optimization of the antibody will be needed 
to confirm findings. Due to time constraints, it was not possible to investigate 
the previously described recruitment of SHP-1 with Siglec-7.   
A few preliminary experiments looking at NK cytotoxicity of targets expressing 
the LFA-1 ligand, ICAM-1, also suggested that cytotoxicity responses were 
dampened in a Siglec-7 dependent manner. However, repeat experiments will 
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be needed to validate these findings and to clearly elucidate the mechanisms 
by which Siglec-7 recognition of ligands occurs.  
The results obtained here may help define some of the factors involved in the 
modulation of NK cell function via the inhibitory receptor, Siglec-7. Upregulation 
of gangliosides and changes in glycosylation patterns on tumour targets may 
trigger strong inhibitory signals by Siglec-7 and increase the threshold needed 
by activatory signals to act on these targets. Effective strategies at blocking this 
receptor may enhance NK effector actions and thereby a stronger innate 
immune response against tumours.  
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Appendix 
 
1. Optimizing detection of liposome incorporated GD3 and GM1 with anti-
GD3 antibody and cholera toxin subunit B (CTB), respectively 
In order to confirm the presence of GM1 and GD3 incorporated in liposomes, an 
anti-GD3 monoclonal antibody (R24 mAb) and biotinylated cholera toxin subunit 
B (CTB) was used to detect these gangliosides. Detection with antibody and 
toxin was optimized with respect to the secondary antibody dilution, as shown in 
figure A1.   
 
 
 
 
 
Figure A1: Optimizing R24 and CTB for the detection of GD3 and GM1 respectively. 
Liposomes carrying GD3 and GM1 were plated onto microtitre plates. Plates were 
incubated with either 10 µg/ml of R24 mAb or 1 µg/ml of CTB, for 1 hour at room 
temperature. Plates were washed and then incubated with anti-mouse HRP or 
Streptavidin HRP for 1 hour at room temperature. Plates were washed and then TMB 
substrate added for detection. Plates were read at 450nm. Error bars represent 
standard deviation (n=3).  
2. Titration of anti-GD1a antibody (MOG35) antibody  
Expression of GD1a on B16 (78) cells was tested using the mouse anti-GD1a 
antibody, MOG35. This antibody and 2 other non-specific antibodies (MOG1 
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and MOG16) was a kind gift from Dr. Hugh Willison(Greenshields et al., 2009). 
GD1a, coated onto 96-well titre plates were detected using various 
concentrations of the antibody by ELISA (Figure A2). The results obtained, 
suggests that the working range of this antibody is between 20 µg/ml and 2.5 
µg/ml. 
 
 
 
 
 
Figure A2: Optimization of GD1a detection using anti-GD1a antibody (MOG35): 96-well 
microtitre plates were coated with 100 µl of GD1a at 2 µg/ml (dissolved in methanol). 
Methanol alone was used as the blank in the assay. The plate was left to dry overnight at 
40C. The plate was then blocked with 5% marvel in PBA, for one hour at room 
temperature. Different dilutions of the anti-GD1a antibody and non-specific antibodies 
(MOG1 and MOG16 @ 20 µg/ml) were diluted in blocking buffer and left to incubate for 
one hour at room temperature (RT). Plate was washed with 1%PBA (x3). Anti-mouse HRP 
(1/5000 dilution in TBA) was added to the plate and left to incubate for 1 hour at RT. Plate 
was washed again before carrying out detection with TMB substrate. Error bars 
represent standard deviation between samples (n=3).  
3. Expression of GD1a in B16 (78) GM1 positive cells 
MOG35 antibody was then used to check for expression of GD1a on B16 (78) 
transfected with GM2s and expressing GM1 (Figure A3). The human 
neuroblastoma cell line, SH-SY5Y, was used as a positive control (data not 
shown). Only < 1% of GM1 positive cells expressed GD1a.  
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Figure A3: Expression of GD1a on B16 (78) GM1 cells: B16 (78) wild type and GM1 
expressing cells were harvested and stained for GM1 and GD1a using CTB and anti-GD1a 
antibody respectively, as described in section 3.5.3 .  
 
4. Phosphorylation of Akt following LFA-1 recognition of ICAM-1 
 
 
 
 
 
Figure A4: Comparing LFA-1 mediated AKT phosphorylation between wild type NK92 
cells and Siglec-7 expressing NK92 (C14):  Whole cell lysates were blotted for Ser473Akt 
and total Akt. Experiments were conducted as described in figure 4.16. Densitometry not 
done since only one experiment conducted. 
 
 
 
 
 A 
  NK92 (WT)  NK92 S7 (C14)
B16 (78) B16 (78) GM1  
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5. Sialic acid independent adhesion of NK92 Siglec-7 cells to ICAM-1-Fc 
As discussed in section 4.5.2, repeat experiments analysing the effect of sialic 
acid on the adhesion of Siglec-7 expressing NK92 cells to ICAM-1-Fc. In this 
experiment the Siglec-7 R124A mutant was also tested (polyclonal cells and 
clone A). Sialidase untreated and treated ICAM-1-Fc was used in the 
experiment. As shown in figure 4.14, the adhesion of Siglec-7 expressing cells 
and the mutant was reduced and this was independent of sialic acid.  
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Figure A5: Sialic acid independent adhesion of NK92 WT or NK92 Siglec-7 (C14) cells to 
ICAM-1-Fc : 96 well tissue culture plates with protein A or PLL, followed by ICAM-1-Fc. 
ICAM-1-Fc coated plates were treated (A) without sialidase or (B) with 0.17 IU/ml of 
sialidase for 1 hour at 37 0C. Sialidase treatment was quenched using 10%FCS. 2 x 10 E5 
cells are washed and resuspended in 1XHBSS (-Ca2+, +Mg2+). EDTA treated cells were 
used as negative control. Cells were added to wells, spun down and incubated for 30 
minutes at 370C. Unbound cells were then removed from the plate by gravity wash and 
bound cells were fixed, stained and plates read at 570 nm. Cells added to PLL coated 
plate was used as control to obtain maximal binding of cells (data not shown). Error bars 
represent standard deviation between samples , n = 5.  
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6. Adhesion of Siglec-7 expressing NK92 cells to different preparations of 
ICAM-1-Fc 
The adhesion of NK92 wild type cells and Siglec-7 expressing cells to different 
preparations of ICAM-1-Fc (from CHO cell clone 54 and clone 17) was 
analysed. The sugar binding mutant of Siglec-7 (polyclonal cells and Clone A) 
was also included in this experiment. Treatment of each group of cells with 
EDTA was used as a negative control in this experiment. The results reconfirm 
findings described in section 4.5.1(Chapter 4). Siglec-7 expression on NK92 
cells negatively regulates the adhesion of cells to ICAM-1-Fc. The reduced 
adhesion of Siglec-7 sugar binding mutant (R124A) to ICAM-1-Fc also confirms 
the sialic acid independent nature of ligand recognition by Siglec-7. 
 
Figure A5: Siglec-7 negatively affects adhesion of NK92 Siglec-7 (C14) cells to ICAM-1-Fc 
: Experiment was carried out as explained in figure A5. EDTA treated cells were used as 
negative control. Cells added to PLL coated plate was used as control to obtain maximal 
binding of cells (data not shown). Error bars represent standard deviation between 
samples , n = 5.  
 
 
